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Abstract 
Introduction: Constitutive NO (synthesized by eNOS) is an endogenous vasodilator and 
independent modulator of cardiac hypertrophy. Hypertension accounts for 
approximately 50% of morbidity, alongside other risk factors such as ischaemic heart 
disease and obesity. Inorganic nitrate, through sequential reduction in vivo to NO, exerts 
potent BP lowering effects. However, its effects on cardiac hypertrophy/HF independent 
of BP lowering remain unknown. Thus, we investigated the effects of dietary nitrate in 
BP-dependent (ANGII) and independent (isoprenaline) models of cardiac dysfunction. 
 
Methods: C57Bl6 mice underwent minipump infusion of ANGII or isoprenaline and 
received 15 mM KNO3 or KCl drinking water. Echocardiographic, BP telemetry, organ 
bath, histological and molecular assessments were made. Furthermore, as some 
benefits of nitrate appeared dependent on xanthine oxidoreductase (XOR), Xdh 
knockout (KO) mice underwent cardiovascular phenotyping with and without ANGII 
infusion, to further investigate the influence of XOR in health and disease.  
Results: Inorganic nitrate attenuated ANGII-induced endothelial dysfunction, 
hypertension, left ventricular (LV) hypertrophy and fibrosis, and reduced H2O2 and 
superoxide generation, whilst increasing nitrite reductase capacity. Furthermore, 
nitrate prevented isoprenaline-induced decline in ejection fraction, reduced cardiac 
fibrosis and superoxide generation. 
Increased physiological BP, and trends towards increased LV hypertrophy and reduced 
ejection fraction were observed in Xdh Heterozygous KO (Het) mice compared to 
littermate controls. Despite higher baseline BPs, Xdh Hets were protected from ANGII-
induced hypertension and associated cardiac dysfunction.  
Conclusions: Inorganic nitrate improved cardiac remodelling both directly (by 
attenuating fibrosis and reducing superoxide generation) and indirectly (through BP-
lowering), demonstrating that dietary nitrate may offer a therapeutic option for BP-
dependent and -independent HF. Furthermore, XOR helped maintain physiological BP in 
wildtype mice (as a nitrite reductase), but upon ANGII infusion was detrimental (as a 
superoxide generator). Xdh Hets were protected from further BP increases and resulting 
cardiac dysfunction, highlighting the complexity of XOR’s role in health and disease.  
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1. CHAPTER ONE - Introduction 
 Heart failure epidemiology 
Heart failure is an incurable, lifelong condition that is a significant burden on medical 
resources in both developed and developing countries (Callender et al. 2014). In the UK 
alone, nearly one million individuals are currently estimated to be living with heart 
failure (NICE 2018), with approximately 200,000 new diagnoses made each year (Conrad 
et al. 2018). An individual’s condition can deteriorate rapidly following diagnosis, with 
data suggesting that approximately 50% of patients diagnosed with heart failure can be 
expected to die within 5 years (Mozaffarian et al. 2016).  
 Risk factors for heart failure development 
1.2.1. Hypertension and heart failure risk 
It has long been recognised that the two main predisposing factors for heart failure 
development are coronary heart disease and chronic hypertension (Ho et al. 1993). 
Chronic hypertension increases an individual’s risk of developing heart failure 2-3 fold 
(Levy et al. 1996) and is the most common risk factor shared by patients with heart 
failure. In hypertensive individuals, the heart initially adapts to increased load by 
increasing heart muscle mass, particularly by increasing wall thickness of the left 
ventricle (LV). This is thought to occur in order to maintain healthy cardiac function and 
minimize wall stress (compensated growth). However, if blood pressure (BP), and 
therefore cardiovascular load and wall stress, remain increased cardiac hypertrophy is 
likely to become accompanied by heart dilation, increased interstitial fibrosis and 
myocyte death (Levy et al. 1990; Cohn et al. 1997; Bernardo et al. 2010). This ultimately 
results in the onset of progressive cardiac dysfunction, with stiffening of the heart walls, 
reduced contractile function and reduced LV ejection fraction (Levy et al. 1987; Levy et 
al. 1990; Drazner et al. 2004; de Simone et al. 2008). 
One example of the impact of hypertension on heart failure risk is evidence 
demonstrating that at the age of 30, individuals with raised BP (i.e. ≥140/90 mmHg) have 
a lifetime risk of heart failure of 63% compared to 46% for normotensive 30-year olds. 
The at risk individual develops cardiovascular disease, on average, 5 years earlier, with 
heart failure and stable angina responsible for the largest proportion of life years lost 
(Rapsomaniki et al. 2014). Hypertension is currently estimated to affect 27% people in 
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the UK, with more than half of them not receiving effective treatment (BHF, 2019). Such 
high levels of incidence have caused some to refer to it as an ‘epidemic’ (Lloyd-Sherlock 
et al. 2014). 
With estimates that hypertension precedes heart failure in 66-90% of cases (Chobanian 
et al. 2003; Dunlay et al. 2009), hypertension is a significant risk factor for death caused 
by heart failure, including its complications such as arrhythmias and sudden death 
(Rapsomaniki et al. 2014). Meta-analyses have shown that controlling high BP 
effectively, it is possible to reduce one’s risk of developing heart failure by ≈52% 
(Meredith & Ostergren 2006). The SPRINT study has further emphasised the importance 
of BP lowering, as the degree to which BP could be lowered (even below traditional 
target BP of <140mmHg) had a significant effect on the incidence of heart failure in this 
population. In an ‘intensive’ treatment group with target BP <120 mmHg, individuals 
had 38% lower relative risk of heart failure development compared to the individuals 
with a traditional treatment target of <140 mmHg (SPRINT Research Group et al. 2015).  
1.2.2. Other risk factors for heart failure development 
However, hypertension is by no means the only risk factor for heart failure 
development. Other significant risk factors include coronary heart disease, obesity and 
smoking (Dunlay et al. 2009), as well as increasing age.  
The incidence of heart failure increases significantly with age; affecting approximately 
1.5% of individuals in the US aged between 40 and 59 years old, 6% aged between 60-
79 and 12.5% over the age of 80 (Benjamin et al. 2019). It is therefore highly likely that 
with people living longer, and with incidences of hypertension, obesity and smoking so 
prevalent in the western world, heart failure rates will also increase. In addition to this, 
improved therapies and faster treatment times for patients suffering cardiac insults, 
such as acute MI, mean more individuals survive the initial event (Gibson et al. 2008; 
Rosamond et al. 1998) and these patients are also highly likely to go on to develop heart 
failure (Velagaleti et al. 2008) – increasing heart failure morbidity further still. 
Projections, based on data in the US, have estimated that the prevalence of heart failure 
will increase by 46% between 2012 and 2030 (Heidenreich et al. 2013). This projection 
is unfortunately proving to be somewhat correct – with the American Heart Association 
confirming that a prevalence of 6.2 million was reported in the US between 2013–2016, 
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compared to 5.7 million between 2009–2012 - a 9% rise in just 4 years (E. J. Benjamin et 
al. 2019). 
 The role of superoxide in hypertension and heart failure 
Over the last two decades, numerous clinical and experimental studies have shown that 
oxidative stress is implicated in the progression of a number of CVD pathologies, 
including cardiac hypertrophy (Li et al. 2002; Satoh et al. 2006) and heart failure 
(Lakshmi et al. 2009; Tsutsui et al. 2011). Studies in isolated cardiomyocytes have shown 
that by reducing oxidative stress using treatments such as vitamin E, hydroxyanisole and 
catalase, the pro-hypertrophic effects of ANGII and TNF-α on neonatal cardiac myocytes 
could be prevented (Nakamura et al. 1998). In vivo models of chronic heart failure have 
also demonstrated progressive increases in myocardial xanthine oxidoreductase (XOR) 
levels, and associated oxidative stress, which can be reduced in the presence of the XOR 
inhibitor allopurinol (Amado et al. 2005; Ekelund et al. 1999). 
In addition to this, the aforementioned risk factors for heart failure development are all 
also associated with increased levels of oxidative stress generation, highlighting at least 
one pathway through which these risk factors may be actively contributing towards 
heart failure development and progression. For example, with regards to endothelial 
dysfunction and subsequent hypertension, although numerous influential factors have 
been implicated in its development, superoxide generation, by enzymes such as 
NAD(P)H oxidase and XOR, represents a major causative factor (Cai & Harrison 2000). 
Not only does the presence of superoxide reduce NO levels, by reacting to form 
peroxynitrite (ONOO-), but it also oxidizes tetrahydrobiopterin (BH4), a crucial cofactor 
for endothelial NO synthase (eNOS) activity.  
With superoxide generation implicated in so many pathological pathways associated 
with cardiac hypertrophy, heart failure and their risk factors, it is not surprising that 
attempting to reduce oxidative stress in patients would be of interest. Unfortunately, 
however, translation of the use of antioxidants to patients has not been straightforward 
and no clear benefits have been observed in clinical trials using traditional antioxidants 
(Myung et al. 2013). It is important to note however that reducing oxidative stress and 
accumulating superoxide damage via other, more specific downstream mechanisms, 
with targeted treatments, could still be beneficial. 
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 Current therapies and therapeutic targets for heart failure 
1.4.1. Preventative measures 
With many environmental factors capable of significantly increasing an individual’s risk 
of developing cardiac hypertrophy/heart failure, it is important initially for clinicians to 
carefully manage each individual’s risk. For example, risk factors such as hypertension, 
reduced glucose tolerance, increased total cholesterol:HDL ratio, obesity and cigarette 
smoking all increase one’s risk of developing heart failure (Kannel & Belanger 1991). 
However, they are all factors, which are generally modifiable, either by lifestyle changes, 
or with medical intervention. It is therefore extremely important for all individuals to be 
made aware of, and aim to adjust, such modifiable factors accordingly, particularly those 
who also have non-modifiable risk factors, such as having suffered MI, which put them 
at substantially greater risk of developing heart failure. However, for patients who have 
already shown signs of developing cardiac hypertrophy/heart failure, what options are 
currently available in terms of treatment?  
1.4.2. Treating cardiac hypertrophy/heart failure 
One way in which many currently available treatments (discussed further below) aim to 
reduce pathological hypertrophy is by reducing BP. In experimental models, cardiac 
hypertrophy caused by increased haemodynamic load can be decreased by ≈25% after 
just 1 week of reducing this load (Hill & Olson 2008). Regression of left ventricular 
hypertrophy (LVH) in patients has been demonstrated following treatment with a 
variety of drugs which reduce haemodynamic load, as well as by life-style modifications 
(Liebson et al. 1995; Xing et al. 2017). However, it is worth noting that whilst many 
successful heart failure drugs are anti-hypertensives, not all anti-hypertensives reverse 
cardiac hypertrophy to the same degree, despite perhaps producing similar reductions 
in BP (Ferreira Filho et al. 2010). BP severity is therefore considered not to be the only 
factor important in cardiac hypertrophy development and progression, with other 
hormonal and cell signalling pathways also implicated. 
1.4.3. Renin-angiotensin system (RAS) therapeutics 
ANGII is a vital component of the RAAS and plays a key role in regulating BP and fluid 
balance in the body. ANGII is a peptide produced by enzymatic cleavage of 
angiotensinogen à ANGI à ANGII (see Figure 1.1). Some of the known effects of ANGII 
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on the cardiovascular system include vasoconstriction and water retention when bound 
to ANGII type I receptors (AT1 receptor), resulting in increased BP (de Gasparo et al. 
2000), as well as inducing smooth muscle cell proliferation (Daemen et al. 1991).  
Figure 1.1 Key pathways of the renin-angiotensin aldosterone system (RAAS). 
Schematic diagram illustrating the key components of the RAAS and the physiological changes that can result, 
highlighting angiotensinogen cleavage by renin to give angiotensin I (ANGI), and ANGI cleavage by angiotensin 
converting enzyme (ACE) to give angiotensin II (ANGII). Physiological changes shown include those resulting from 
ANGII binding to ANGII type 1 receptors (AT1 receptors) and ANGII type 2 receptors (AT2 receptors). AT2 receptors are 
highly expressed in foetal tissues, with expression greatly decreasing following birth. It is therefore primarily the AT1 
receptors that responds to ANGII in adult tissues (Li et al., 2012). 
Studies have shown that heterozygous (Het) and homozygous AT1 knockout (KO) mice 
have decreased BP compared to controls (Ito et al. 1995). Moreover, several studies 
show that restricting ANGII activity therapeutically (both in patients and animal models) 
reduces BP, cardiac hypertrophy and ventricular remodelling (reviewed recently by 
(Ferrario 2016)). Competitive ANGII receptor antagonists such as losartan, as well as ACE 
inhibitors, are used to treat heart failure, since they reduce left ventricular mass (LVM) 
in hypertrophic patients, as well as significantly reducing BP (Ferrario 2016). Meta-
analyses of clinical trial data have also shown angiotensin converting enzyme (ACE) 
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inhibitors reduce LVM more effectively than other well established hypertensive 
treatments, such as diuretics and β-blockers (Dahlöf 2001). These drugs also significantly 
reduce death and hospital administration rates for heart failure and re-infarction in 
patients with MI-induced left-ventricular dysfunction or heart failure (Flather et al. 
2000). The mechanisms through which RAS-targeted drugs are likely to act, to 
ameliorate cardiac hypertrophy, are both indirect (through decreasing BP) and direct 
(through moderating ANGII signalling in hypertrophic and oxidative stress pathways in 
the vasculature and myocardium). These mechanisms of ANGII activity will be discussed 
further below, but ultimately, the multiple mechanisms through which ANGII acts in the 
body to worsen cardiac and vascular dysfunction highlight why RAAS therapeutics have 
been relatively successful in treating both hypertension and cardiac hypertrophy.  
1.4.4. β-adrenergic receptor blockers 
Other widely used therapeutics for treating cardiac hypertrophy are β-adrenergic 
receptor blockers. These are anti-hypertrophic, reduce LVM (Dahlöf 2001), increase 
exercise capacity of patients (Vyssoulis et al. 1995) and reduce mortality (Doughty et al. 
1997). It is thought that in addition to being anti-hypertensive, the anti-oxidant and anti-
proliferative properties of β-blockers such as carvedilol may be responsible for 
enhancing the beneficial effects of these drugs (Moser & Frishman 1998). A recent meta-
analysis has further highlighted β-blocker efficacy in regressing LVH, finding that 
regression following use of β-blockers in hypertensive cardiac hypertrophy patients was 
comparable to that in patients using ACE inhibitors or ANGII receptor blockers, and was 
greater than in those using diuretics or calcium channel blockers (Xing et al. 2017). 
1.4.5. Diuretics 
Diuretics have been used for some time as symptomatic treatment for heart failure, and 
act by effectively reducing blood volume (and thus BP) by increasing excretion of ions 
(such as Na+) and water through the kidneys. However, they are generally used in 
combination with other treatments such as ACE inhibitors, ANGII receptor blockers or 
β-blockers. Thiazide diuretics (which increase excretion of sodium by blocking 
resorption in the kidney via the electroneutral sodium-chloride co-transporter (NCCT)) 
are most commonly used for this purpose (Blowey 2016). Tolerance to diuretics can be 
particularly problematic, and can occur both in the short and long-term by differing 
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mechanisms (Brater 1998). This is therefore one major disadvantage to their use, in 
addition to the risks of severe electrolyte imbalances (Clayton et al. 2006) and potential 
worsening of kidney function (Reungjui et al. 2008). Due to these potential side effects, 
and the fact that other interventions, such as those discussed above, have generally 
proved to be more efficacious in treating cardiac hypertrophy, they are rarely used as a 
first line therapy. More often, diuretics are added to the treatment regimen later on, 
only if deemed necessary (Blowey 2016).  
1.4.6. Natriuritic peptides and neprysilin inhibitors 
Natriuretic peptides are endogenous signalling molecules which are of particular 
interest with regards to heart failure. Despite the presence of brain natriuretic peptide 
(BNP) widely being used clinically as a marker of heart failure, rather than being a 
negative signalling molecule, this peptide family (comprising atrial natriuretic peptide 
(ANP), BNP and c-type natriuretic peptide (CNP)) is in fact regarded as having potential 
positive impacts on cardiac structure and function. The natriuretic peptides have the 
ability to help counter regulate the increases in RAAS signalling which often occur in 
heart failure. Administration of exogenous natriuretic peptides such as Nesiritide 
(recombinant human BNP), showed promise in early trials with regards to 
haemodynamics and natriuresis (Publication Committee for the VMAC Investigators 
(Vasodilatation in the Management of Acute CHF) 2002). However, in a large-scale 
randomised controlled trial, there was no significant improvement in patient outcome 
(O'Connor et al. 2011).  
 
ANP, BNP, CNP are broken down and deactivated by an enzyme called neprilysin. 
Logically, by inhibiting this enzyme it would be hoped that increases in natriuretic 
peptides would follow – and in turn an improvement in outcome. Racecodotril (an oral 
neprilysin inhibitor) and Candoxatrilat (an IV formulation), did successfully increase 
natriuresis and excretion of ANP. However, in a long-term study using the candoxatril 
pro-drug, BP reduction was not sustained (Bevan et al. 1992). Later, it was found that 
neprilysin, in addition to natriuretic peptides, also breaks down ANGII (Richards et al. 
1992). Therefore, by inhibiting neprilysin not only are the natriuretic peptides being 
increased, but so are ANGII levels. It is therefore understandable that neprilysin 
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inhibition is likely to result in counter-intuitive actions from the build-up of resulting 
peptides (Dalzell et al. 2014).  
1.4.7. Combination therapies 
Whilst various combinations of pre-existing single drugs (for example thiazide diuretics 
and RAAS inhibitors mentioned above) are often used in patients to treat heart failure, 
one particularly successful recent example of a novel combination therapy is 
sacubitril/valsartan. Sacubitril/valsartan harnesses the benefits of both neprilysin 
inhibition (building up natriuretic peptide levels as mention above) and RAAS inhibition 
(preventing the counterintuitive ANGII build up).  
The ‘Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality 
and morbidity in Heart Failure’ trial (PARADIGM-HF) tested whether sacubitril/valsartan 
was superior to enalapril in reducing the primary end point of CV death or HF 
hospitalisation (McMurray et al. 2014). This trial was terminated early, on the 
recommendation of the Data Monitoring Committee, due to a sustained and highly 
significant reduction in the risk of the primary composite end point (CV death or HF 
hospitalisation) and in CV mortality in the sacubitril/valsartan group compared with the 
enalapril group. At the end of the trial, there was a 20% relative risk reduction in the 
primary end point and each of its components, as well as a 16% reduction in all-cause 
mortality. Both sudden death and death from worsening HF, were equally reduced, and 
both first hospitalisations for HF and total hospitalisations were reduced (21% and 23%, 
respectively) (Packer et al. 2015).  Hypotension was significantly more common with 
sacubitril/valsartan than with enalapril (14% vs 9% in the in the sacubitril/valsartan and 
enalapril groups respectively, p<0.001), although this rarely led to study-drug 
discontinuation. Conversely, renal dysfunction, hyperkalaemia and cough were less 
common with sacubitril/valsartan than with enalapril. Furthermore, it has recently been 
reported that changes in log2–NT-proBNP concentrations over 12 months in study 
participants correlated with changes in left ventricular (LV) ejection fraction (r = −0.381), 
LV end-diastolic volume index (r = 0.320), LV end-systolic volume index (r = 0.405), left 
atrial volume index (r = 0.263), and ratio of early diastolic filling/early diastolic annular 
velocity (r = 0.269) (Januzzi et al. 2019). 
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 Limitations of current therapies 
Whilst some patients benefit from the treatments discussed above, a significant 
proportion of patients remain resistant to their effects (even following combination 
therapies). It must also be noted that RAAS therapeutics have particular limitations with 
regards to efficacy in certain patient populations (specifically black patients) (Saunders 
et al. 1990; Rahman et al. 1997; Cushman et al. 2000; Exner et al. 2001; ALLHAT 
Collaborative Research Group 2002), which means they are somewhat restrictive in 
terms of application. It must also be considered that ACE is not the only enzyme capable 
of converting ANGI à ANGII, and in recent years, the pathways involved in the RAAS 
have been found to be more complex than the key pathways shown in Figure 1.1 
(Ferrario et al. 2014). The potential compensatory, or tissue specific, alternative 
pathways for ANGII formation, involving enzymes such as chymase, represents a further 
limitation to such therapies for heart failure patients, as simply inhibiting ACE may not 
be the most optimal treatment method for the long term (Ihara et al. 1999; Arakawa & 
Urata 2000).  
Unfortunately, the above treatment options and findings also refer specifically to 
patients classified as having heart failure with reduced ejection fraction (HFrEF). 
Unfortunately, patients with heart failure with preserved ejection fraction (HFpEF) do 
not respond in the same way to these treatments, and no effective treatment has yet 
been found for this patient population (Ilieșiu & Hodorogea 2018).  
Crucially, it must also be noted that even in responsive patients, cardiac 
hypertrophy/heart failure may be improved but it is never truly reversed. Progression 
of the condition can still occur, albeit at a potentially slower rate, leaving prognosis 
largely uncertain. Ultimately, when heart failure has progressed beyond a point of 
current therapies being efficacious, with blood flow to the rest of the body highly 
compromised, a heart transplant is the only viable option for patients. The wait for a 
suitable donor can be lengthy and patients with a particularly poor chance of survival 
may have to undergo invasive surgery to implant a left ventricular assist device (LVAD) 
in order to restore cardiac function until a heart becomes available (NICE, 2019). 
Therefore, despite current treatments often helping to control hypertrophy and heart 
failure to some degree, there is a constant quest to develop more effective and safe 
treatments for patients in the hope that the number of patients requiring LVAD and 
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heart transplantation procedures in the future can be significantly reduced. 
 Developing new treatments 
Relative success in the implementation of various available treatments resulted in 
improved prognosis for heart failure patients over a decade - with 6 month mortality 
rates decreasing from 26% to 14% between 1995 and 2005 (Mehta et al. 2009). 
However, unfortunately despite this improvement, 5-year mortality in 2016 is estimated 
to be approximately 50% (Mozaffarian et al. 2016) and heart failure remains considered 
an incurable, lifelong condition, with current therapies focusing on prolonging and 
improving life quality for patients as much a possible (Al-Mohammad et al. 2010), but 
not actively curing the disease.  
With no current therapies proven to be effective in the HFpEF patient population, and 
heart failure morbidity on the increase there is a significant unmet need for, and thus a 
requirement to develop, novel therapeutics. For this to happen, it is vital to better 
understand the pathophysiology and molecular mechanisms responsible for 
development of cardiac hypertrophy and heart failure, with the hope of identifying 
potential new therapeutic targets. With increased hemodynamic stress, directly 
associated with hypertension, an important physiological determinant in the 
development of LVH and heart failure (Devereux et al. 1983), research into such 
mechanisms may ultimately help uncover potential new targets in the search for 
prevention and possibly cure.  
 The potential of inorganic nitrate 
1.7.1. Nitric oxide in vasculature 
Nitric Oxide (NO), derived from the endothelium via endothelial NO synthase (eNOS), is 
critical in maintaining healthy vascular homeostasis, acting as a vasodilator (maintaining 
healthy systemic BP). NO also mediates multiple other beneficial cardiovascular effects 
proposed to be mediated by activation of soluble guanylyl cyclase (sGC) and subsequent 
elevation of cyclic guanosine monophosphate (cGMP) (Napoli & Ignarro 2001; Loscalzo 
2001; Napoli et al. 2006) (see Figure 1.2). 
 27 
Figure 1.2 L-arginine-NO and nitrate-nitrite-NO reaction pathways and key biological effects exerted by resulting 
NO. 
Schematic illustrating the production of NO via the L-arginine-NO (eNOS) (black) and the nitrate-nitrite-NO (blue) 
pathways. Figure also highlights some key beneficial effects of NO exerted through sGC-mediated increases in cGMP 
signaling (---), such as vasodilation, anti-platelet and anti-proliferative effects. The conversion of NO to nitrite (NO2-) 
and nitrate (NO3-) by oxidation is also highlighted (red). 
A failure of endothelial cells to produce sufficient bioactive NO in the vasculature, for 
example as a result of endothelial dysfunction and eNOS uncoupling, is therefore 
harmful in a number of ways and has been implicated in the pathogenesis of 
hypertension and LVH – both cardiovascular morbidities which are significant risk 
factors for developing heart failure (Brunner et al. 2005; Katholi & Couri 2011; Panza et 
al. 1990; Treasure et al. 1993). Furthermore, New York Heart Association (NYHA) class 
III heart failure patients exhibit significantly blunted flow-mediated dilatation (FMD) 
responses (Smith et al. 1996), and heart failure patient serum contains reduced levels 
of NO metabolites and cGMP (a biomarker of NO activity), compared to age-matched 
controls (Bhushan et al. 2014). These findings support the view that NO deficiency is 
likely occurring in these patient populations and may be implicated in heart failure 
pathogenesis and disease progression.   
Not only could NO deficiency increase the risk of LVH development indirectly (due to 
reduced vasodilation, contributing to chronically raised BP, but constitutive NO is also 
considered a direct negative-modulator of cardiac hypertrophy. Reduced NO 
bioavailability and endothelial dysfunction has been associated with hypertension in a 
number of animal models (Lockette et al. 1986; Tesfamariam & Halpern 1988), in 
humans with hypertension, as well as patients with LVH and long-term coronary heart 
L-arginine
Figure 2: L-arginine-nitric oxide and nitrate-nitrite-nitric oxide reaction pathways and key biolog ical
effects exerted by resulting NO.
Schematic illustrating the production of NO via the L-arginine-nitric oxide (eNOS) (black) and the nitrate-
nitrite-nitric oxide (blue) pathways. Figure also highlights some key beneficial effects of NO exerted
through sGC-mediated increases in cGMP signalling (---), such as vasodilation, anti-platelet and anti-
proliferative effects. The conversion of NO to NO2- and NO3- by oxidation is also highlighted (red).
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disease (Panza et al. 1990; Panza et al. 1993; Treasure et al. 1993; Schächinger et al. 
2000).  
In addition to this, loss of constitutive NO production has been identified as an 
important modulator of cardiac hypertrophy directly. For example, in animal models 
chronic inhibition of endogenous NO synthesis using the NO synthase inhibitor L-
nitroarginine methyl ester (L-NAME) has been associated with increased myocardial 
fibrosis in rats without any other stimulus (Pechánová et al. 1999),  also leading to 
enhanced cardiac fibrosis development in rats co-dosed with a low dose ANGII regimen, 
which alone did not cause cardiac fibrosis (Hou et al. 1995).  
Both nNOS and eNOS KO mice have also been shown to develop cardiac hypertrophy 
spontaneously, with double KO mice developing yet more severe cardiac hypertrophy 
(McNamara et al. 2003). In eNOS KO mice, an increased cardiac hypertrophic response 
and worse cardiac function compared to wildtype (WT) mice has been reported 
following transverse aortic constriction (TAC) (Ichinose et al. 2004; Buys et al. 2007). 
Although it must be noted that in models where pressure-overload is yet more severe, 
and eNOS uncoupling occurs (where monomeric eNOS begins to produce O2- instead of 
NO), more extreme cardiac hypertrophy/fibrosis and worsening of cardiac function has 
been reported (Takimoto et al. 2005).  
In patients with heart failure, a genetic variant of eNOS, resulting in shortened enzyme 
half-life, is also associated with increased mortality (McNamara et al. 2003). The low-
level expression of NO produced by nNOS and eNOS therefore appears protective in 
cardiac hypertrophy, with significant antihypertrophic effects. It is therefore thought 
that the loss of low-level constitutive NO generation from eNOS in the cardiovascular 
system, as a result of endothelial dysfunction, may result in the loss of a crucial braking 
mechanism of cardiac hypertrophic pathways.  
My PhD hypothesis therefore postulates that providing NO therapeutically, through 
replacement of lost endogenous NO, will prevent/slow development of cardiac 
hypertrophy/heart failure via both blood-pressure dependent and BP-independent 
mechanisms. 
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1.7.2. How can we provide NO therapeutically? 
Traditionally, delivering NO therapeutically (for example in angina, where the aim is to 
treat periods of acute cardiac ischaemia by rapidly dilating coronary blood vessels) has 
been achieved using organic nitrates (such as nitroglycerin (GTN)). Additionally, organic 
nitrates are used in acute decompensated heart failure, when sudden worsening of 
heart failure symptoms occurs (Alzahri et al. 2016). However, due to the development 
of tolerance to NO donors such as GTN (Münzel et al. 2005), and with these donors even 
capable of inducing endothelial dysfunction following prolonged exposure (Gori et al. 
2010), their protective effects are short-lived and chronic treatment for CVD with such 
therapies are not suitable. It has therefore been the focus of numerous research groups 
to develop novel NO donors that are capable of exerting beneficial effects on the 
vasculature in vivo without the development of tolerance. However, even in potentially 
promising compounds, proposed to act via alternative mechanisms to the traditional 
organic nitrates (using cytochrome YP3A4 metabolism as opposed to cytochrome 
P450/XOR/glutathione-S-transferase and/or aldehyde dehydrogenase 2), tolerance has 
still been observed in clinical trials (Knox et al. 2016). Thus, alternative approaches, 
which provide sustained, long-term NO delivery to the vasculature are still highly sought 
after. One such approach that has gained support over the last decade is that of the 
nitrate-nitrite-NO pathway. 
1.7.3. Nitrateà Nitriteà NO 
It has recently been demonstrated that upon provision of dietary inorganic nitrate (NO3-
), both healthy volunteers and hypertensive individuals exhibit increased plasma nitrate, 
nitrite (NO2-) and cGMP levels, with significant decreases in BP (Larsen et al. 2006; Webb 
et al., 2008a; Ghosh et al. 2013; Kapil et al. 2014). 
The efficacy of nitrate in these individuals is explained by the enterosalivary circuit 
(Figure 1.3). Food containing inorganic nitrate, or oral nitrate salt supplementation, 
once consumed and digested makes the nitrate available for absorption across the 
surface of the upper intestine into the circulation. Nitrate then circulates in the blood, 
and whilst a substantial proportion of this is excreted, a significant amount is extracted 
from the blood by the salivary glands (Tannenbaum et al. 1976). This is an active process 
that relies on exchange via the sialin transporter (Qin et al. 2012) and results in a nitrate 
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concentration up to 10x that found in plasma accumulating in the saliva (Lundberg & 
Govoni 2004; Spiegelhalder et al. 1976). When this nitrate-rich saliva is released into the 
oral cavity, facultative bacteria here reduce nitrate to nitrite (Xie et al. 2009), which is 
then swallowed and absorbed across the gut wall into the circulation, increasing plasma 
nitrite levels (Webb, Patel, Loukogeorgakis, Okorie, Aboud, Misra, Rashid, Miall, 
Deanfield, N. Benjamin, Macallister, A. J. Hobbs & Ahluwalia 2008a). Disruption of this 
enterosalivary circuit is sufficient to prevent increases in plasma nitrite ordinarily seen 
following oral inorganic nitrate supplementation, and prevents the beneficial effects on 
BP which would normally be seen (Kapil et al. 2013; Webb, Patel, Loukogeorgakis, 
Okorie, Aboud, Misra, Rashid, Miall, Deanfield, N. Benjamin, Macallister, A. J. Hobbs & 
Ahluwalia 2008a). Following increases in plasma nitrite, endogenous nitrite reductases 
in the circulation, such as Xanthine Oxidoreductase (XOR), reduce this nitrite further to 
produce bioactive NO (H. Li et al. 2001; Lundberg, Weitzberg & Gladwin 2008a; Lundberg 
& Weitzberg 2010a; Modin et al. 2001). NO can then exert its beneficial effects on the 
cardiovascular system. This means of delivering NO has thus far proved to be effective 
in a wide variety of both acute and chronic studies (Gee & Ahluwalia 2016), with no side-
effects reported after up to 17 months of supplementation (Hezel et al. 2015). 
 
Figure 1.3 The enterosalivary circuit. 
Schematic illustrating the critical steps of the enterosalivary circuit, describing how conversion of Nitrate à Nitrite 
à NO occurs following consumption of dietary inorganic nitrate. 
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Figure 3: The enterosalivary circuit  
Schematic illustrating the critical steps of the enterosalivary circuit, describing how conversion of Nitrate à Nitrite à 
Nitric Oxide occurs following consumption of dietary inorganic nitrate. 
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1.7.4. Postulated benefits of Nitrate supplementation in cardiac 
dysfunction 
1.7.4.1. BP reduction 
Whilst some studies in certain patient subpopulations have not shown reductions in BP 
with inorganic nitrate (Bondonno et al. 2014; Bondonno, A. H. Liu, Croft, Ward, Shinde, 
Moodley, Lundberg, Puddey, Woodman & Hodgson 2015a; Gilchrist et al. 2013), it is 
widely accepted that in the majority of studies in healthy individuals and hypertensive 
individuals without further comorbidities, inorganic nitrate significantly reduces BP (Gee 
& Ahluwalia 2016; Siervo et al. 2013). 
It is possible that a reduction in BP as a result of inorganic nitrate treatment could 
potentially reduce the extent of cardiac hypertrophy/dysfunction observed. Anti-
hypertensive medications including RAAS therapeutics and calcium channel blockers 
have both been shown to induce some degree of reverse remodelling in the 
hypertrophic heart (Yui et al. 2010), and as previously discussed, clinical trials 
demonstrate clear benefits of anti-hypertensives in heart failure patients. Thus, it is 
possible that via a similar mechanism the same could be true of inorganic nitrate. 
Although BP reduction in itself is unlikely sufficient to reverse the condition entirely, 
particularly in cases of advanced disease, it may still be capable of reversing remodelling 
to some extent and slowing disease progression. 
1.7.4.2. Reducing cardiac hypertrophy directly 
As previously mentioned, deletion of the eNOS and/or nNOS genes in mice, or 
pharmacological inhibition of NO synthesis, for example using L-NAME, can 
independently lead to development of, or further exacerbate, cardiac hypertrophy, 
fibrosis and worsen cardiac function (Hou et al. 1995; Pechánová et al. 1999; Scherrer-
Crosbie et al. 2001; Barouch et al. 2002; Barouch et al. 2003; Ichinose et al. 2004; 
Dawson et al. 2005; Buys et al. 2007). 
Conversely, genetic overexpression of eNOS specifically in mouse cardiomyocytes 
improves post-MI survival, improves cardiac output and fractional shortening, and limits 
ventricular remodelling (Janssens et al. 2004).  
In vitro studies in neonatal rat cardiomyocytes, have shown that exogenous treatment 
with NO via s-nitroso-N-acetyl-D,L-penacillamine (SNAP) is capable of inhibiting 
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noradrenaline-induced hypertrophy; an effect mediated by cGMP signalling (Calderone 
et al. 1998). Since these observations there have been a variety of studies indicating that 
increased cGMP signalling is capable of reducing cardiac hypertrophy and remodelling 
(Hammond & Balligand 2012). The NO donor spermine NONOate (SNO), when applied 
to cardiomyocytes isolated from C57Bl6 WT mice, was also found to have a negative 
ionotropic effect when applied in addition to isoprenaline. However this effect was not 
seen in cells isolated from sGC α1 KO mice, further supporting that sGC signalling is likely 
an important mediator of NO reducing noradrenaline-induced cardiac hypertrophy 
(Cawley et al. 2011). These effects have so far been supported clinically by recent 
observations in HFrEF patients with sGC activator vericiguat in phase IIb studies. 
Exploratory analyses in this study highlighted a clinically significant reduction in NT-
proBNP in the vericiguat treated patients (Gheorghiade et al. 2015). Such findings were 
not replicated in a similar study in HFpEF patients, however quality of life metrics were 
significantly improved in this patient population (Pieske et al. 2017). Vericiguat Phase III 
trials are now underway in HFrEF patients (the  Vericiguat Global Study in Subjects With 
HFrEF (VICTORIA) study) (Armstrong et al. 2018). 
Such results support the importance of NO as a down-regulator of hypertrophy and 
fibrosis, and both in vitro, in vivo and clinical studies suggest that these beneficial effects 
are likely to be both as a result of direct and indirect signalling mechanisms. Endothelial 
dysfunction, where eNOS fails to produce endogenous NO in the vasculature, is 
therefore likely a key regulator of cardiac hypertrophy, not only by causing an increase 
in BP via reduced vasodilatory responses, but also by direct signalling in the 
myocardium. It is therefore possible that by utilising inorganic nitrate to provide NO 
therapeutically, by impacting these signalling pathways, in addition to reducing BP, this 
could potentially prevent cardiac hypertrophy development/worsening. Inorganic 
nitrate has already been shown to successfully reduce lung fibrosis in a mouse model of 
pulmonary hypertension (Baliga et al. 2012) and we therefore postulate that it may be 
possible for inorganic nitrate to reduce cardiac fibrosis in a mouse model of cardiac 
dysfunction.  
1.7.4.3. Down-regulation of AT1R 
It has previously been shown that the NO donor SNAP can down-regulate expression of 
AT1 receptors in vascular smooth muscle cells (Ichiki et al. 1998). AT1 receptors are 
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responsible for many of the adverse effects of prolonged ANGII signalling, including 
development of hypertension, oxidative stress and cardiovascular remodelling 
(Dasgupta & Zhang 2011). Not only may this contribute to any potential reduction in BP 
in ANGII-infused mice receiving nitrate supplementation (in addition to the direct 
vasodilatory effect of NO) but it may also be worth considering whether inorganic 
nitrate may also be capable of down-regulating these receptors in these, and other cell 
types. As ANGII causes cardiac hypertrophy development both indirectly (through 
increasing BP via vasoconstriction), and indirectly through ANGII triggering hypertrophic 
pathways in cardiomyocytes (Kurdi & Booz 2011), down-regulation of its receptors 
through NO delivery could potentially reduce the extent of hypertrophy observed in 
cases where increased ANGII signalling is occurring. Whilst ANGII is not considered to be 
the only driver of hypertension, cardiac hypertrophy and heart failure development by 
any means, it’s involvement in concert with inflammatory, hormonal and oxidative 
stress mechanisms is considered to contribute significantly to heart failure 
pathophysiology (Zablocki & Sadoshima 2013). The general success of RAAS 
therapeutics for heart failure, as discussed in section 1.4.3, further highlights the 
importance of pathways involving ANGII in the progression of heart failure, and the 
potential for clinical improvement through pathways which involve reductions in RAAS 
signalling. 
1.7.4.4. Reducing superoxide damage and repurposing of XOR 
As previously mentioned, studies in isolated cardiomyocytes have indicated that by 
reducing oxidative stress using anti-oxidants, hypertrophy of these cells could be 
attenuated (Nakamura et al. 1998). Moreover, in cultured vascular smooth muscle cells 
exposed to ANGII, transfection with antisense p22phox (a crucial component of 
NADH/NADPH oxidase) significantly reduced H2O2 accumulation, and overexpression of 
catalase, as well as superoxide dismutase inhibition reduced the extent of hypertrophy 
observed (Zafari et al. 1998). Whilst translation of the use of antioxidants to the clinic 
has not been straightforward (Myung et al. 2013), it should not be ruled out that 
reducing oxidative stress and accumulating superoxide damage via downstream 
mechanisms, with other specifically targeted treatments, may still be beneficial. In this 
regard, it has been reported that targeting the nitrate-nitrite-NO pathway 
therapeutically may be beneficial in models of renal and cardiovascular disease by 
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reducing the oxidative stress and increasing NO bioavailability (Carlstrom et al. 2011; 
Ling et al. 2018; Peleli et al. 2016; Tripatara et al. 2007). 
In vivo models of chronic heart failure have demonstrated progressive increases in 
myocardial XOR levels, and associated oxidative stress (Amado et al. 2005; Ekelund et 
al. 1999). Accordingly, XOR has been implicated in the superoxide generation in 
cardiovascular pathology (Berry & Hare 2004). The enzyme is extremely complex, 
demonstrating varying activities depending on substrate/binding site, oxidation state 
and availability of terminal electron acceptors (for a comprehensive review on XOR in 
pathology see (Battelli et al. 2014)).  
Figure 1.4 Biochemistry and electron flux in a single XOR monomer. 
Schematic illustrating potential flows of electrons (e-), shown by arrows, during purine catabolism in an XOR 
monomer, with the FAD subunit in either XO or XDH form. As XO, the reduced FAD site reacts with molecular oxygen 
to form superoxide  (O2-) or hydrogen peroxide (H2O2), depending on whether FADH or FADH2 are utilised respectively. 
As XDH the reduced FAD site reacts with NAD+ to form NADH. Key subunits within the XOR monomer include: the 
molybdenum binding site, two iron sulphur units (Fe-S) and a single FAD binding site. Binding at the molybdenum site 
can be inhibited using Mo-directed inhibitors allopurinol and febuxostat (as shown in the diagram), and binding at 
the FAD site inhibited using FAD-directed inhibitor diphenyleneiodonium (DPI). 
It has been understood for some time that the molybdenum-binding subunit of XOR is 
responsible for catalysing oxidation of hypoxanthine to xanthine, and xanthine to uric 
acid. It is also known that XOR exists in two interconvertible states - XDH (the reduced 
form of the enzyme) and XO (the oxidised form). The principal form present under 
physiological conditions in vivo is XDH, but this can be converted to XO by either 
sulfhydryl oxidation (reversible) or proteolysis (irreversible) (Stirpe & Corte 1969; Enroth 
et al. 2000). The importance of this oxidation state is critical following the hydroxylation 
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Figure 4: Biochemistry and electron flux in a single XORmonomer
Schematic illustrating potential flows of electrons (e-), shown by arrows, during purine catabolism in an XOR monomer, with the FAD
subunit in either XO or XDH form. As XO, the reduced FAD site reacts with molecular oxygen to form superoxide (O2-) or hydrogen peroxide
(H2O2), dep nding on whether FADH or FADH2 are utilised respectively. As XDH the r duced FAD site reacts with NAD+ to form NADH. Key
subunits within the XOR monomer in lude: t e molybdenum binding site, two iron sulphur units (F -S) and an FAD bind g site. Binding at
the molybdenum site can be inhibited using Mo-directed inhibitors allopurinol and febuxostat (as shown in the diagram), and binding at
the FAD site inhibited using FAD-directed inhibitor diphenyleneiodonium (DPI).
Allopurinol/Febuxostat
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of purines at the molybdenum site as, regardless of oxidation state, electrons are 
generated here and go on to be used at the FAD site. However, depending on the 
oxidation state of the FAD site, the resulting products will differ. XDH typically uses NAD+ 
as its terminal electron acceptor (and molecular oxygen only in times of NAD+ 
deficiency). However, XO utilizes only oxygen as a terminal acceptor, resulting in 
substantial superoxide formation (Hille & Massey 1981), contributing to the 
accumulated oxidative stress present in pathological conditions such as heart failure 
(Tsutsui et al. 2011). The electron flux in XOR and reactions of XO and XDH are 
summarised in Figure 1.4.  
Particularly importantly for this study, XO has also been known for some time to catalyse 
the reduction of nitrite à NO  (Millar et al. 1998; Zhang et al. 1998; Godber et al. 2000; 
H. Li et al. 2001) and does so optimally in the presence of reducing substrates NADH 
and/or xanthine. Under hypoxia and acidosis however, the capacity of XO to reduce 
nitrite is further increased, which is thought to help explain the success of nitrite infusion 
in ischaemia reperfusion (IR) injury (Webb et al. 2004; D. A. Jones et al. 2015). Nitrite 
reduction to NO can be inhibited using allopurinol (molybdenum-directed inhibitor) or 
DPI (FAD-directed inhibitor). It is therefore thought that NADH acts as an electron donor 
at the FAD site, whilst nitrite binds to the molybdenum site where it is reduced, releasing 
NO (Zhang et al. 1997). The functional importance of the nitrite reductase capacity of 
XOR was first demonstrated in a study by Webb et al., (2004) where sodium nitrite 
perfusion reduced infarct size following IR injury in the rat heart in ex vivo Langendorff 
heart preparation. This effect was dependent on XOR activity, and importantly 
suggested that both xanthine and NADH can facilitate nitrite reduction. Also, in a study 
investigating the effects of nitrite on BP in the spontaneously hypertensive rat (SHR) 
model, significant reductions in BP were observed with dietary nitrite supplementation. 
Importantly, this effect was also prevented by the addition of XOR inhibitor allopurinol, 
highlighting the importance of this enzyme in these beneficial effects of nitrite (Ghosh 
et al. 2013). Interestingly, in these studies, this activity of XOR was evident under 
physiological conditions i.e. normoxia and neutral pH. The authors suggest that the 
increased XOR expression and activity in hypertension increased the role of XOR in its 
biological activity in this setting. 
With XOR’s known capacity to act as a nitrite reductase, in the presence of high 
 36 
concentrations of nitrite, it may be possible to re-direct enzyme activity towards 
favourable nitrite reduction and away from generating harmful superoxide. It has 
therefore been postulated that by providing abundant nitrite (via diet as inorganic 
nitrate or nitrate salt supplementation), the beneficial effects on the cardiovascular 
system may be two-fold. Not only could the resulting NO be of benefit in terms of 
encouraging blood vessel dilation and reducing hypertrophy, smooth muscle cell 
proliferation, platelet reactivity, and inflammatory cell activation/recruitment, but with 
nitrite acting as a substrate for XO, the ability of XOR to generate superoxide may also 
be reduced due to a ‘repurposing’ of the enzyme (discussed in (Khambata et al. 2015)). 
The reduction of nitrite to NO and ‘repurposing’ of XOR are summarised in Figure 1.5. 
Figure 1.5 Nitrite reduction to NO – biochemistry, electron transfer and repurposing or XOR. 
Schematic illustrating the reduction of nitrite (NO2-) to NO by XOR, occurring optimally in the presence of NADH as 
the reducing substrate and in hypoxia. Electrons (e-) during nitrite reduction are shown to flow (green) from NADH at 
the FAD site through iron-sulphur subunits (Fe-S) to nitrite at the molybdenum site. In essence this process is the 
opposite to that which occurs during purine catabolism, where electrons flow (red) from hypoxanthine/xanthine at 
the molybdenum subunit to O2 or NAD+ at the FAD site. By utilising the nitrite reductase pathway it has been 
postulated that with high concentrations of nitrite present, a ‘repurposing’ of the enzyme could potentially occur, 
resulting in reduced superoxide formation, at the same time as increasing NO release (i.e. with electron transfer 
following the direction of the green arrows instead of red). 
1.7.4.5. Improving exercise and muscle performance and cardiac 
contractility 
Recently, significant evidence has been generated supporting the view that inorganic 
nitrate supplementation exerts beneficial effects on aerobic exercise endurance in heart 
failure. Exercise endurance in patients with HFpEF was increased by ≈24% following 6.1 
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Figure 5: Nitrite reduction to nitric oxide – biochemistry, electron transfer and repurposing or XOR
Schematic illustrating the reduction of nitrite (NO2-) to nitric oxide (NO) by XOR, occurring optimally in the presence of NADH as the
reducing substrate and in hypoxia. Electrons (e-) during nitrite reduction are shown to flow (green) from NADH at the FAD site through
iron-sulphur subunits (Fe-S) to nitrite at the molybdenum site. In essence this pr cess is the opposite to that which occurs during purin
catabolism,where electrons flow (red) from hypoxanthine/xanthine at the molybdenum subunit to O2 or NAD+ at the FAD site. By utilising
the nitrite reductase pathway it has been postulated that with high concentrations of nitrite present, a ‘repurposing’ of the enzyme could
potentially occur, resulting in reduced superoxide formation, at the same time as increasing NO release (i.e. with electron transfer
following the direction of the greenarrows instead of the red).
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mmol/day KNO3 supplementation in the form of beetroot juice (compared to patients 
receiving placebo control juice). The same effect, however, was not seen following a 
single 6.1 mmol KNO3 dose, suggesting that beneficial effects require a longer-term 
dosing regimen (Eggebeen et al. 2016). Exercise endurance was also improved in a 
similar study where HFpEF patients received 6 mmol KNO3 supplementation three times 
daily and in addition to observing improvements in exercise in endurance, quality of life 
scores for patients were also improved (Zamani et al. 2017).  
Zamani et al., (2015) deduced that improvements in HFpEF patient exercise 
performance induced by dietary nitrate likely do not occur as a result of increased O2 
uptake, but are due to improved exercise-induced vasodilation, cardiac output reserve, 
diastolic function and limited remodelling (as suggested by reduction in arterial wave 
reflections) (Zamani et al. 2015). These successes in treating HFpEF patients, however, 
have not been so clearly demonstrated in HFrEF. In a study by Hirai et al., (2017) nitrate 
supplementation failed to improve exercise tolerance assessed by low and high intensity 
cycle testing in patients with HFrEF (Hirai et al. 2017). However, in a different study, 
increased knee extensor power was observed in HFrEF patients following 11.2 mmol 
KNO3 supplementation (Coggan et al. 2015)  
A study investigating the effects of nitrate supplementation on mouse skeletal muscle 
found significantly higher concentrations of Ca2+ released following electrical 
stimulation in fast twitch muscle fibres in mice fed 1 mM NaNO3. This increase in Ca2+ 
translated to a significant increase in contractile force, with contraction rate being ≈35% 
faster in the nitrate fed mice. Also observed were increases in Ca2+ handling proteins as 
measured by western blot (Hernández et al. 2012). Further research has mirrored these 
findings in mouse cardiac muscle, with increased left ventricle pressure measured in 
Langendorff experiments and increased in vitro contractility of cardiomyocytes 
following NaNO3 dietary supplementation, as well as increases in free Ca2+ and Ca2+ 
handling protein expression (Pironti et al. 2016). In vitro experiments using mouse 
cardiomyocytes have also shown NO increases contractility, with local NO signalling 
from nNOS implicated in cardiomyocyte mechanotransduction (Jian et al. 2014) 
indicating how on a subcellular level, NO may have potential to impact cardiomyocyte 
contractility, therefore having an effect on cardiac performance as a whole.  
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Inorganic nitrate has also been found to have beneficial effects on mitochondrial energy 
efficiency, with mouse skeletal muscle mitochondria exhibiting improved oxidative 
phosphorylation following dietary nitrate supplementation (Larsen et al. 2011) and 
improved haemodynamics have been observed in healthy rats and those with MI-
induced heart failure (Ferguson et al. 2013; Ferguson et al. 2016). 
Such findings, help explain some of the benefits on muscle performance observed 
following nitrate supplementation, but further understanding is required to elucidate 
why these changes are sufficient to improve cardiac output and exercise performance 
in HFpEF but not HFrEF. Ultimately, further investigation into mitochondrial, muscle and 
haematological dynamics will be required to further understand the effects of NO on 
cardiac muscle structure and function in health, and also in these two similar, yet 
disparate diseases.   
1.7.5. Particular hope for HFpEF? 
However, particularly with regards to HFpEF, it can be postulated that inorganic 
nitrate/NO delivery appears to have huge potential as an effective therapeutic. This may 
be by improving cardiac remodelling via direct pathways such as those discussed above 
(e.g. AT1R expression etc), or by improving exercise capacity, muscular performance and 
haemodynamics, and perhaps in turn encouraging remodelling indirectly. The relative 
contributions of each of these mechanisms to the clinical improvements observed in 
patients remains to be deduced. During my PhD studies we carried out BP-dependent 
and -independent models of cardiac dysfunction, to address some of these issues. 
 Mouse models of cardiac dysfunction 
There are multiple animal models of cardiac dysfunction which we could have utilised 
to investigate pre-clinical potential of inorganic nitrate as a treatment in heart failure 
(Houser et al. 2012). Mouse models are often popular due to the ever-increasing 
number of genetically modified strains available. It is for this reason that we primarily 
focus on mouse models in our lab – as proteins of interest which might identified as a 
result of a study have the potential to have genetically modified mouse variants 
generated (or are already widely available). Comparable studies can then we carried out 
in future genetically modified mouse models. The most popular mouse models of 
cardiac dysfunction are described below. 
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1.8.1. Pressure overload of the heart using surgical banding  
Surgical banding of the abdominal, ascending or transverse aorta is a frequently used 
model for cardiac dysfunction. This model is considered to most closely represent the 
clinical features of cardiac dysfunction caused by aortic stenosis (AS) in humans and 
clear benefits of this model include the ability to use this in both small and large animals. 
In large animals onset can be developed to be gradual, and more representative of the 
human condition (Tagawa et al. 1998; Ye et al. 2001). However, in small animals (rats 
and mice) trans-aortic constriction (TAC) causes an abrupt increase in LV afterload and 
high incidence of post-operative mortality (Sakata et al. 1998). This makes the mouse 
model less similar to the clinical manifestation of AS, and thus whilst a popular model, 
is by no means an ideal comparison to the human condition. 
1.8.2. Coronary artery ligation 
Another popular surgical method used for inducing cardiac dysfunction in mice is 
coronary artery ligation. Dilated cardiomyopathy in particular can be modelled in 
animals using ischaemic injury induced by surgical coronary artery ligation (Pfeffer et al. 
1979; Prabhu et al. 2000). The coronary artery is tied either temporarily or permanently, 
and the degree of LV remodelling and dysfunction in this model are directly proportional 
to the infarct size (Fletcher et al. 1981). With this in mind, this model takes time to 
perfect in order to get equivalent dysfunction in different treatment/control groups.  
1.8.3. Osmotic minipump infusion of drugs 
Osmotic minipumps are a particularly effective way to deliver consistent drug doses over 
medium to long term in small animals. 
1.8.3.1. ANGII model of BP-dependent cardiac dysfunction 
ANGII plays a major role in regulating BP and fluid balance in the body. ANGII is a peptide 
produced by enzymatic cleavage of angiotensinogen à ANGI à ANGII (see Figure 1.1). 
Some of the known effects of ANGII on the cardiovascular system include 
vasoconstriction when bound to AT1 receptors, resulting in increased BP as well as 
inducing smooth muscle cell proliferation (reviewed extensively in (de Gasparo et al. 
2000)). As well as the RAAS being implicated in BP control and fluid homeostasis, the 
local RAAS of the heart is also known to be activated during times of hemodynamic 
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stress, for example during pressure overload (Sadoshima et al. 1993; Lijnen & Petrov 
1999). 
1.8.3.1.1. Previous studies using ANGII infusion 
ANGII has been used for some time as a mouse model of cardiac dysfunction. In 
previously reported studies, doses of between 1.4 and 2.8 mg/kg/day of ANGII have 
been shown to rapidly and significantly increase BP in mice, raising systolic BP from 
approximately 115 mmHg to 170 mmHg (Francois et al. 2004; Kawano et al. 2005; 
Crowley et al. 2006). Doses between 1.5 and 2.8 mg/kg/day have also been shown to 
induce cardiac hypertrophy and remodelling, measured using echocardiography, 
histology, heart weight:body weight ratios and molecular markers of hypertrophy 
(Kawano et al. 2005; Crowley et al. 2006; Zhong et al. 2010; Becher et al. 2012; Mori et 
al. 2012). 
Such studies use osmotic minipumps to chronically deliver ANGII for between 3 and 4 
weeks by osmotic infusion. Therefore, for my PhD I have used a dose of 2 mg/kg/day 
ANGII to be infused by Alzet® osmotic minipumps (Durect Corporation, USA) for 3 weeks. 
1.8.3.1.2. ANGII-induced mechanisms of cardiac 
dysfunction 
The majority of ANGII-induced cardiac hypertrophy is considered to occur through BP-
dependent mechanisms. ANGII increases BP through a number of pathways, including 
direct vasoconstriction, stimulating the sympathetic nervous system and increasing 
aldosterone synthesis (which helps control ion and water uptake in the kidneys) (Kim & 
Iwao 2000). In addition to this, ANGII induces smooth muscle cell growth, migration and 
proliferation, as well as increases collagen (type I and II) synthesis in fibroblasts. These 
effects can therefore lead to thickening and stiffening of blood vessel walls (Fyhrquist et 
al. 1995).  
The ANGII model of cardiac dysfunction is therefore thought to reflect, fairly accurately, 
the development of hypertension-induced cardiac hypertrophy/heart failure in humans, 
where the heart initially adapts to increased load by increasing heart muscle mass, 
increasing wall thickness of the LV in order to maintain healthy cardiac function and 
minimize wall stress (often referred to as compensated growth). However, if BP (and 
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therefore cardiovascular load and wall stress) remain increased, cardiac hypertrophy is 
likely to become accompanied by heart dilation, increased interstitial fibrosis and 
myocyte death (Levy et al. 1990; Weber et al. 1993; Cohn et al. 1997; Bernardo et al. 
2010). This ultimately results in stiffening of the heart walls, reducing contractile 
function and LV ejection fraction, causing cardiac dysfunction and an increased risk of 
heart failure, arrhythmias and sudden death (Levy et al. 1987; Levy et al. 1990; Drazner 
et al. 2004; de Simone et al. 2008). 
However, it is also worth noting that direct ANGII signalling in the heart can cause 
increased synthesis of collagen in fibroblasts, as well as enhancing cardiomyocyte 
growth and proliferation in vitro (McEwan et al. 1998) It is, therefore, likely that ANGII 
may also encourage pathological cardiac hypertrophy by enhancing fibrosis of the 
myocardium directly. Thus, BP independent mechanisms of cardiac hypertrophy caused 
by ANGII are also likely to occur to some degree in this model.  
As previously mentioned, inhibition of NO synthesis (and therefore increasing BP) using 
L-NAME leads to exacerbated cardiac fibrosis in rats concomitantly receiving low dose 
ANGII, which alone was insufficient to cause increases in BP or cardiac fibrosis (Hou et 
al. 1995). Myocyte hypertrophy and inflammatory cell recruitment in ANGII+L-NAME 
treated mice was found to not be entirely dependent on BP, as these effects were not 
observed in rats given only L-NAME, despite exhibiting a similar increase in BP. Thus, 
suggesting that the additional ANGII stimulus had an effect on cardiovascular signalling 
and remodelling other than by increasing BP. 
One study by Mazzolai et al., 1998 found that normotensive transgenic mice over-
expressing ANGII specifically in the cardiomyocytes showed some degree of mild 
hypertrophy (categorized by enlarged myocytes) at 20 weeks of age. However, the 
degree of hypertrophy was far greater, and observed in mice as young as 8 weeks old 
when mice were hypertensive. Also, in a study by Xu et al., (2010), using similar 
transgenic mice treated with deoxycorticosterone acetate salt to suppress the systemic 
RAS, when hemodynamic conditions remained unchanged, ANGII expressed in cardiac 
tissue failed to change heart size or cardiac output. However, in hypertensive mice, the 
cardiac expression of ANGII significantly enhanced inflammation, oxidative stress and 
cell death.  
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From these studies, it therefore appears that ANGII has a direct effect on the heart and 
that this can contribute to the extent of cardiac hypertrophy. However, this appears to 
occur primarily in the presence of a stimulus such as increased BP and hemodynamic 
stress (Mazzolai et al. 1998; J. Xu et al. 2010). Therefore, the use of ANGII infusion seems 
an appropriate model of BP-induced hypertrophy for the purpose of this study. 
1.8.3.2. Isoprenaline model of cardiac dysfunction 
Isoprenaline, also known as isoproteranol hydrochloride, is a synthetic, non-selective β-
adrenergic agonist, which acts in a similar way to endogenous signalling hormone 
epinephrine (adrenaline). The chemical structure of isoprenaline is shown in Figure 1.6. 
 
 
 
 
 
Figure 1.6 Schematic illustrating the chemical structure of isoprenaline hydrochloride. 
Figure 1.7 illustrates the signalling cascade induced by isoprenaline binding to β1-
adrenergic receptors. Isoprenaline binding to β1 adrenoreceptors induces positive 
chronotropic, dromotropic and ionotropic effects. In other words, isoprenaline 
increases cardiac output as a result of increased heart rate, increased electrical impulse 
conduction from the AV node, and increased strength of cardiac contractions as well as 
increasing rate of cardiomyocyte relaxation. For these reasons, isoprenaline has been 
used in the clinic to treat conditions such as bradycardia (slow heart rate) and heart 
block (irregular heartbeat). In addition to this, β1 binding by isoprenaline reduces 
peripheral vascular resistance (afterload) (Granata et al. 1970) and increases the return 
of blood to the heart (preload).  
It has been discovered that in mice, due to the extra strain put on the heart, chronic 
doses of isoprenaline (15-60 mg/kg/day for 1-2 weeks) result in increased heart size and 
weight:body weight ratios, increased ventricle wall thickening (as measured by 
echocardiography), decreased ejection fraction, fractional shortening and BP and 
increased cardiac fibrosis (Friddle et al. 2000; Bueno et al. 2002; Oudit 2003; Nakayama 
et al. 2009). 
Figure 6: Schematic illustrating the chemical
structure of isoprenaline hydrochloride
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As a result of these effects, chronic isoprenaline dosing is therefore a commonly used 
model of BP-independent cardiac dysfunction. For my BP-independent model of cardiac 
dysfunction, I therefore used a dose of 15 mg/kg/day isoprenaline hydrochloride, 
infused by Alzet® osmotic minipumps (Durect Corporation, USA) for 3 weeks.  
Figure 1.7 β1 adrenergic signaling cascade mediating changes in cardiac contractility by isoprenaline. 
Schematic illustrating the signaling cascade initiated by β1-adrenergic agonist (e.g. isoprenaline (Iso) and 
norepinephrine (NE)) binding to β1-adrenergic receptors (β1-AR), resulting in changes in cardiac contractility. β-
adrenergic agonist binding to β1-AR GPCR results in the activation of stimulatory G-proteins, which stimulate adenylyl 
cyclase (AC) generation of 3’,5’-cyclic monophosphate (cAMP) from adenosine triphosphate (ATP). Increased levels 
of cAMP can alter activity of HCN voltage-gated K+ channels (known as ‘pacemaker channels’) as well as  increasing 
the activity of cAMP-dependent protein kinase A (PKA) which mediates a series of phosphorylation events in a variety 
of intracellular substrates including L-type Ca2+ channels (LTCC), phospholemman (PLM), sarcoplasmic 
phospholamnan (PLB) and ryanodine receptors (RyR) and sarcomeric proteins troponin I (TnI) and cardiac myosin-
binding protein C (MyBPC). Such phosphorylation events each contribute to the increased contractility of cardiac 
muscle and enhanced repolarization. PKA also phosphorylates β-adrenergic receptor kinase (βARK) which in turn 
phosphorylates β1-AR, acting as a feedback signaling mechanism. Adapted from Triposkiadis et al., 2009 and Feldman 
et al., 2005. 
 Experimental aims 
For my PhD studies I have used two experimental mouse models to investigate the 
effects of nitrate supplementation on cardiac dysfunction – a BP-dependent model and 
a BP-independent model. In both of these models I investigated whether dietary 
inorganic nitrate has any effect on cardiac performance and remodelling by comparing 
heart weight:body weight ratios, cardiac histology and echocardiographic 
measurements such as LV wall thickness and ejection fraction. For the BP-dependent 
and BP-independent models of cardiac dysfunction I used osmotic minipump infusions 
of ANGII and isoprenaline respectively. This allowed me to maintain consistency in the 
methodology used, with the only variable altered being the drug administered. 
Figure 7: β1 adren rgic signaling casc de medi ting change in cardiac contractility by
isoprenaline
Schematic illustrating the signaling cascade initiated by β1-adrenergic agonist (e.g.
isopren line (Iso) and norepinephrine (NE)) bindi g to β1-adrenergic rec ptors (β1-AR),
resulting in chang s i cardiac contractility. β-a renergic agonist binding to β1-AR GPCR
results in the activation of stimulatory G-proteins, which stimulate adenylyl cyclase (AC)
generation of 3’,5’-cyclic monophosphate (cAMP) from adenosine triphosphate (ATP).
Increased levels of cAMP can alter activity of HCN voltag -gated K+ channels (k ow as
‘pacemaker channels’) as well as increasing the activity of cAMP-dependent protein kinase
A (PKA) which mediates a series of phosphorylation events in a variety of intracellular
substrates including L-type Ca2+ channels (LTCC), phospholemman (PLM), sarcoplasmic
phospholamnan (PLB) and ryanodine receptors (RyR) and sarcomeric proteins troponin I
(TnI) and cardiac myosin-binding protein C (MyBPC). Such phosphorylation events each
contribute to the increased contractility of cardiac muscle and enhanced repolarization. PKA
also ph sphorylates β-adr ergic receptor kinase (βARK) which in turn phosph rylates β1-
AR, acting as a feedback signaling mechanism. Adapted from Triposkiadis et al., 2009 and
Feldman et al., 2005.
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Using both a BP-dependent and BP-independent model of cardiac dysfunction enable 
determination of the potential direct cardiac effects of dietary nitrate versus any cardiac 
improvements secondary to BP changes. To further tease apart mechanisms in these 
models I have:  
• Investigated the effects of inorganic nitrate on ANGII-induced increases in BP 
using BP telemetry probes and organ bath pharmacology to assess blood vessel 
reactivity in response to vasorelaxants and vasoconstrictors.  
• Assessed whether nitrate alters cardiac structure and function using 
echocardiography, and cardiac histology - staining for the presence of collagen 
by picrosirius red. 
• Assessed changes in mRNA expression in the heart using RT-PCR to assess 
fibrotic, inflammatory and ANGII signaling pathways. 
• Assessed changes in protein expression using western blot to assess XOR and 
NADPH oxidase pathways. 
• Assessed NO bioactivity by measuring plasma nitrite and nitrate levels (using 
ozone chemiluminescence) and cGMP protein levels following treatment with 
nitrate supplementation versus controls. 
• Assessed changes in oxidative stress markers using lucigenin 
chemiluminescence. 
• Examined the impact of XOR in cardiac dysfunction by using an Xdh KO mouse 
model. 
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2. CHAPTER TWO – Methods 
 C57Bl6 mice: sourcing and husbandry 
Male C57Bl6J mice were sourced from Charles River Laboratories (UK) at 6-7 weeks of 
age and were individually housed upon arrival. Mice were kept in Individually Ventilated 
Cages (IVCs) with food and water available ad libitum throughout studies. Room lighting 
was on a 07:00 – 19:00 GMT schedule and humidity and room temperature monitored 
according to Home Office regulations (maintained at 55±10% and 19-23°C respectively). 
A total of 361 animals were used. All animal experiments were conducted according to 
The Animals (Scientific Procedures) Act 1986.  
Mice were manually randomised to water feeding treatment groups upon arrival to the 
facility. For randomization of individual mice to ANGII or control treatment, this was 
done using http://www.randomization.com random permutation of integers. Due to 
having to maintain reliable water changing schedules, and the fact that some control 
mice had no minipump implanted, blinding to treatment was not possible in all 
situations when carrying out echocardiography or tail cuff protocols. However, during 
data analysis, or ex vivo studies, blinding was ensured so as not to allow bias with 
regards to the more critical stage of analysing results. 
Mice were weighed three times weekly, with food and water weights recorded, allowing 
food and water consumption to be calculated.  
 KNO3 and KCl supplemental feeding 
For inorganic nitrate vs. control water feeding, mice received 15 mM KNO3 (treatment) 
or 15 mM KCl (control) in replacement of their usual drinking water. This treatment 
regimen was based upon previous studies demonstrating this to be an effective method 
for elevating circulating plasma nitrite and nitrate levels compared to control mice 
(Baliga et al. 2012). With C57Bl6 mice drinking approximately 6 ml/day (Bachmanov et 
al. 2002), this equates to consuming approximately 90 μmol of nitrate per day, and 
resulted in a rise of 0.3 μM plasma nitrite in studies by Baliga et al (2012). In clinical 
studies, average increases in plasma nitrite concentrations of 0.3 and 0.5 µM were 
observed following consumption of a single 250 ml dose of beetroot juice, and resulted 
in demonstrable clinical reductions in BP (Kapil et al. 2010; Kapil et al. 2015). Using a 15 
 47 
mM KNO3 dose in mouse drinking water is therefore expected to result in a rise in 
plasma nitrite similar to that reported in human studies where healthy volunteers or 
hypertensive patients ingested 250 ml/day of beetroot juice.  
15 mM KCl was used as a placebo control in this study in order to provide an equimolar 
salt load. Potassium, rather than a sodium salt, was used since this better simulated 
dietary interventions delivering NO3-, which often contain a substantial concentration of 
potassium (Webb et al., 2008a). In addition, since potassium has been suggested to be 
responsible for some of the BP lowering effects of diets rich in fruit and vegetables 
(Whelton et al. 1997; Geleijnse et al. 2003; Haddy et al. 2006), using KCl as a placebo, 
controls for any potential effects we may see from potassium. 
 Measuring nitrate/nitrite concentrations in supplemental drinking 
water 
2.3.1. Tap vs. Milli-Q (MQ) filtered water 
In this study it was essential that the amount of nitrate ingested by the mice was 
carefully controlled. Therefore, the nitrite and nitrate content of MQ filtered water 
(Merck Millipore filtration system, UK) and tap water were compared using ozone 
chemiluminescence (see section 7.19) to ensure the tap water typically used to feed 
mice in the animal unit did not contain excessive levels of nitrite or nitrate which could 
influence experimental results.  
1 ml aliquots of MQ filtered water and tap water were therefore collected across a 
number of different days. These were stored at -20 °C until defrosted and ozone 
chemiluminescence utilised for measurement of nitrite and nitrate concentrations.  
2.3.2. Changes in nitrate/nitrite over time in running tap water 
In order to maintain consistency of 15 mM KNO3 and KCl water formulations, tap water 
was also tested for fluctuations in nitrite and nitrate concentrations after different 
lengths of running time. 1 ml tap water samples were collected at T0 secs, T30 secs, T120 secs, 
T240 secs and T360 secs after turning the tap on. These samples were then stored at -20 °C 
until analysed using ozone chemiluminescence (see section 7.19). 
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2.3.3. 15 mM KNO3 stability 
In order to measure the stability of nitrate in drinking water over time, a 15 mM KNO3 
stock was made up in tap water. 1 ml aliquots were then collected on days 0, 3, 4, 5, 6 
and 7 following formulation. These aliquots were stored at -20 °C until analysed using 
ozone chemiluminescence (see section 7.19).  
2.3.4. Measuring nitrate/nitrite present in other experimental 
components 
For surgical and echocardiographic methods, a variety of gels and creams are used, 
some for a prolonged period of time. There is little evidence to suggest that nitrite 
and/or nitrate can be absorbed through skin. However, it has been suggested in some 
case studies, for example in burns victims, that it may be possible for nitrate to be 
absorbed through the skin (Harris et al. 1979).  
Therefore, in order to ensure mice were not being exposed to high nitrite/nitrate levels 
through these products, these gels/creams were formulated into aqueous solutions so 
that nitrite and nitrate concentrations could be measured using ozone 
chemiluminescence (see section 7.19). Gels/creams tested included Aqua Gel® 
Lubricating Gel (CIVCO Medical Solutions, USA), Redux Crème (Parker Laboratories, Inc., 
USA) and Veet® For Men Hair Removal Gel Cream (Boots, UK). 
For nitrite and nitrate measurements, Aqua Gel was diluted 1:10, Redux Crème 1:100 
and Veet® 1:1000 in MQ filtered water. 
 Implantation of osmotic minipumps for subcutaneous infusion of 
ANGII and isoprenaline 
2.4.1. Minipump filling 
ANGII or Isoprenaline was infused using ALZET® model 1004 osmotic minipumps (Durect 
Corporation, USA), shown in Figure 2.1, releasing 2 mg/kg/day ANGII SC (Sigma Aldrich®, 
UK) or 15 mg/kg/day isoprenaline respectively.   
Mice were weighed on the day of minipump filling and an average mouse weight 
calculated. Weight increase throughout the duration of the study was taken into 
account using mouse weight predictions for C57Bl6J mice of various ages (Table 2.1). 
The estimated average mouse weight at the midpoint of the study was used for 
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calculating the drug concentration required for filling minipumps. 
For example, if the average mouse weight at 
10 weeks old was 25.6 g, and a minipump was 
scheduled to be implanted for 3 weeks, mice 
would be estimated to gain approximately 
2.8 g between 10 weeks and 13 weeks of age 
(JAX, 2019). Therefore, at 11.5 weeks old 
weight can be estimated as approximately 
25.6+1.4 = 27 g. A weight of 27 g would 
therefore be used to calculate the drug 
concentration required for filling the 
minipumps. 
The drug concentration required for filling 
minipumps is determined by the pump 
model, pump flow rate, and average mouse 
weight. A ‘Drug Concentration Calculator’ is 
available on the ALZET® website (ALZET, 2019) and essentially calculates the 
concentration of drug required using the following equations: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟏:	𝑚𝑎𝑠𝑠	𝑓𝑙𝑜𝑤	(µ𝑔/ℎ𝑟)
= 𝑣𝑜𝑙𝑢𝑚𝑒	𝑓𝑙𝑜𝑤	𝑟𝑎𝑡𝑒	(µ𝑙/ℎ𝑟)		𝑥	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	(µ𝑔/µ𝑙) 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟐:	𝑚𝑎𝑠𝑠	𝑓𝑙𝑜𝑤	(µ𝑔/ℎ𝑟) =
D𝑑𝑜𝑠𝑒	(µ𝑔/𝑘𝑔/𝑑𝑎𝑦)	𝑥	𝑚𝑜𝑢𝑠𝑒	𝑤𝑒𝑖𝑔ℎ𝑡	(𝑘𝑔)H
24(ℎ𝑟𝑠)  
For a predicted mouse weight of 27 g: 
𝑚𝑎𝑠𝑠	𝑓𝑙𝑜𝑤	(µ𝑔/ℎ𝑟) =
2000µ𝑔/𝑘𝑔/𝑑𝑎𝑦
24ℎ𝑟𝑠 𝑥	0.027𝑘𝑔 = 2.25µ𝑔/ℎ𝑟	 
With a volume flow rate of 0.12 µl/hr (standard for an ALZET® osmotic minipump, model 
1004) and desired mass flow of 2.25 µg/hr for a 27 g mouse: 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	(µ𝑔/(µ𝑙) =
2.25µ𝑔/ℎ𝑟
0.12µ𝑙/ℎ𝑟 = 18.75	µ𝑔/µ𝑙 
Table 2.1 Typical C57Bl6J mouse weights. 
Table shows average mouse weights from 400 - 500 
mice obtained at weaning from three different barrier 
levels (standard, high, maximum) from two Jackson 
Laboratory facilities (The Jackson Laboratory, 2014). 
Mice were fed a typical laboratory diet (6% fat) and 
were weighed the same day each week until 20 weeks 
of age. No statistically significant difference was 
found between facility or barrier level groups. This 
table was used to help estimate expected weight gain 
by mice at certain ages in our experiments. 
Table 1: Typical mouse weights (The 
Jackson Laboratory, 2014)  
Table shows average mouse weights from 
400 - 500 mice obtained at weaning from 
three different barrier levels (standard, high, 
maximum) from two Jackson Laboratory 
facilities. Mice were fed a typical laboratory 
diet (6% fat) and were weighed the same day 
each week until 20 weeks of a e. No 
statistically significant difference was found 
between facility or barrier level groups. This 
table was used to help estimate expected 
weight gain by mice at certain ages in our 
experiments. 
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A drug concentration of 18.75 µg/µl would therefore need to be formulated. Minipump 
fill volumes were calculated by recording the weight of empty minipumps, then 
recording the weight again after filling. The fill volume was then calculated assuming 
that 1 mg = 1 μl of ANGII drug solution: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟑:	𝐷𝑟𝑢𝑔	𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛	(µ𝑙)
= 𝐹𝑖𝑙𝑙𝑒𝑑	𝑝𝑢𝑚𝑝	𝑤𝑒𝑖𝑔ℎ𝑡	(𝑚𝑔) − 𝐸𝑚𝑝𝑡𝑦	𝑝𝑢𝑚𝑝	𝑤𝑒𝑖𝑔ℎ𝑡	(𝑚𝑔) 
Minipumps were primed at 37°C in 5 ml sterile saline in a 15 ml tube for 48-72 hours. 
Until implantation, and during surgery preparation, minipumps were maintained at this 
temperature in surgical theatre using a heat box set at 37°C. 
Figure 2.1 A cross-sectional view of an ALZET® minipump (Durect Corporation, 2014a) and photographic images of 
an ALZET® model 1004 minipump prior to and after filling. 
Figure illustrating A) A cross-sectional schematic diagram of the internal structures of an ALZET® osmotic minipump, 
including the drug formulation (agent), osmotic layer, semipermeable membrane, impermeable reservoir and the 
flow regulator (Durect Corporation, 2014a), and photographic images showing B) the pump and flow regulator as 
supplied before filling, and C) the scale of an ALZET® model 1004 minipump when filled, prior to implantation. 
2.4.2. Minipump implantation surgery 
Anaesthesia was induced using 5% Isofluorane/0.4 litre min-1 O2 in an induction box and 
maintained using approximately 2.5% Isofluorane/0.4 litre min-1 O2 through a nose cone, 
with the mouse in a prone position. Vetergesic (100 µl of 3 µg/ml SC) was administered 
upon anaesthesia induction to give sufficient post-surgery analgesia.  
A region of hair approximately 2 cm2 was removed from the base of the neck and 
shoulders of the mouse using Veet® For Men Hair Removal Gel Cream (Boots, UK) and 
the area rinsed with sterile saline. The mouse was covered with Press’n Seal® (GLAD®, 
USA) draping and a hole cut in the draping for surgical access before applying Hydrex 
Pink disinfectant (Ecolab, UK) to the exposed skin. Mouse temperature was maintained 
using a rectal thermometer and Physitemp TCAT-2LV thermostatic heating pad 
(Physitemp Instruments Inc., USA). 
Figure 10: A cross-sectional view of an ALZET® minipump (DURECT Corporation, 2014a) and 
photographic images of an ALZET® model 1004 minipump prior to and after filling. 
Figure illustrating A) A cross-sectional schematic diagram of the internal structures of an ALZET® osmotic 
minipump, including the drug formulation (agent), osmotic layer, semipermeable membrane, impermeable 
reservoir and the flow regulator (DURECT Corporation, 2014a), and photographic images showing B) the 
pump and flow regulator as supplied before filling, and C) the scale of an ALZET® model 1004 minipump when 
filled, prior to implantation. 
A)	 B)	 C)	
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A transverse incision of approximately 1 cm was made across the base of the neck and 
a subcutaneous pocket created by blunt dissection. The pocket was lubricated with 
sterile saline before removing the minipump from its 15 ml tube, wiped over with 70% 
IMS and implanted (flow moderator first). The incision was then sutured closed using 4-
0 coated VICRYLTM resorbable sutures (ETHICON*, UK) and 0.5 ml sterile saline (Baxter, 
UK) administered SC before ceasing anaesthesia and recovering the animal in a heated 
cage.  
 BP telemetry  
2.5.1. Telemetry probe implantation 
TA11PA-C10 radiotelemetric probes (Data Sciences International, USA) were surgically 
implanted to allow individual BP recording in freely moving, conscious mice over the 
course of 3-4 weeks. A schematic illustrating the approximate dimensions of a BP probe 
can be seen in Figure 2.2A. Implantation surgery was performed on 9-week old C57Bl6J 
mice under aseptic conditions in accordance with Home Office regulations. 
Prior to implantation, the tips of BP probes were re-gelled and the baseline pressure of 
probes measured using Dataquest A.R.TTM acquisition software (Data Sciences 
International, USA). Probes were sterilised in 2% Gluteraldehyde solution (Fluka 
Analytical, Sigma Aldrich®, UK (diluted 1:25 in MQ filtered water)) for approx. 30 
minutes then rinsed in sterile saline (Baxter, UK) immediately before implantation.  
Anaesthesia of mice was induced using 5% Isoflurane/0.4 litre min-1 O2 and maintained 
using approximately 2.5% Isoflurane/0.4 litre min-1 O2. 100 µl of Vetergesic (3 µg/ml SC) 
was administered to give sufficient post-surgery analgesia and mouse core temperature 
was maintained during surgery using a rectal thermometer and Physitemp TCAT-2LV 
thermostatic heating pad (Physitemp Instruments Inc., USA). 
With the mouse laid vertically (head downwards) in a supine position, fur was removed 
from the neck and upper chest using Veet® For Men Hair Removal Gel Cream (available 
from Boots, UK) and the area rinsed with sterile saline. The surgical site was covered 
with Press’n Seal® (Glad®, USA) draping and a hole cut in the draping for surgical access 
before applying Hydrex Pink disinfectant (Ecolab, UK) to the exposed skin. 
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Figure 2.2 Schematic of a BP telemetry probe and BP telemetry probe implantation surgery. 
Schematic diagram illustrating A) the approximate dimensions of a BP probe and B) the set-up of a mouse during BP 
probe implantation surgery, with mouse laid vertically in a supine position, secured using tape. Anaesthesia was 
maintained during the procedure using 2.5% Isofluorane/0.4 litre min-1 O2 inhaled through a nose cone and 
temperature maintained using a rectal thermometer and Physitemp TCAT-2LV thermostatic heating pad (Physitemp 
Instruments Inc., USA). The probe catheter was inserted into the left carotid artery and held in place by sutures. The 
probe body was implanted subcutaneously, as illustrated, along with the portion of the probe catheter which isn’t 
fed into the carotid artery. 
 
A ventral midline incision was made between the submandibular area and the sternum 
and stretched by blunt dissection to approximately 2 cm wide. The salivary glands were 
separated, and the left carotid artery identified and separated from the vein and the 
vagus nerve. Two lengths of 5-0 SofsilkTM non-resorbable suture (CovidenTM, UK) were 
tied loosely around the artery, and stretched to extend the artery until blood flow 
temporarily ceased. Sterile saline was added to the body cavity and the BP probe 
inserted into a small incision made in the artery. The probe was secured firmly in 
position using a third 5-0 SofsilkTM non-resorbable sutures (CovidenTM, UK). The initial 
sutures, which had been placed to prevent blood flow, were then used to further secure 
the probe in position. The salivary glands could then be placed back into position. 
A subcutaneous pouch was then made for the telemeter body, where the battery could 
lie on the right-hand side of the abdomen, below the ribs. With the telemeter body in 
place, the salivary glands were pulled back together, and the incision closed using 4-0 
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coated VICRYLTM resorbable sutures (Ethicon*, UK). 0.5 ml sterile saline (Baxter, UK) was 
then administered SC before recovering the mouse in a heated cage. 
A schematic illustrating the positioning of the mouse for surgery and the approximate 
positioning of a BP probe subcutaneously can be seen in Figure 2.2B. 
2.5.2. Telemetry recording 
Mice were recovered for 7-10 days post-surgery before recording BP data. After 
recovery, baseline BP readings were taken before osmotic minipumps were implanted. 
Mice were then recovered prior to beginning further BP recordings. To switch on the 
telemetry probe and begin data acquisition, a magnet was held close beneath the cage 
near the belly of the mouse, until a signal and live BP measurement could be observed 
on the computer programme. Each probe comes with a finite battery life. Therefore, 
when recording was complete after a 24-hour recording window, the magnet was used 
to switch off the probe again until the next recording period.  
For one day of BP recording, BP was recorded continuously for 24 hours starting at 13:00 
GMT. Mean arterial BP (MAP), systolic BP (SBP), diastolic BP (DBP), heart rate (HR), pulse 
pressure (PP) and mouse activity were recorded, with data points collected once every 
15 seconds for 2 minutes at 15-minute intervals across a 24-hour period.  
 Tail cuff BP measurement 
In a subset of study mice, tail cuff BP data was collected using a CODA mouse BP set up 
(Kent Scientific Corporation, US). For each time point data were averaged from 4 
consecutive days of sampling. On each of these days, mice were placed in a restrainer 
and left to acclimate in a custom-made heat box (Clinipath Ltd, UK) with an ambient 
temperature of 30 °C for 10 mins prior to beginning recordings. Mice were subjected to 
5 acclimation cycles followed by a further 10 cycles of data acquisition. Average MAP, 
SBP and DBP were calculated to generate a single n for each mouse.  
A priori exclusion criteria were: any individual cycles which had readings of ± 15 mmHg 
from the mouse’s daily average were excluded; If a mouse had a day where the average 
was ± 15 mmHg from that mouse’s average for that time point, then the day was 
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excluded; Any mice whose readings were ± 15 mmHg from the group average at the end 
of the study were excluded. 
 Echocardiography 
Baseline echocardiographic data was obtained using 7 control, untreated C57Bl6J male 
mice aged 12-13 weeks. Data from these mice were compared to that published 
previously to ensure our methods produced data consistent with similar studies. In the 
ANGII pre-treatment and reversal, and isoprenaline pre-treatment studies, 
transthoracic echocardiography was performed using a Vevo 770 imaging system with 
an RMV-707B 30-MHz transducer (FujiFilm VisualSonics Inc., Netherlands). In the Xdh 
KO mouse studies, the Vevo 3100 system was used for measurements of cardiac 
structure and function. For both machines the standard practical protocols remained 
the same, but with the Vevo 3100 we were also able to measure doppler flow of the 
pulmonary artery and aortic arch.  
In both cases, anaesthesia was induced using 5% Isofluorane/0.4 litre min-1 O2 and 
maintained using 1.5 - 2% Isofluorane/0.4 litre min-1 O2. Redux Crème (Parker 
Laboratories, Inc., USA) was placed on the back of each paw and the mouse secured in 
a supine position, on a Vevo mouse-handling platform (FujiFilm VisualSonics Inc., 
Netherlands), with paws taped to electrodes allowing observation of ECG and breathing 
rate. Body temperature was monitored using a rectal probe, and was maintained 
between 36.8 – 37.2°C using a heated stage and a heat lamp when required. A schematic 
illustrating the positioning of the mouse for echocardiography imaging can be seen in 
Figure 2.3.  
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Figure 2.3 Mouse echocardiography set-up, plane of m-mode imaging and example echocardiography trace. 
Schematic diagrams illustrating A) the set-up of a mouse during echocardiography, with the mouse in a supine 
position, secured using tape, with paws positioned on pads measuring ECG and breathing rate and B) the plane of 
echocardiography imaging for m-mode traces (- - -) and C) an example of an m-mode trace recorded from a control 
C57Bl6J mouse. Anaesthesia was maintained during the procedure using 1.5 - 2% Isofluorane/0.4 litre min-1 O2 inhaled 
through a nose cone. Temperature was monitored using a rectal temperature probe. IVS = Intraventricular Septum, 
LVID = Left Ventricule Internal Dimension, LVPW = Left Ventricle Posterior Wall. 
 
Chest fur was removed using Veet® For Men Hair Removal Gel Cream (available from 
Boots, UK) and Aqua Gel® Lubricating Gel (CIVCO Medical Solutions, USA) applied 
liberally to the chest. Three two-dimensional M-mode images were obtained for each 
mouse, from the same short-axis view. These images were then used for taking 
measurements of intraventricular septum (IVS) diameter, left ventricle internal 
dimension (LVID) and left ventricle posterior wall (LVPW) diameter in both systole (s) 
and diastole (d). From these measurements, left ventricle ejection fraction and left 
ventricle fractional shortening were calculated. For each mouse, 6 measurements of 
IVSs, LVIDs, LVPWs, IVSd, LVIDd and LVPWd were taken (blind) from M-mode images 
acquired during echocardiographic imaging. Calculations for ejection fraction (EF) and 
fractional shortening (FS) were made by the Vevo software using the following 
equations: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟒:	𝐸𝐹(%) = Y
(𝑒𝑛𝑑	𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐	𝑣𝑜𝑙𝑢𝑚𝑒 − 𝑒𝑛𝑑	𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐	𝑣𝑜𝑙𝑢𝑚𝑒)
𝑒𝑛𝑑	𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐	𝑣𝑜𝑙𝑢𝑚𝑒 Z 𝑥	100 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟓:	𝐹𝑆(%) = ]
𝐿𝑉𝐼𝐷𝑑 − 𝐿𝑉𝐼𝐷𝑠
𝐿𝑉𝐼𝐷𝑑 a 𝑥	100 
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Six measurements of each parameter were averaged for each mouse to generate a 
single n.  
2.7.1. ANGII and isoprenaline study echocardiography 
Echocardiography was conducted on all mice in the ANGII pre-treatment and reversal 
studies using the Vevo 770 on the day prior to mouse sacrifice and tissue collection. For 
isoprenaline studies, echocardiography was carried out on the Vevo 770 sequentially 
during the study, with data collected at baseline (the day prior to minipump 
implantation) and at weeks 1, 2 and 3 to determine cardiac function. 
2.7.2. Xdh WT (+/+) vs. Het (+/-) echocardiography 
For the Xdh WT (+/+) vs. Het (+/-) study, echocardiographic measurements were carried 
out on the Vevo 3100 machine at 8, 12 and 16 weeks of age. In mice undergoing ANGII 
infusion, imaging at 12 weeks of age was used as baseline data, with 16-week imaging 
carried out following 4 weeks of ANGII infusion. In addition to the aforementioned 
cardiac measurements, it was also possible to collect doppler flow data within the aortic 
arch from these mice. 
 End of study blood collection under terminal anaesthesia 
At the end of our studies, mice had terminal anaesthesia induced using 5% 
Isofluorane/0.4 litre min-1 O2, maintained with 2.5-3% Isofluorane/0.4 litre min-1 O2. 
Sodium citrate (Sigma Aldrich®, UK) was used to create a 3.8% (w/v) solution by 
dissolving 7.6 g sodium citrate in 20 ml MQ filtered water. 80 μl of 3.8% sodium citrate 
was used in a 1 ml syringe for blood collection, acting as an anti-coagulant for blood 
draws. Blood was taken by cardiac puncture, or when hearts were to be used for 
histology, from the thoracic aorta (at the branch point to the left kidney), using a 23G 
needle and 1 ml syringe Note: Most Xdh mice were used for Langendorff and therefore 
blood was not collected from these mice. 
3-Isobutyl-1-methylxanthine (IBMX) was added to a 300 μl aliquot of whole blood 
collected prior to centrifugation in order to prevent phosphodiesterase (PDE) inhibitors 
breaking down cGMP in samples. This would allow measurement of cGMP in frozen 
plasma samples using a cGMP assay. To achieve this, a 100 mM stock of 3-Isobutyl-1-
methylxanthine (Sigma Aldrich®, UK) was made up in dimethyl sulfoxide (Sigma Aldrich®, 
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UK). This stock was then diluted 1:9 in sterile saline to give a 10 mM working solution. 3 
μl of this 10 mM solution was used per 300 μl blood to give a final concentration of 100 
μM IBMX.  
The remaining blood was placed in an empty 1.5 ml tube. Both tubes were centrifuged 
for 5 minutes at 13,000 g at 4°C before IBMX-treated and untreated plasma were 
removed and aliquoted from their respective tubes and stored separately from the cell 
pellets. All plasma and cell pellet samples were snap frozen in liquid nitrogen then stored 
at -80°C. 
 Tissue extraction 
After blood collection the following tissues were dissected: heart, thoracic aorta, aortic 
arch, lungs, liver, kidneys, spleen, tongue, salivary glands and mesentery. All tissues 
were rinsed briefly in phosphate buffered saline (PBS) and placed in 1.5 ml 
microcentrifuge tubes, snap frozen in liquid nitrogen and stored at -80°C.  
 Plasma nitrite and nitrate concentrations determined by ozone 
chemiluminescence 
Ozone chemiluminescence was used to determine the concentration of nitrite and 
nitrate present in samples of plasma. Prior to chemiluminescence measurement of 
plasma, samples were deproteinated using Vivaspin 500 filter columns (Sartorius Stedim 
Biotech, SA). Each column was washed twice with 200 μl MQ filtered water by 
centrifuging at 14,000 g for 15 minutes at room temperature, to remove any possible 
pre-existing nitrite/nitrate contamination. Following this, each plasma sample was 
centrifuged through a Vivaspin 500 filter at 14,000 g for 60 minutes at 4°C. Samples were 
then snap frozen in liquid nitrogen and stored at -80°C until used in an ozone 
chemiluminescence assay. As healthy urine does not contain any protein, defrosted 
urine samples could be used directly in ozone chemiluminescence without being 
filtered. 
2.10.1. Ozone chemiluminescence 
Ozone chemiluminescence is an assay based on the reaction between NO and ozone 
(O3), which generates Nitrogen Dioxide (NO2), some of which exists in an excited state 
with unstable electrons (NO2*). When this excited form returns to ground state, a 
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photon (hv) of light will be emitted, which can be detected and measured quantitatively. 
Equation 6 and Equation 7 describe the chemical reactions which are occurring: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟔:𝑁𝑂 + 𝑂f → 𝑁𝑂h∗ 	+	𝑂h 
The reaction between NO and O3 occurs in the gas phase. 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟕:	𝑁𝑂h∗ → 	𝑁𝑂h + ℎ𝑣 
For nitrite and NOx quantification a Sievers 280i Nitric Oxide Analyzer (Sievers, USA) was 
used. In order to quantify levels of nitrite or NOx in a sample, the metabolite in question 
can be reduced to NO in order to allow direct quantification by the resulting light 
emission following its reaction with O3.  
2.10.2. Nitrite measurements 
A schematic illustrating the equipment setup for nitrite measurement is shown in Figure 
2.4. All nitrite measurements were conducted at room temperature. To allow 
quantification of nitrite present in a sample it must be chemically reduced to NO. The 
purge vessel therefore contains a reducing agent, 1% (w/v) potassium iodide (Sigma 
Aldrich®, UK) in glacial acetic acid (AnalaR Normapur, VWR, UK). 5 ml of reducing agent 
was added to the purge vessel and nitrogen bubbled through for 10 minutes prior to 
starting measurements in order to remove all oxygen. 
A standard curve was generated by preparing a 1 mM sodium nitrite (NaNO2) stock 
solution by dissolving 0.069 g NaNO2 (Sigma Aldrich®, UK) in 1 L of MQ filtered water. 
The nitrite concentration of MQ water was tested first, by injecting 25 μl into the purge 
vessel (a peak should not be seen). Then 0.1 μM, 1 μM and 10 μM dilutions of the 1 mM 
NaNO2 stock were used to construct a calibration curve for nitrite measurements. 20 μl, 
40 μl and 50 μl of each dilution was used in turn, beginning with the smallest volume of 
the most dilute sample. Once a satisfactory calibration curve had been created (see 
Figure 2.5), the concentrations of nitrite in an unknown sample could be tested. For 
filtered plasma samples, 30 μl of each sample was injected into the purge vessel. When 
samples are added to the vessel, the following reaction occurs: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟖:	𝐼l +	𝑁𝑂hl +	2𝐻n → 𝑁𝑂 +
1
2 𝐼h + 𝐻h𝑂 
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Figure 2.4 Schematic of ozone chemiluminescence equipment set-up for nitrite measurements  
Schematic diagram illustrating the set-up of equipment for ozone chemiluminescence nitrite measurements in water 
and filtered plasma samples. 
 
Figure 16: Schematic of ozone chemiluminescence equipment set-up for nitrite 
measurements  
Schematic diagram illustrating the set-up of equipment for ozone chemiluminescence 
nitrite measurements in water and filtered plasma samples. 
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Figure 2.5 A typical nitrite calibration curve in ozone chemiluminescence experiments. 
Figure illustrating A) peaks observed following injections of nitrite standard concentrations (20, 40 and 50 μl injections 
of 0.1 μM, 1 μM and 10 μM NaNO2) and B) the resulting standard concentration curve. 
2.10.3. NOx measurements 
A schematic illustrating equipment setup for NOx measurement is shown in Figure 2.6. 
In order to measure nitrate levels in a sample, the equipment was adjusted and reducing 
agent changed to 0.1 M vanadium (III) chloride (Sigma Aldrich®, UK) in 1 M hydrochloric 
acid (Sigma Aldrich®, UK). This was refluxed in the purge vessel at 95°C under nitrogen. 
These reducing conditions cause nitrate and nitrite to be converted NO (which is 
measured upon reaction with O3). A gas bubbler filled with 1 M sodium hydroxide 
Figure 17: A typical nitrite calibration curve in ozone chemiluminescence experiments
Figure illustrating A) peaks observed following injections of nitrite standard concentrations (20, 40 and 50 μl
injections of 0.1 μM, 1 μM and 10μM NaNO2) and B) the resulting standard concentration curve.
A)
B)
20	μl	of	0.1	μM NaNO2
40	μl	of	0.1	μM NaNO2
50	μl	of	0.1	μM NaNO2
20	μl		of1	μM NaNO2
40	μl	of	1	μM NaNO2
50	μl	of	1	μM NaNO2
20	μl		of	10	μM NaNO2
40	μl	of	10	μM NaNO2
50	μl	of	10	μM NaNO2
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(NaOH) was attached between the purge vessel and the NO analyser to prevent vapour 
damage to the analyser.  
Equation 9 illustrates the reduction of nitrate to NO: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟗:	2𝑁𝑂fl +	3𝑉f +	2𝐻h𝑂 → 2𝑁𝑂 +	3𝑉𝑂hn +	4𝐻n  
The measurement of nitrite and nitrate concentrations in a sample is referred to as 
‘NOx’. To calculate the concentration of specifically nitrate in a sample, it is therefore 
necessary to measure both nitrite and NOx concentrations, then use the following 
equation: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟏𝟎: [𝑁𝑂s] − [𝑁𝑂hl] = [𝑁𝑂fl] 
Figure 2.6 Schematic of ozone chemiluminescence equipment set-up for nitrate measurements. 
Schematic diagram illustrating the set-up of equipment for ozone chemiluminescence nitrate measurements in water 
and filtered plasma samples. 
 
 
 
 
 
 
 
 
 
 
Figure 18: Schematic of ozone chemiluminescence equipment set-up for nitrate measurements  
Schematic diagram illustrating the set-up of equipment for ozone chemiluminescence nitrate measurements in 
water and filtered plasma samples. 
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Figure 2.7 A typical NOx calibration curve in ozone chemiluminescence. 
Figure illustrating A) peaks observed following injections of nitrate standard concentrations (20, 40 and 50 μl 
injections of 1 μM NaNO3, then 20, 40, 50 and 70 μl injections of 10 μM NaNO3 and 10 μl of 100 μM NaNO3) and B) 
the resulting standard concentration curve. 
A 1 mM sodium nitrate (NaNO3) stock solution was prepared by dissolving 0.085 g 
NaNO3 (Sigma Aldrich®, UK) in 1 L of MQ filtered water. For constructing a NOx 
calibration curve, 1 μM, 10 μM and 100 μM dilutions were made. Again, before creating 
a NOx calibration curve, MQ water was tested as a blank sample. Then 20 µl, 40 µl then 
50 µl of 1 µM NaNO3 were added to the purge vessel in turn, followed by 20 µl, 40 µl, 
A)
B)
20 μl  of 1 μM NaNO3
40 μl of 1 μM NaNO3
50 μl of 1 μM NaNO3
20 μl of 10 μM NaNO3
40 μl of 10μM NaNO3
50 μl  of 10 μM NaNO3
10 μl of 100 μM NaNO3
70 μl of 10 μM NaNO3
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50 µl then 70 µl of 10 µM NaNO3. Finally, 10 µl of 100 µM NaNO3 was added. See Figure 
2.7 for a typical nitrate calibration curve trace.  
When measuring NOx in water samples, original samples were diluted 1:1000 (first 1:10, 
then 1:100) for NOx measurements. 10μl of each sample was then injected into the 
purge vessel in turn. Plasma sample dilutions are shown in Table 2.2. When sufficient 
sample volume was available, injections were carried out in duplicate and average 
concentrations calculated to generate a single value.  
Table 2.2 Plasma dilutions for ozone chemiluminescence. 
Table shows dilutions used for mouse plasma and urine samples 
during ozone chemiluminescence measurement of NOX.  
 
 
 
 
 
 cGMP assay 
A cGMP assay was carried out in mouse plasma using a commercially available Biotrak 
cGMP enzyme immunoassay kit (GE Healthcare, UK). This is a competitive 
enzymeimmunoassay, where cCAMP peroxidase competes with cGMP for substrate 
binding to a rabbit anti-cGMP antibody. Therefore, the level of colour developed by 
cCAMP peroxidase as a result of antibody binding, and the subsequent reaction with 
substrate mix, is inversely proportional to the concentration of cGMP present in the 
sample. Thus, the greater the amount of cGMP in the unknown (or standard), the less 
colour generated upon addition of the enzyme substrate. Protocol 2 from the instruction 
manual was used for determination of cGMP concentrations in plasma.  
3 μl of a 10 mM IBMX solution (formulation described in section 2.8) was added to 300 
μl whole blood upon collection prior to spinning down to separate plasma and blood 
pellet. This was to inhibit breakdown of cGMP by phosphodiesterases. The plasma 
aliquot collected was snap frozen and stored -80°C before being used for the cGMP 
assay.  
2.11.1. Reagent preparation 
Treatment Group Dilution
KNO3 Control 1:10
KCl Control n/a
ANGII + KNO3 Pre 1:10
ANGII +KCl Pre n/a
ANGII + KNO3 Rev 1:10
ANGII +KCl Rev n/a
Iso + KNO3 Pre 1:10
Iso + KCl Pre n/a
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Prior to beginning the assay, reagents were equilibrated to room temperature. To 
prepare the assay buffer the bottle contents (10 ml) were transferred to a 500 ml glass 
cylinder and made up to 500 ml with MQ water. To prepare the acetylation standard 2.5 
ml of diluted assay buffer was added to the acetylation standard bottle and mixed until 
completely dissolved. To prepare the antibody 11 ml diluted assay buffer was added to 
the antibody bottle, and the contents gently mixed until dissolved. To prepare the cGMP 
conjugate 11 ml diluted assay buffer was added to the bottle and the contents gently 
mixed until dissolved. To prepare the wash buffer, the contents were transferred to a 
500 ml measuring cylinder and made up to 500 ml with MQ water. 
2.11.2. Preparation of standards and samples 
Standards had to be used within 1 hour of preparation, so were made up accordingly. 9 
microcentrifuge tubes were labelled 2, 4, 8, 16, 32, 64, 128, 256, 512 (referring to the 
fmol amount of cGMP standard which will be present in the final well). 500 µl diluted 
assay buffer was added to all tubes except the 512 fmol tube. 500 µl of standard (10.24 
pmol/ml) was added to the 512 tube, and 500 µl also added to the 256 tube. Serial 
dilutions were then made up by transferring 500 µl of each stock in turn, beginning with 
transferring 500 µl from the 256 tube to the next tube (128). This was repeated for the 
rest of the tubes to give 1:2 dilutions. For the zero standard, only 500 µl diluted assay 
buffer was present. 500 µl of each unknown sample was required for the assay. For each 
plasma sample we used diluted 1:200 assay buffer. 
2.11.3. cGMP assay protocol 
After having prepared the assay reagents at room temperature, the acetylation reagent 
was prepared by mixing 1 volume acetic anhydride with 2 volumes trimethylamine in a 
glass vessel. This was kept covered with parafilm and prepared under a fume hood to 
protect against the fumes. The volume required was determined by the number of 
samples to be run - with 50 µl of acetylation reagent required per standard/unknown. 
50 µl of acetylation reagent was added to each standard and unknown’s microcentrifuge 
tube. When adding the acetylation reagent, the pipette tip was placed in contact with 
the microcentrifuge tube to allow fluid to run down the side. The sample was then 
vortexed immediately after addition. 
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100 µl of antiserum was added into all wells of a 96 well plate (except for the blank and 
NSB well). Starting with the most dilute, 50 µl of all standards and unknowns were 
pipetted into the appropriate wells according to the plate template in Figure 2.8. 150 µl 
of assay buffer was added to non-specific binding (NSB) well. The plate was covered and 
gently mixed, then incubated at 4°C for 2 hours. At this point the conjugate was removed 
from the fridge to equilibrate to room temperature. After the 2-hour incubation step, 
100 µl of diluted conjugate was added into all wells except the blank. The lid was 
replaced, and plate incubated for 60 minutes at 4°C. At this point the wash buffer was 
taken out of the fridge to equilibrate to room temp, and TMB was taken out after 30 
min to equilibrate to room temp.  
The contents of all wells were aspirated and washed 4 times with wash buffer, with the 
plate blotted on tissue to remove any residual buffer. 200 µl of enzyme substrate was 
added into all wells, the plate covered and mixed for 30 min at room temp. 100 µl 1M 
sulphuric acid was added to all wells and the plate read at 450 nm using the TECAN 
Sunrise 96 well plate reader.  
Figure 2.8 Example plate layout for cGMP immunoassay. 
All standards and unknown samples were plated in duplicate (white and blue). NSB = non-specific binding. Samples 
denoted by A = angiotensin study mice and Is = isoprenaline study mice.  
 Heart weight:body weight and left ventricle:body weight ratios 
At the end of the study, mice were weighed before blood/tissue extraction. In cases 
where minipumps and/or probes were removed from the mouse, these were also 
weighed and the weight subtracted from the total mouse weight to give an acurate 
mouse weight. When the heart was removed from the mouse, this was rinsed, blotted 
on tissue paper and weighed. In samples where the heart did not have to remain whole 
for histology or other assessments, the left and right ventricle were also seperated and 
weighed individually. Heart weight: body weight (mg/g) ratio (HW:BW) and/or left 
ventricle: body weight ratio (LV:BW) could then be calculated for each mouse.  
 
 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A Blank Blank 64 64 A115 A115 A112 A112 Is77 Is77 Is76 Is76
B NSB NSB 128 128 A117 A117 A116 A116 Is79 Is79 Is78 Is78
C 0 0 256 256 A119 A119 A118 A118 Is83 Is83 Is86 Is86
D 2 2 512 512 A121 A121 A120 A120 Is91 Is91 Is90 Is90
E 4 4 A107 A107 A123 A123 A122 A122 Is95 Is95 Is92 Is92
F 8 8 A109 A109 A125 A125 A126 A126 Is97 Is97 Is94 Is94
G 16 16 A111 A111 A108 A108 A128 A128 Is99 Is99 Is100 Is100
H 32 32 A113 A113 A110 A110 Is75 Is75 Is101 Is101 Is102 Is102
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 Heart histology 
Picrosirius red PSR staining identifies areas of connective tissue deposition, with 
collagen showing red, and muscle/other tissue elements yellow. At the end of studies 
whole hearts were fixed in 10% Formalin solution (5ml) and embedded in paraffin at 
Blizzard Institute Core Pathology Facility (UK) prior to PSR staining. Hearts were 
randomly assigned to be sectioned in either the transverse or dorsal plane. 4 μm 
sections were cut using a microtome (Thermo Scientific, UK) and heart sections stained 
with PSR; 0.1 g sirius red F3BA ((Direct red 80), Sigma Aldrich, UK) in 100 ml saturated 
aqueous picric acid (Sigma Aldrich, UK). Images were acquired using a NanoZoomer slide 
scanner (Hamamatsu) and viewed using NDP View software. 3 left ventricle, 3 
intraventricular septum and 3 right ventricle fields of view were randomly selected at 
x20 magnification (see Figure 2.9) and PSR staining quantified using manual 
thresholding techniques in ImageJ software. Manual thresholds were set for each image 
at which the red collagen deposition could be clearly distinguished from the yellow 
tissue. The area of red staining, relative to the area of yellow was quantified. An average 
of all 9 fields of view was calculated for each mouse to give a single n value. 
Quantification was conducted blind to treatments.  
Figure 2.9 Fields of view selected at x20 magnification for histology. 
Schematic illustrating examples of the fields of view selected at x20 magnification for histology analysis. Images of 4 
μm thick heart sections stained with Picrosirus Red were acquired using a NanoZoomer slide scanner (Hamamatsu) 
and viewed using NDP View software. 3 left ventricle, 3 intraventricular septum and 3 right ventricle fields of view 
were randomly selected from all samples. Hearts were sectioned either in the A) transverse or B) dorsal plane.  
 Organ bath pharmacology 
At the end of the study, aortae from a subset of study mice were used in organ bath 
assays in order to characterize vasoreactivity in response to various vasodilators and 
vasoconstrictors. Thoracic aortae were dissected from mice and fat and connective 
tissue were carefully removed whilst immersed in Krebs solution. The aorta was cut into 
Left ventricleRight ventricle Left atrium
Left ventricle
Right ventricle
Right atrium
A) Transverse B) Dorsal
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rings ~3 mm long with 3 or 4 rings typically generated from each mouse. Rings were then 
mounted onto the wires of the organ bath, with care taken not to damage the 
endothelium during the mounting process. Organ baths had a total fill volume of 10 ml 
and contained Krebs solution (see section 7.19.1) heated to 37°C and bubbled with 95% 
O2, 5% CO2. A schematic illustrating the organ bath equipment and set-up is shown in 
Figure 2.10. 
Figure 2.10 Thoracic aorta organ bath set-up. 
Schematic diagram illustrating the set-up of a typical organ bath with a 3 mm ring of thoracic aorta mounted on the 
wires. The vessel is mounted in physiological (Krebs) solution, maintained at 37°C by the heated water jacket, and 
bubbled with carbogen. Total organ bath volume is 10 ml. 
 
Post mounting, tension of aortic rings was set at 0.3 g and rings left to equilibrate for 45 
minutes, washed every 15 minutes (with each wash consisting of 2 repeat washes) and 
tension adjusted back to 0.3 g when necessary. Following this equilibration period, rings 
were contracted with 48 mM KCl (adding 120 μl of 4 M KCl to the bath). Once the 
contraction had plateaued, rings were washed once every 10 minutes for 30 minutes 
(with each wash consisting of 2 repeat washes) and the KCl contraction repeated again. 
After maximal contraction had again been reached, rings were washed once every 10 
minutes for 30 minutes (with each wash consisting of 2 repeat washes). 
To test endothelial integrity, rings were pre-contracted with 10-5 M phenylephrine (PE) 
and once a stable level of contraction had been reached, 10-5 M ACh added to induce 
vessel relaxation. When maximal relaxation in response to acetylcholine (ACh) had 
occurred, rings were washed once every 10 minutes for 30 minutes (with each wash 
consisting of 2 repeat washes).  
waste	
Transducer	
Fixed	wire	
Water	out	
Water	in	
Heated	water	jacket	
Physiological	(Krebs)	solu>on,	
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Figure 14: Thoracic aorta organ bath set-up 
Schematic diagram illustrating the set-up of a typical organ bath with a 3 mm ring of thoracic aorta 
mounted on the wires. The vessel is mounted in physiological (Krebs) solution, maintained at 
37°C by the heated water jacket, and bubbled with carbogen. Total organ bath volume is 10 ml. 
Carbogen	gas	bubbler	
 68 
1 of 3 randomly assigned concentration-response curves was then constructed in each 
vessel. A cumulative contraction concentration response curve to PE (10-9 – 3 x 10-5 M), 
or in PE-pre-contracted vessels, a relaxation curve to ACh (10-9 – 3 x 10-5 M) or Spermine 
NO-NOate (SNO) (10-9 – 3 x 10-5 M) was constructed.  
Figure 2.11 Typical organ bath experimental design. 
Schematic illustrating examples of typical organ bath experiments conducted on mouse aortas at the end of this 
study. Experiments comprise two 48 mM KCl contraction responses and a 10-5 M ACh relaxation response followed 
by either A) a cumulative ACh or SNO relaxation curve following precontraction with 10-5 M PE, or B) a cumulative PE 
contractile concentration response curve. Each treatment is interspersed with wash steps (W), with tension returned 
to baseline of 0.3 g at these points.  
 
For PE pre-contractions of both ACh and SNO curves, one of two conditions were used. 
Some rings were pre-contracted with a standard concentration of 10-5 M PE – ensuring 
all aortae received an equal concentration of vasoconstrictor prior to inducing 
relaxation. This condition is likely to more accurately mimic in vivo conditions of aortic 
vessels, where equal levels of vasoconstrictive stimulation would be expected to be 
present in these mice. Alternatively, PE concentration was titrated until vessel tension 
reached EC75 of KCl maximal contraction. This condition allowed comparison of response 
to ACh and SNO when the level of pre-contracted vessel tone is equal in all vessels.  
Figure 2.11 shows a typical example of an organ bath experiment, and a table of volumes 
and drug concentrations used for single concentrations and cumulative concentrations 
can be found in Table 2.3.  
A)
B)
W W W48mM 
KCl
48mM 
KCl
10-5M 
PE
10-5M PE
pre-contraction
ACh or SNO cumulative 
relaxation response
W W W48mM 
KCl
48mM 
KCl
10-5M 
PE
PE cumulative 
contractile response
10-5M 
ACh
10-5M 
ACh
W   W W   W W   W
W   W W   W W   WW   W   W
W   W   W
Te
ns
io
n 
(g
)
Te
ns
io
n 
(g
)
 69 
Table 2.3 Table showing working concentrations (M) and final concentrations in a 10 ml organ bath resulting from 
either a cumulative concentration response (µL) or a single concentration (µL) of these working concentrations. 
 
Data Analysis: 
Any aortic ring from control mice with a relaxation of <50% in response to 10-5 M ACh 
was excluded from data analysis, as this suggests that the endothelium has been 
damaged during dissection/mounting. However, as it is possible that endothelial 
dysfunction may occur in ANGII-infused animals, all rings from ANGII-infused animals 
(regardless of their endothelial response), were used for data analysis.  
PE contraction was represented relative to maximal 48 mM KCl contraction, using the 
following equation: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟏𝟏:		
𝑡𝑒𝑛𝑠𝑖𝑜𝑛	𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 − 𝑏𝑎𝑠𝑎𝑙	𝑡𝑒𝑛𝑠𝑖𝑜𝑛
𝐾𝐶𝑙	𝑐𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 − 𝑏𝑎𝑠𝑎𝑙	𝑡𝑒𝑛𝑠𝑖𝑜𝑛 	𝑥	100 
ACh and SNO relaxation was calculated using the following equation: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟏𝟐:		
𝑝𝑟𝑒𝑐𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑒𝑑	𝑡𝑒𝑛𝑠𝑖𝑜𝑛 − 𝑡𝑒𝑛𝑠𝑖𝑜𝑛	𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑
𝑝𝑟𝑒𝑐𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑒𝑑	𝑡𝑒𝑛𝑠𝑖𝑜𝑛 − 𝑏𝑎𝑠𝑎𝑙	𝑡𝑒𝑛𝑠𝑖𝑜𝑛 	𝑥	100 
Concentration response curves could then be plotted, and EC50 values for each curve 
calculated. Vessel contraction in response to 48 mM KCl and 10-5 M PE, and relaxation 
in response to 10-5 M ACh was also calculated for each ring.  
2.14.1. Krebs and drug formulations 
A working concentration of Krebs Ringer Solution containing: 6.9 g/L sodium chloride, 
0.35 g/L potassium chloride, 0.29 g/L magnesium sulphate, 0.16g potassium dihydrogen 
orthophosphate, 2.1 g/L anhydrous sodium hydrogen carbonate and 2 g/L D-glucose, 
was prepared by diluting a 10x stock (Sigma Aldrich®, UK) 1:10 with MQ filtered water. 
This was bubbled through with carbogen and 2.5 ml/L of 1 M Calcium chloride (CaCl2) 
 
 
Working  
Concentration (M) 
Final concentration 
in bath 
Cumulative concentration 
response (μl) 
Single concentration  
(μl) 
-9 10-6  10-9 (1nM) 10 10 
-8.5 10-6 3 x 10-9 (3nM) 20 30 
-8 10-5 10-8 (10 nM) 7 10 
-7.5 10-5 3 x 10-8 (30 nM) 20 30 
-7 10-4 10-7 (100 nM) 7 10 
-6.5 10-4 3 x 10-7 (300 nM) 20 30 
-6 10-3 10-6 (1 µM) 7 10 
-5.5 10-3 3 x 10-6 (3 µM) 20 30 
-5 10-2 10-5 (10 µM) 7 10 
-4.5 10-2 3 x 10-5 (30 µM) 20 30 
-4 10-1 10-4 (100 µM) 7 10 
-3.5 10-1 3 x 10-4 (300 µM) 20 30 
-3 10-0 10-3 (1 mM) 7 10 
-2.5 10-0 3 x 10-3 (3 mM) 20 30 
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(VWR - AVS Titrinorm, UK) added. Stock solutions of 10-2 M PE, ACh and SNO were made 
freshly by dissolving (R)-(-)-PE hydrochloride (Sigma Aldrich®, UK), ACh chloride (Sigma 
Aldrich®, UK) or SNO (Cayman Chemical Company, USA) in MQ filtered water. These 
were then serially diluted to yield 10-3, 10-4, 10-5 and 10-6 M solutions. 
 Langendorff ex-vivo heart prep 
In some experiments, hearts from mice were excised and mounted used in a 
Langendorff perfusion system. A 5x stock of Krebs was made up in MQ water and 
refrigerated until use. 5x stock contained 34.63g/L NaCl, 1.76g/L KCl, 1.48g/L MgSO4, 
0.82g/L KH2PO4, 10.8g/L Glucose, 10.5g/L NaHCO3, 1.1g/L Sodium Pyruvate. This stock 
was diluted to a 1x solution on day of experiment. 1 x Krebs solution was filtered using 
Whatman microfibre 1µm filter paper (Fischer Scientific, UK) and bubbled with carbogen 
before 1.7 ml/L of CaCl2 (1.7 mM) was added. The pH was measured and maintained at 
pH7.4 ± 0.05 by adjusting carbogen bubbling as required.                                                                      
2.15.1. Langendorff set-up 
The water bath temperature was set so that the Krebs 
in the reservoir system was 37 ± 0.5°C. The heart was 
perfused at a flow rate of 2 ± 0.5 ml/min. Briefly, 100 µL 
of heparin (5000 iu/ml, IP) was given prior to induction 
of anaesthesia with 5% isoflurane, 0.4 ml/min oxygen. 
Anaesthesia was maintained with 3% isoflurane, 0.4 
ml/min oxygen. An incision was made just below the 
sternum, the heart removed and washed in a modified 
ice-cold Krebs solution (see section 2.15). 
In a petri dish, the aortic arch was visualised, and fat, connective tissue and thymus 
trimmed as required. The aorta was isolated and then tied to the perfusion set-up as 
depicted in Figure 2.16.  The apex of the heart was submerged in effluent Krebs. 
Following mounting, the afterload pressure was gradually increased to 100 mmHg to 
achieve a coronary perfusion pressure (CPP) of approximately 75-120 mmHg. Under 
these conditons, the spontaneous heart rate is 300-400 BPM. Hearts not achieving 300 
BPM were excluded. Following a 15 min period of CPP stabilisation the experimental 
protocol was carried out. Concentration response curves were created with 0.01, 0.1 
Perfusion flow
Effluent
Figure 2.12 Schematic illustrating the 
mounting of a mouse heart in the 
Langendorf set up, with perfusion 
flow in through the aorta. 
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and 1 nmol SNP, and 0.1, 1 and 10 nmol bradykinin, as shown in Figure 2.13. This was 
then followed by a 15 min response to 300 µM L-NAME. 
Figure 2.13 Typical Langendorff experimental design. 
Schematic illustrating the time course of a typical Langendorff experiment, with a 15-minute equilibration period, 
concentration responses to sodium nitroprusside (SNP) and bradykinin (BK), and a 15-minute response to L-NAME. 
2.15.2. Drug formulation 
2.15.2.1. Sodium nitroprusside (SNP) 
Approximately 1.5 mg of SNP (Sigma Aldrich, UK) was used to make a 10 mM stock 
solution of SNP in MQ. Serial dilutions were generated to give 0.1 mM, 0.01 mM and 
0.001 mM working concentrations. Injections of 10µL each would result in 1 nmol, 0.1 
nmol and 0.01 nmol respectively.  
2.15.2.2. Bradykinin 
0.5 ml of a 10 mM stock of Bradykinin (Bachem, Switzerland) was made up in Lobind 
tubes (5.3 mg in 0.5 ml). This was divided into 10 µL aliquots in Lobind tubes and stored 
at -20	°C. Frozen stocks were then used to make serial dilutions 1:10 (10µL stock:90µL 
MQ water) to get working concentrations of 1 mM, 0.1 mM and 0.01 mM. Injections of 
10µL into the Langendorff would result in 10, 1 and 0.1 nmol respectively. 
2.15.2.3. L-NAME 
1 ml of 300 mM stock of L-NAME (Sigma Aldrich, UK) was required, so 80.91 mg was 
weighed and dissolved in 1 ml MQ water. This stock was diluted 1:1000 by adding 0.5 
ml stock to 499.5ml Krebs to give a 300 µM solution. This L-NAME solution was then 
perfused through the heart for 15 mins (time from L-NAME actually reaching the heart). 
 Quantitative reverse transcription polymerase chain reaction 
(RT-PCR) 
15 min
0.01 nmol 
SNP 0.1 nmol 
SNP 1 nmol 
SNP
0.1 nmol 
BK 1 nmol 
BK 10 nmol 
BK
300 µM L-NAME 
15 min
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Expression of key molecular markers of cardiac hypertrophy were determined in mouse 
heart tissue using RT-PCR. Genes selected for analysis were: AT1Ra, BNP, CTGF, Col1a, 
Col3, NLRP1, NLRP3, TGFb and XOR. The primer sequences used are shown in Table 2.4.  
Table 2.4 Primer sequences to be used for RT-PCRs on mRNA from mouse hearts. 
Table shows primer sequences used for RT-PCRs investigating mRNA expression of various genes often implicated in 
cardiac hypertrophy/heart failure signaling, including: Angiotensin receptor type 1 (AT1Ra), brain natriuretic peptide 
(BNP), type I collagen (COL1A), type 3 collagen (COL3), connective tissue growth factor (CTGF), NLR Family Pyrin 
Domain Containing 1(NLRP1), NLR Family Pyrin Domain Containing 3 (NLRP3), transforming growth factor β (TGFβ) 
and xanthine oxidoreductase (XDH). 18S ribosomal RNA (18S) was used as an internal control ‘housekeeping gene’. 
BLAST results for each primer pair show the predicted product length and references show papers where these 
sequences have been used previously. 
2.16.1. RNA extraction from heart tissue 
For RNA isolation, whole mouse hearts were each placed in 594 μl of RLT buffer from 
the RNeasy® Fibrous Tissue Minikit (Qiagen Ltd, UK) with 6 μl ß-mercaptoethanol in a 
CK-28 2 ml tube (Bertin Technologies, FR) and homogenised using a Precellys®24 
homogeniser with protocol: 6000 (rate) for 15 seconds (x2) with a 5 second pause. A 
Cryolys® machine was used to maintain sample temperatures of 4 - 10°C during 
homogenisation. All further procedures were conducted at room temperature unless 
otherwise specified.  
Once homogenised, 150 μl of homogenate was added to 590 μl of RNase free water with 
10 μl of proteinase K, and incubated at 55°C for 10 minutes. This sample was then 
centrifuged at 10,000 g for 3 min and supernatant transferred to a new tube. 375 μl of 
100% ethanol was added and pipetted repeatedly to mix. 700 μl of the resulting sample 
was added to an RNeasy® mini column (in a 2 ml collection tube) and centrifuged for 15 
secs at 10,000 g. The flow-through was discarded and process repeated with the 
remainder of the lysate. 350 μl Buffer RW1 was then added to the column and 
centrifuged for 15 secs at 10,000 g and flow-through discarded. The RNeasy® DNase 
stock solution was diluted 1:7 in Buffer RDD, and 80 μl added to each RNeasy® 
membrane, and incubated for 15 min at room temp. 350 μl Buffer RW1 was then added 
to the column and centrifuged for 15 secs at 10,000 g. Flow-through was discarded, then 
Gene FWD 5'-3' RVS 5'-3' BLAST Results Reference
18S AGCCTGCGGCTTAATTTGAC CAACTAAGAACGGCCATGCA 121bp Villar, I.C. et al., 2011
AT1Ra AACAGCTTGGTGGTGATCGTC CATAGCGGTATAGACAGCCCA 135 bp Zhou et al., 2011
BNP TATCTGTCACCGCTGGGAGG TTGTGAGGCCTTGGTCCTTC 151bp Gaspar-Pereira, S. et al., 2012
COL1A TCCTGCTGGTGAGAAAGGAT TCCAGCAATACCCTGAGGTC 103bp Villar, A.V. et al., 2013
COL3 TCGGAACTGCAGAGACCTAAA CCCCAGTTTCCATGTTACAGA 122 bp van Bilsen et al., 2014
CTGF CACAGAGTGGAGCGCCTGTTC GATGCACTTTTTGCCCTTCTTAATG 163 bp van Bilsen et al., 2014
NLRP1 ATGTGGACCCAACCTTCAAA GTACGTGCTCCTGGAAAGGT 108 bp Sand et al., 2018
NLRP3 TGCTCTTCACTGCTATCAAGCCCT ACAAGCCTTTGCTCCAGACCCTAT 85 bp Kaushik et al., 2012
TGFβ1 GGATACCAACTATTGCTTCAGCTCC AGGCTCCAAATATAGGGGCAGGGTC 156bp Sullivan, D.E. et al., 2009
XDH GGTTGTTTCCACTTCCTCCA TTCCAAGGAAACCTCTGTCG 103 bp Yang et al., 2009
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500 μl Buffer RPE added and centrifuged for 15 secs at 10,000 g. Another 500 μl Buffer 
RPE was added and centrifuged for 2 min at 10,000 g. The entire collection tube was 
discarded with flow-through, and the RNeasy® column placed in a new 2 ml tube and 
centrifuged at full speed for 1 min to dry membrane. The collection tube was discarded 
with flow-through and RNeasy® column placed in a new 1.5 ml microcentrifuge tube. 50 
μl RNase-free water was added to the membrane and centrifuged for 1 min at 10,000 g 
to elute RNA. Resulting RNA concentration was measured using a ND-1000 UV/Vis 
NanoDrop spectrophotometer (NanoDrop Technologies, US). This concentration was 
then used to calculate the volume of RNA solution required to give 1 μg of RNA in the 
RNA to cDNA conversion reactions below. The 50 μl RNA eluate was split into two 25 μl 
aliquots for snap freezing and stored at -80°C until used for RNA to cDNA conversion. 
2.16.2. RNA to cDNA conversion 
RNA was converted to cDNA by first making a ‘RT1 mix’ in a 0.2ml Thermo-tube (Thermo 
Scientific, UK), comprising 1 μg RNA, 2 μl random hexamers (Life Technologies, UK, 
Product number: 48190-011), 1 μl 10 mM dNTP mix (Life Technologies, UK Product 
18427-013) and made up to 12 μl total volume with molecular grade H2O (5Prime, UK). 
This mixture was heated to 65°C for 5 minutes in a PTC-225 Peltier Tetrad Thermal Cycler 
(MJ Research, US), then removed and placed on ice. This step allows optimal primer 
annealing. 
‘RT2 mix,’ comprising 4 μl First Strand Buffer, 2 μl 0.1 M Dithiotreitol (DTT), 1 μl Moloney 
Murine Leukaemia Virus (M-MLV) reverse transcriptase (Life Technologies, UK) and 1 μl 
RNase OUT Recombinant Ribonuclease Inhibitor (Life Technologies, UK. Product code: 
10777-019) was then added to each tube. With RT2 mix added, tubes were heated again 
in the PTC-225 Peltier Tetrad Thermal Cycler (MJ Research, US) under the conditions 
shown in Table 2.5. 
Assuming approximate conversion of 1 μg of RNA to 1 μg of cDNA, the resulting cDNA 
was diluted 1:10 in H2O to give 5 ng/μl. This cDNA was then aliquoted and stored at -
80°C until used in RT-PCR assays. 
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Step  Temperature Time 
Extension 25°C 10 min 
Reverse transcription 37°C 50 min 
Enzyme deactivation 70°C 15 min 
Storage  4°C Forever 
Table 2.5 Table illustrating the stages of RNA to cDNA conversion reaction: with step description, temperature 
and length of time used. 
2.16.3. RT-PCR assay 
RT-PCR assays were conducted using SYBR green ROX mix (Thermo Scientific Abgene, 
UK) in 384 well plates, with primers (Table 2.4) sourced from Thermo Fischer Scientific. 
Each RT-PCR well contained 10 μl of SYBR green mix (Thermo Scientific Abgene, UK), 0.2 
μl of 10 μM forward and 0.2 μl of 10 μM reverse primers (Thermo Fisher Scientific, UK), 
and 5.6 μl H2O (5Prime, UK). Cycling conditions are shown in Figure 2.14. An ABI7900 HT 
Realtime PCR System (Applied Biosystems®, Life Technologies, UK), with SDS 2.3 
computer software, was used to run and analyse plates. All samples were run in 
duplicate and gene expression was measured relative to internal control 18S and 
expressed relative to KCl fed controls using ΔΔCT analysis (Livak & Schmittgen 2001). 
Figure 2.14 RT-PCR cycling conditions. 
Schematic illustrating the cycling conditions used for RT-PCR assays in an ABI7900 HT Realtime PCR System (Applied 
Biosystems®, Life Technologies, UK). 
 Pierce® Bicinchoninic Acid (BCA) Protein Assay 
STEP	1	
Ini$al	
Hea$ng	
STEP	2	
Amplifica$on	
x40	Cycles	
STEP	3	
Dissocia$on	
Curve	
60°C	
15	sec	
95°C	
15	min	
95°C	
15	sec	
95°C	
15	sec	
95°C	
15	sec	
60°C	
1	min	
Figure	20:	RT-PCR	cycling	condi@ons	
Schema$c	 illustra$ng	 the	 cycling	 condi$ons	used	 for	RT-PCR	assays	 in	an	ABI7900	HT	Real$me	PCR	
System	 (Applied	 Biosystems®,	 Life	 Technologies,	 UK),	 with	 SDS	 2.3	 computer	 soQware.	 Reporter	 =	
SYBR,	Passive	reference	=	ROX.	
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Protein samples were diluted as required (previously determined to be 1:100 for liver 
protein, and 1:50 for heart) in leftover protease inhibitor cocktail following the 
homogenisation protocol used each particular assay. Specific protease inhibitor 
formulations are described in the appropriate methods sections below. Standard 
protein concentrations were prepared for a standard curve, using bovine serum albumin 
(BSA) provided in the BCA kit (Thermofisher, UK). A typical standard curve is shown in 
Figure 2.15. BSA was diluted in the same protease inhibitor cocktail used for tissue 
homogenisation.  
Figure 2.15 A typical standard curved from a Pierce®BCA protein assay as described in section 2.17. 
The BCA working reagent mix was made according to manufacturer’s instructions and 
in a 96-well plate, 25 μl of each standard or unknown were added to wells in duplicate 
followed by 200 μl of working reagent. The plate was then incubated at 37° C for 30 
minutes and read using a TECAN sunrise plate reader, at a wavelength of 595 nm.  
 Measurement of xanthine oxidase activity 
Xanthine oxidase activity was measured in liver homogenates using a commercially 
available colorimetric XO assay kit (abcam, UK). The assay measures levels of hydrogen 
peroxide (H2O2) produced by XO enzyme following oxidation of xanthine. The H2O2 
produced reacts stoichiometrically with the OxiRed Probe in the reaction mix, 
generating a change in colour intensity, which is detected by a plate reader at 570 nm 
and is proportional to the level of XO activity.  
y = 0.6147x + 0.0163
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Livers were homogenized in CK-28 2 ml tubes using a Cryolys® and Precellys®24 
homogeniser (Bertin Technologies, FR) in a 1:4 ratio (tissue weight (mg): buffer volume 
(μl)) in the XO assay buffer supplied with the kit. This homogenate was then centrifuged 
at 16,000 g for 10 minutes. A standard curve was generated using 0, 0.1, 0.2, 0.3, 0.4 
and 0.5 nmol/well of H2O2 standards. Liver samples were diluted 1:3 (50 μl sample: 150 
μl XO assay buffer) and 50 μl of this added to the plate in triplicate. Two of these sample 
wells were used for the XO reaction, with full reaction buffer added. The remaining 
sample well had negative control buffer added.  
XO reaction buffer consisted of 44 μl assay buffer, 2 μl xanthine substrate mix, 2 μl 
enzyme mix and 2 μl Oxired probe, per standard/unknown. Negative control buffer 
consisted of 46 μl assay buffer, no xanthine substrate mix, 2 μl enzyme mix and 2 μl 
Oxired probe mix, per standard/unknown.  
The colour was measured using a Dynex MRX Revelation plate reader (Dynex 
Technologies Limited, UK) at 25°C, taking readings every 2 minutes for 3 hours at 570 
nm. The point at which XO activity was observed during this period was determined by 
establishing when absorbance readings rose above that of the negative control. A 10-
minute period from this time was then analysed, using the same 10-minute period for 
both treatment groups. A reading at T1 (activity = A1) was used and again at T2 (activity 
= A2) after incubation for 10 minutes. The signal generated by XO activity during this 
period is: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟏𝟑:	ΔA	 = 	A1 − A2 
Background control signal was subtracted from all readings before calculation of ΔA, 
then ΔA used on the standard curve to gain B nmol of H2O2 (generated between T1 and 
T2 by XO). XO activity was then calculated as: 
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏	𝟏𝟒:	𝑋𝑂	𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
(𝐵	𝑥	𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝐹𝑎𝑐𝑡𝑜𝑟)
(𝑇2 − 𝑇1)	𝑥	𝑉 = 𝑛𝑚𝑜𝑙/𝑚𝑖𝑛/𝑚𝑙 = 𝑚𝑈/𝑚𝑙 
One unit of XO is defined as the amount of enzyme that catalyzes the oxidation of 
xanthine, yielding 1 μmol of uric acid and H2O2 per minute at 25°C. 
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A typical standard curve is shown in Figure 2.16. The protein concentration of each 
sample determined using a Pierce® BCA Protein Assay Kit (Thermoscientific, UK) was 
used to correct the assay results retrospectively for variations in protein loading. 
Figure 2.16 A typical standard curve from an XO assay as described in section 2.18. 
 Measurement of nitrite reductase activity 
Nitrite reductase activity was measured in both heart and liver homogenates using gas 
phase chemiluminescence, as described previously (Webb et al. 2004). Heart and liver 
samples were homogenised in a 1:4 and 1:2 ratio respectively (tissue weight (mg): buffer 
volume (μl)) in buffer consisting of PBS with the protease inhibitors listed in Table 2.6. 
Table 2.6 Details of protease inhibitors added to 10 ml PBS buffer for tissue homogenisation for nitrite reductase 
and lucigenin-enhanced chemiluminescence assays. 
Table shows stock concentrations of protease inhibitors formulated and the volume to be added to 10 ml of buffer in 
order to acquire the final concentrations shown. Benzamidine was made up fresh on day of experiment, but other 
protease inhibitors were made as stocks, aliquoted and stored at -20 °C. 
 
The protein concentration of the homogenate was determined using a Pierce® BCA 
Protein Assay Kit (Thermo Fisher Scientific, UK), as described in section 2.17. 
Experiments were performed in a sealed 10-ml glass reaction chamber containing citric 
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Protease Inhibitor Stock Concentration
Volume Added 
to 10 ml PBS
Final 
Concentration
Benzamidine 1mg/ml 10 µl 5.7 μM
Antipain 1mg/ml 10 µl 1.5 μM
Aprotinin 1 mg/ml 10 µl 0.15 μM
Leupeptin 1 mg/ml 20 µl 4.2 μM
Pepstatin A 0.7 mg/ml 10 µl 1.5 μM
AEBSF 100 mg/ml 10 µl 400 μM
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acid/Na₂HPO₄ buffer at pH 7.4 (physiological levels) or pH 6.8 (representing acidosis), 
and KNO2 (10-1000 μM) in a total volume of 1 ml. This solution was bubbled with 
nitrogen gas (100%) via an NO scrubbing air filter (Sievers, USA). Headspace NO 
concentration was measured in parts per billion by continuous sampling using a 280A 
Nitric Oxide Analyzer (Sievers, USA). The impact of biological tissue on NO production 
from NO2- was determined by the addition of heart or liver supernatant (150 and 200 μg 
of protein respectively) and measurement of NO over 2 min, calculating the rate of 
NO production (nmol per g of tissue per s) from the area under the curve.  
 Oxidative stress quantification - lucigenin-enhanced 
chemiluminescence (LECL) 
Bis-N-methylacridinium nitrate (lucigenin) is a cell-permeable chemiluminescent probe, 
which acts specifically to detect superoxide generation. Lucigenin is reduced by 
superoxide initially to become a lucigenin radical cation, which can go on to react with 
a second superoxide to form lucigenindioxetane. This molecule is unstable and as it 
breaks down into two N-methylacridone molecules, one of these contains an excited 
electron and emits a photon of light energy as it returns to ground state (Lee et al. 2012). 
We used a LECL protocol to measure superoxide generation in cardiac tissue collected 
from mice following 3 weeks of either ANGII or isoprenaline infusion, to investigate 
whether dietary nitrate exerted any influence over superoxide generation. 
For the LECL assay, hearts were weighed and snap frozen immediately following 
collection. On the day of the LECL assay, hearts were homogenised in CK-28 2 ml tubes 
using a Cryolys® and Precellys®24 homogeniser (Bertin Technologies, FR) in a 1:5 ratio 
(tissue weight (mg): homogenisation buffer (μl)). The resulting homogenate was 
centrifuged at 4°C for 2 mins at 9000 RCF and supernatant collected for the assay. The 
protein concentration of supernatant was determined using a Pierce® BCA Protein Assay 
Kit (Thermoscientific, UK). 
The LECL assay was performed in a 96-well Cellstar clear, flat-bottomed, tissue culture-
treated plate (Greiner Bio-one, UK) with a final volume of 200 μl per well. All treatment 
groups for one heart sample were run simultaneously (Figure 2.17). 100 μg protein was 
used per well with LECL Assay Buffer volumes calculated to make a well volume of 200 
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μl with experimental substrate(s) xanthine, NADPH or NADH added at 100μM per well, 
followed by 10μM lucigenin.  
The LECL reagents were prepared as follows:  
LECL Homogenization Buffer LECL Homogenization Buffer was made fresh on day 
of experiment, consisting of PBS with 20 mM monobasic potassium phosphate and 1 
mM EGTA. Protease inhibitors were added in the concentrations shown in Table 2.6.  
LECL Assay Buffer LECL Assay Buffer consisted of a 1:1 (10 ml: 10 ml) mix of Buffer 
A and Buffer B with final pH adjusted to 10.4 using HCl. Buffer A consisted of 80ml of 0.1 
M Sodium Carbonate (Na2CO3) and 20 ml of 0.1 M Sodium Bicarbonate (NaHCO3), pH 
11.5. Buffer B consisted of Hank’s Balanced Salt Solution (HBSS - without red phenol 
(Sigma Aldrich®, UK)) with 1 mM HEPES (Sigma Aldrich®, UK) added, pH 7.4.  
Diphenyleneiodonium chloride (DPI) A 20 mM solution of DPI (Sigma Aldrich®, 
UK) was formulated in DMSO, then diluted 1:100 by serial dilution in LECL Assay Buffer 
to give 200 μM working solution. 
Allopurinol A 20 mM solution of allopurinol (Sigma Aldrich®, UK) was formulated 
in DMSO, then diluted 1:100 by serial dilution in LECL Assay Buffer to give 200 μM 
working solution.  
Febuxostat A 20 mM solution of febuxostat (Cambridge Bioscience, UK) was 
formulated in DMSO, then diluted 1:1000 by serial dilution in LECL Assay Buffer to give 
20 μM working solution. 
Xanthine A 200 mM solution of xanthine (Sigma Aldrich®, UK) was formulated in 
1 M NaOH, then diluted 1:100 by serial dilution in LECL Assay Buffer to give 2mM 
working solution. 
NADH and NADPH NADH and NADPH (Sigma Aldrich®, UK) were each dissolved 
directly into LECL Assay Buffer as 20mM and then diluted to 2mM.  
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Lucigenin A 20mM solution of lucigenin (Cambridge Bioscience, UK) was formulated 
directly into LECL Assay Buffer, then serially diluted to 200μM. This was prepared 15-20 
minutes before starting the assay in dark-adapted conditions.  
Figure 2.17 Plate layout for Lucigenin-enhanced Chemiluminescence assay. 
Schematic illustrating the plate layout used for a 96 well plate in a Lucigenin-enhanced Chemiluminescence (LECL) 
assay on protein from one mouse heart. Final well volume = 200 μl, and wells containing protein were loaded with 
100 μg protein per well. Control wells with no protein had their well volume adjusted accordingly using LECL Assay 
Buffer. Substrates and inhibitors were added in the configurations shown above, and the concentrations illustrated 
here reflect final well concentrations. For each added substrate/inhibitor, suitable working stocks were made so that 
10 μl of each solution could be added to acquire the final well concentrations shown in the template. Abbreviations 
are as follows: HBSS = Hank’s Balanced Salt Solution (red phenol-free), Xant = Xanthine, NADH = nicotinamide adenine 
dinucleotide, NADPH = nicotinamide adenine dinucleotide phosphate, DPI = diphenyleneiodonium chloride. 
 
Working solutions were formulated so that 10μl could be added to appropriate wells 
according to the protocol (See Figure 2.17 for typical plate layout). Plating was 
conducted as follows: LECL Assay Buffer (calculated to make well volume up to 200 μl), 
protein (100 μg protein per well), DPI/febuxostat/no inhibitor (incubated plate for 30 
minutes on ice), experimental substrate(s) (xanthine/NADPH/NADH) then lucigenin. The 
plate was immediately read following addition of lucigenin using a Perkin Elmer Wallac 
1420 Victor2 plate reader (Perkin Elmer, USA), with the chamber warmed to 37 °C. 
Luminescence was measured for 50 repeat readings with 30 seconds of interval between 
each repeat. 
 
 
 
Figure	21:	Plate	layout	for	Lucigenin-enhanced	Chemiluminescence	assay	
Schema'c	 illustra'ng	the	plate	 layout	used	for	a	96	well	plate	 in	a	Lucigenin-enhanced	Chemiluminescence	(LECL)	assay	on	protein	from	
one	mouse	heart.	Final	well	volume	=	200	μl,	and	wells	containing	protein	were	loaded	with	100	μg	protein	per	well.	Control	wells	with	no	
protein	 had	 their	well	 volume	 adjusted	 accordingly	 using	 LECL	Assay	Buffer.	 Substrates	 and	 inhibitors	were	 added	 in	 the	 configura'ons	
shown	above,	and	the	conc ntra'ons	illustrated	her 	reflect	final	well	concentra'ons.	For	e ch	added	sub rate/inhibitor,	suitable	working	
stocks	 were	 made	 so	 that	 10	 μl	 of	 ach	 solu' n	 could	 be	 added	 to	 a quir 	 the	 final	 well	 concentra'ons	 shown	 in	 the	 template.	
Abbrevia'ons	 are	 as	 follows:	 HBSS	 =	 Hank’s	 Balanced	 Salt	 Solu'on	 (red	 phenol-free),	 Xant	 =	 Xanthine,	 NADH	 =	 	 nico'namide	 adenine	
dinucleo'de,	NADPH	=	nico'namide	adenine	dinucleo'de	phosphate,	DPI	=	diphenyleneiodonium	chloride.	
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 XOR immunoblotting in liver 
Liver samples were snap frozen upon collection and were later defrosted and 
homogenised in a 1:2 ratio (tissue weight (mg): homogenisation buffer volume (μl)). 
Homogenisation buffer and protease inhibitors are shown in Table 2.7 and Table 2.8. 
Table 2.7 Table showing recipe for making the homogenisation buffer used for western blot tissue homogenisation. 
The buffer above was made up in MQ water and adjusted to pH7.4 prior to addition of protease inhibitors shown in 
Table 2.8. 
 
Table 2.8 Details of protease inhibitors and detergent added to 10 ml homogenisation buffer for tissue 
homogenisation in preparation for western blot assays. 
Table shows stock concentrations of protease inhibitors formulated and the volume to be added to 10 ml of buffer in 
order to acquire the final concentrations shown. Benzamidine was made up fresh on day of experiment, but other 
protease inhibitors were made as stocks, aliquoted and stored at -20 °C. 
The resulting homogenate was centrifuged at 4°C for 2 mins at 9000 RCF and the 
supernatant collected. The protein concentration of supernatant was determined using 
a Pierce® BCA Protein Assay Kit (Thermoscientific, UK), as previously described in 2.17. 
Samples were subjected to SDS/PAGE (0.1% w/v) immunoblotting analysis using the 
following rabbit antibodies to XOR (1:2000, RRID: 133268) and b-actin (1:5000, RRID: 
16039) and visualised using ClarityTM Western ECL Substrate (Bio-Rad, US). 
Chemiluminescence was automatically recorded and analysed with the FluorChem E 
imager (Protein Simple, US). Primary and secondary antibodies were purchased from 
Abcam (UK).  
 
 
Molecular 
Weight
g per 200 ml 
MQ H2O
Final 
Concentration
Tris-HCl 157.6 0.3152 5.7 μM
Sodium Chloride 58.44 0.5844 1.5 μM
Sodium Pyrophosphate 446.1 2.6766 0.15 μM
EDTA 292.2 0.1168 4.2 μM
Stock 
Concentration
Volume Added 
to 10 ml Buffer
Final 
Concentration
Benzamidine 1mg/ml 10 µl 5.7 μM
Antipain 1mg/ml 10 µl 1.5 μM
Aprotinin 1 mg/ml 10 µl 0.15 μM
Leupeptin 1 mg/ml 20 µl 2.1 μM
Pepstatin A 0.7 mg/ml 10 µl 1.5 μM
AEBSF 100 mg/ml 10 µl 400 μM
Sodium orthovanadate 37 mg/ml 50 µl 1 mM
Sodium fluoride 21 mg/ml 1 ml 50 mM
Triton-X n/a 100 µl 1%
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 Power calculations 
Preliminary data from the ANGII pre-treatment study (n=4) showed early trends towards 
differences in LVPW thickness between ANGII-infused mice with KNO3 compared to KCl 
pre-treatment when m-mode assessments of LV wall thickness were compared. Thus, 
with indications that there may indeed be an effect of nitrate on cardiac wall thickness 
(ANGII+KCl: 0.81±0.14 mm (mean ± SD) ANGII+KNO3: 1.3 ± 0.4), power calculations 
based on this data were carried out. Power calculations indicated that with an effect size 
of 1.6, n = 12 would be required to detect statistical differences with 95% power  (Figure 
2.18). This is within the range reported in a previous study by Matsumoto et al., using 
ANGII infusion to induce cardiac hypertrophy. Here, a significant difference in LVPW 
(~0.9 mm compared to 1.2 mm), was detected with n = 7-15 (Matsumoto et al. 2013). 
Because of some unanticipated deaths caused by both ANGII and isoprenaline infusion 
in our models, additional n values were added to account for some of these deaths in 
order to result in n = 12-13 for echocardiography data.  
Figure 2.18 G*Power results for power calculations based on preliminary data from ANGII-infused mice receiving 
KNO3 (group 1) or KCl (group 2) pre-treatment. 
 83 
 
 
 
CHAPTER THREE - 
 The Effect of Dietary Nitrate 
on a BP-dependent Model of 
Cardiac Dysfunction 
 
 
 
 
 
 84 
3. CHAPTER THREE - The effect of dietary nitrate on a BP-dependent model 
of cardiac dysfunction 
With dietary nitrate widely recognised as having BP lowering affects in both clinical and 
animal studies (Gee et al., 2016), and hypertension being one of the most signifcant risk 
factors in cardiac hypertrophy and heart failure development (Chobanian et al., 2003; 
Dunlay et al., 2009; Ho et al., 1993; Levy et al., 1996), our primary aim was to establish 
whether dietary nitrate was capable of reducing BP sufficiently to attenuate cardiac 
hypertrophy in a BP-dependent model of cardiac dysfunction. To investigate this, both 
3-week and 5-week ANGII mouse models were adopted, with either nitrate/control pre-
treatment or reversal treatments respectively. 
 BP-dependent model of cardiac dysfunction – ANGII 
Upon delivery, mice were randomly assigned to one of 6 treatment groups – KNO3 
control, KCl control, ANGII + KNO3 pre-treatment, ANGII + KCl pre-treatment, ANGII + 
KNO3 reversal or ANGII + KCl reversal (see Figure 3.1A and Figure 3.1B). 
Controls - Mice received 15 mM KNO3 or 15 mM KCl water ad libitum for 5 weeks. This 
dose was chosen since it has previously been shown to be effective in raising both 
plasma nitrite and nitrate concentrations compared to KCl controls (Baliga et al. 2012; 
Ghosh et al. 2013). Average nitrate intake for all mice was determined through 
assessment of water consumption. 
ANGII Pre-treatment - Mice received 15 mM KNO3 or 15 mM KCl water ad libitum for 2 
weeks prior to beginning a 3-week subcutaneous (SC) infusion of 2 mg/kg/day ANGII 
(Sigma Aldrich®, UK) in saline, from ALZET® 1004 osmotic minipumps (Durect 
Corporation, USA). Drinking water treatments were continued throughout the 
remainder of the study, alongside ANGII infusion. After 3 weeks of ANGII infusion, 
echocardiography was used to determine cardiac structure and function, including 
measurements of LV wall thickness, ejection fraction and fractional shortening (see 
section 2.7 for further details). Prior to ANGII infusion, some pre-treatment study mice 
also underwent surgery to implant BP telemetry probes (model TA11PA-C10, Data 
Sciences International, USA) to allow conscious BP measurement during the study (see 
section 2.5 for further details). Another subset of mice underwent tail cuff BP 
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measurements during the final week of ANGII infusion (see section 2.6 for further 
details). 
ANGII Reversal - Mice underwent surgery to implant an ALZET® 1004 osmotic minipump 
(Durect Corporation, USA) releasing 2 mg/kg/day ANGII (Sigma Aldrich®, UK) in saline, 
SC. After 2 weeks, this pump was surgically replaced with a new pump, releasing 2 
mg/kg/day ANGII for a further 3 weeks. Mice therefore received ANGII for a total of 5 
weeks. During the final 2 weeks of ANGII infusion mice concomitantly received 15 mM 
KNO3 or 15 mM KCl in their drinking water ad libitum. At the end of the study, 
echocardiography was used to determine a range of cardiac measurements.  
Figure 3.1 Experimental Design for ANGII studies. 
Schematic illustrating the experimental design for A) ANGII pre-treatment and B) ANGII reversal studies. Schematics 
illustrate the duration of 15mM KCl (control) or 15mM KNO3 (treatment) feeding and ANGII infusion. The points of 
osmotic minipump (*) and BP telemetry probe implantation (▼) are marked, and days on which BP telemetry (BP), 
echocardiography (Echo) and tail cuff BP (tail cuff) measurements were taken are indicated. 
 ANGII formulation 
For the filling of osmotic minipumps, ANGII (Sigma Aldrich®, UK) was dissolved under 
sterile conditions to yield a 25 mg/ml stock solution in sterile saline. This 25 mg/ml stock 
was then diluted accordingly in LoBind tubes (Eppendorf, UK) for minipump filling 
according to mouse weights and pump specifications. 25 mg/ml ANGII was stored at 4°C 
for up to 3 days or at -20°C for up to 1 month. If stored at -20°C, ANGII was not freeze-
thawed more than twice.  
 
 
15 mM KCl or 15 mM KNO3
2 mg/kg/day ANGII
Day 0 Day 7 Day 14 Day 21 Day 28 Day 35
15 mM KCl or 15 mM KNO3
2 mg/kg/day ANGII
Day 0 Day 7 Day 14 Day 21 Day 28 Day 35
*
* *
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*
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▼ BP BP Echo
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 KNO3 and KCl supplemental feeding 
3.3.1. Tap vs. MQ filtered water 
Prior to formulating supplemental feeding waters, ozone chemiluminescence was used 
to determine what the levels of nitrate and nitrite were in tap water and MQ filtered 
water (Figure 3.2). Samples were collected across a number of days, and at varying times 
of day. 
Results show there were significantly higher concentrations of both nitrite (P=0.0005) 
and nitrate (P=0.0006) in tap water compared to MQ filtered water (Figure 3.2). 
However, whilst this difference was evident, the concentrations measured in tap water 
were low, and deemed highly unlikely to influence our experiments with regards to 
increasing mouse nitrite/nitrate consumption to a level that would significantly affect 
circulating plasma levels. Tap water was therefore used to formulate all feeding waters 
for our studies.  
Figure 3.2 Nitrite and nitrate concentrations in Milli-Q (MQ) filtered water and tap water. 
Graphs show A) nitrate (mM) and B) nitrite (μM) concentrations measured using ozone chemiluminescence in MQ 
filtered and tap water. Data are shown as mean ± SEM with n = 9 and n = 18 respectively. Differences between groups 
were tested for statistical significance using Student's T-tests, with p-values shown in the graphs. 
3.3.2. Changes in nitrate/nitrite over time in running tap water  
Having decided to use tap water for treatment formulations, ozone chemiluminescence 
was then used to determine whether there was a significant change in nitrite and nitrate 
concentrations when running tap water over a set period of time. Tap water samples 
were collected at T0 secs, T30 secs, T120 secs, T240 secs, T360 secs on 3 different days and nitrite 
and nitrate concentrations were measured (Figure 3.3).  
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There were no significant differences in nitrite or nitrate concentrations across this 6-
minute period when means of each of the time points were compared using one-way 
ANOVA. Thus, when generating drinking water interventions, it was decided that it did 
not matter when tap water was collected. 
Figure 3.3 Nitrate and nitrite concentrations in tap water at T0 secs, T30 secs, T120 secs, T240 secs and T360 secs. 
Graphs show A) nitrate (mM) and B) nitrite (μM) concentrations measured using ozone chemiluminescence in tap 
water collected at time points T0 secs, T30 secs, T120 secs, T240 secs and T360 secs after starting water flow. Data are 
shown as mean ± SEM with n = 5 at each time point. Data were tested for statistical significance using a one-way 
ANOVA with Dunnet's post-hoc analysis (comparing all time points to T0 secs). P-values are shown in the graphs - no 
significant differences were found. 
3.3.3. 15 mM KNO3 stability  
In order to ensure a supplemental water change schedule of 2 – 3 times per week was 
sufficient for this study to maintain a consistent dose of nitrate, ozone 
chemiluminescence was used to determine the stability of a 15mM KNO3 solution made 
in tap water. Samples were taken on days 0, 3, 4, 5, 6 and 7 following 15 mM KNO3 
formulation, and nitrite and nitrate concentrations measured. There was no significant 
difference when mean concentrations of nitrite and nitrate from these days were 
compared using a one-way ANOVA (Figure 3.4). 
Figure 3.4 Nitrate and nitrite concentration over a one-week period in a 15 mM KNO3 solution. 
Graphs show A) nitrate (mM) and B) nitrite (μM) concentrations measured using ozone chemiluminescence in 
samples of a 15 mM KNO3 solution (formulated in tap water), taken periodically over the course of one week on days 
0, 3, 4, 5, 6 and 7. Data are shown as mean ± SEM with n = 5 for each day. Data were tested for statistical significance 
using a one-way ANOVA with Dunnet's post-hoc analysis (comparing all time points to Day 0). P-values are shown in 
the graphs - no significant differences were found. 
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3.3.4. 15mM KNO3 and 15 mM KCl sample verification 
On 20 random days throughout the feeding study, when supplemental waters were 
changed, samples of freshly made 15 mM KNO3 and 15 mM KCl waters were taken and 
ozone chemiluminescence used to confirm formulations (Figure 3.5). 
There was no significant difference between mean nitrite concentrations in 15 mM KNO3 
and 15 mM KCl water formulation (P=0.7). However, as expected, there was a 
significantly higher nitrate concentration in 15 mM KNO3 compared to 15 mM KCl water 
(P<0.0001), with average nitrate concentrations of 15.5 mM and 0.6 mM respectively.   
Figure 3.5 Nitrate and nitrite concentrations in 15 mM KNO3 and 15 mM KCl feeding waters. 
Graphs show A) nitrate (mM) and B) nitrite (μM) concentrations measured using ozone chemiluminescence in 
samples of 15 mM KNO3 and 15 mM KCl solutions, formulated in tap water, for feeding mice. Water samples were 
taken periodically throughout the course of the study. Data are shown as mean ± SEM with n = 20 (15 mM KNO3) and 
n = 17 (15 mM KCl). Differences between groups were tested for statistical significance using Student's T-tests, with 
p-values shown in the graphs. 
3.3.5. Nitrite/Nitrate levels of other experimental components 
Ozone chemiluminescence was also used to determine the nitrite and nitrate 
concentrations of a variety of gels/creams, which would be used during surgery and/or 
echocardiography. Figure 3.6 shows results obtained, with nitrite and nitrate 
concentrations of these gels/creams compared to concentrations measured in tap 
water. 
Aqua Gel (used on mice during echocardiography imaging) went easily into solution 
when diluted with MQ filtered water. A 1:10 dilution was therefore used for nitrite and 
NOx measurements. However, Redux Crème (used on the paws of mice for ECG 
conduction during echocardiography) and Veet (used to remove hair from mice during 
KCl Water KNO3 Water
0
5
10
15
20
[N
itr
at
e]
 (m
M
)
P<0.0001
A) Nitrate B) Nitrite
KCl Water KNO3 Water
0
1
2
[N
itr
ite
] (
µM
)
P=0.7
 89 
surgery and echocardiography) were less water-soluble. The highest concentration 
achieved in solution was 1:100 for Redux Crème and 1: 1000 for Veet. 
 Ozone chemiluminescence results show that the various gels and creams used during 
experimental protocols did not contain substantial amounts of nitrite or nitrate, and all 
gels/creams had similar or significantly lower concentrations than those of tap water 
(Figure 3.6). These experimental components were therefore highly unlikely to 
contaminate the mice in our study. 
Figure 3.6 Nitrate and nitrite concentrations in gels and creams used in experimental protocols. 
Graphs show A) nitrate (mM) and B) nitrite (μM) concentrations measured using ozone chemiluminescence in a 
variety of gels/creams used in surgical and echocardiography protocols, including: Veet (hair removal cream), Redux 
Crème (ECG conducting gel) and Aqua Gel (for echocardiographic imaging). For reference, these are shown compared 
to nitrate/nitrite concentrations measured in tap water. Data are shown as mean ± SEM with n = 5. Data were tested 
for statistical significance using a one-way ANOVA with Dunnett's post-hoc analysis (comparing all groups to tap 
water). P-values for one-way ANOVA are shown in the graphs and stars represent statistical significance determined 
by post-hoc analyses: 
** = P <0.01 
3.3.6. Plasma nitrite and nitrate concentrations are increased by 15 
mM KNO3 feeding in controls and ANGII infused mice 
Ad libitum 15 mM KNO3 feeding through drinking water significantly raised plasma 
nitrate in both controls and ANGII-infused mice (Figure 3.7A and Figure 3.7B). 
Furthermore, a significant increase in plasma nitrite concentrations were measured in 
control mice fed KNO3 vs. KCl (1.5 ± 0.2 vs. 1.0 ± 0.08, mean ± SEM) and in ANGII  infused 
mice, both on pre-treatment (2.5 ± 0.3 vs. 0.9 ± 0.08) and reversal protocols (3.4 ± 0.5 
vs. 0.8 ± 0.05) – Figure 3.7C and Figure 3.7D. The significant increase in nitrite 
concentration in the plasma is particularly important from a mechanistic point of view, 
as it highlights that the enterosalivary circuit in these mice is intact. It is noteworthy 
however, that the rise in plasma nitrate and nitrite with KNO3 treatment was greater in 
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ANGII infused mice compared to control mice (i.e. ~10-fold and ~2-fold higher 
respectively). 
Figure 3.7 Nitrate and nitrite concentrations in plasma of ANGII pre-treatment and reversal study mice. 
Graphs show A) and B) nitrate (mM) and C) and D) nitrite (μM) concentrations in plasma of control, ANGII pre-
treatment and ANGII reversal mice, fed either 15 mM KNO3 or KCl water. Data are represented as mean ± SEM with 
n ≥ 18. Data were tested for statistical significance using a one-way ANOVA with Sidak’s post-hoc analysis (A and C) 
or Student’s T-tests (B and D). P-values for one-way ANOVAs and T-tests are shown in the graphs. Stars represent 
statistical significance determined by post-hoc analyses: 
* = P<0.05, **** = P<0.0001 
 The effect of ANGII infusion on mouse weight, and food and water 
consumption 
3.4.1. Water and nitrate consumption  
In mice treated with ANGII, water consumption in both KNO3 and KCl-fed mice was 
significantly greater than in controls (Table 3.2). Increased water consumption in these 
treatment groups therefore resulted in an increase in the estimated dose of nitrate 
being delivered to ANGII+KNO3 treated mice, when compared to KNO3-fed controls 
(Table 3.2). 
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3.4.2. Body weight 
There were no significant differences between treatment groups when body weights of 
mice at baseline were compared (Table 3.1). However, when change in body weight 
from the start to the end of each study was compared, this was significantly different 
between groups when compared using a one-way ANOVA (P<0.0001). Sidak’s post-hoc 
analysis showed that ANGII treatment caused a reduction in weight gain over time 
compared to control mice (Table 3.1). Comparison of KCl to KNO3 treatment within 
groups demonstrated no difference between drinking water treatments.  
3.4.3. Food consumption 
There was no significant difference in food consumption in ANGII-infused mice 
compared to controls, but food consumption was significantly increased in isoprenaline-
infused mice. KNO3 feeding treatment had no significant effect on this increase (Table 
3.1). 
 
 
 
 
 
 
 
 
 
 
 
 92 
  
 
Av
er
ag
e
Be
fo
re
 P
um
p
W
ith
 P
um
p
Av
er
ag
e
Be
fo
re
 P
um
p
W
ith
 P
um
p
Av
er
ag
e
Be
fo
re
 P
um
p
W
ith
 P
um
p
KN
O 3
 C
on
tro
l
4.
7 
± 
0.
2
4.
7 
± 
0.
2
4.
7 
± 
0.
2
2.
9 
± 
0.
1
2.
9 
± 
0.
1
2.
9 
± 
0.
1
17
6.
8 
± 
4.
1
17
7.
4 
± 
4.
1
17
9.
9 
± 
5.
1
18
KC
l C
on
tro
l
4.
5 
± 
0.
1
4.
7 
± 
0.
2
4.
5 
± 
0.
1
0.
1 
± 
0.
0
0.
1 
± 
0.
0
0.
1 
± 
0.
0
6.
9 
± 
0.
2
7.
1 
± 
0.
2
6.
9 
± 
0.
2
20
AN
GI
I +
 K
NO
3 P
re
8.
2 
± 
0.
3*
**
*
4.
5 
± 
0.
1
10
.5
 ±
 0
.5
**
**
5.
7 
± 
0.
2*
**
*#
##
#
3.
1 
± 
0.
1*
*#
##
#
7.
2 
± 
0.
4*
**
*#
##
#
35
1.
4 
± 
15
.0
19
1.
8 
± 
4.
4
44
8.
6 
± 
21
.9
19
AN
GI
I +
 K
Cl
 P
re
8.
3 
± 
0.
4*
**
*
4.
7 
± 
0.
2
10
.3
 ±
 0
.6
**
**
0.
2 
± 
0.
0
0.
1 
± 
0.
0
0.
3 
± 
0.
0
14
.3
 ±
 0
.7
8.
1 
± 
0.
3
17
.5
 ±
 1
.1
20
AN
GI
I +
 K
NO
3 R
ev
14
.2
 ±
 0
.9
**
**
n/
a
14
.2
 ±
 0
.9
**
**
9.
6 
± 
0.
6*
**
*#
##
#
n/
a
9.
6 
± 
0.
6*
**
*#
##
#
59
6.
2 
± 
39
.6
n/
a
59
6.
2 
± 
39
.6
18
AN
GI
I +
 K
Cl
 R
ev
13
.3
 ±
 0
.6
**
**
n/
a
13
.3
 ±
 0
.6
**
**
0.
4 
± 
0.
0
n/
a
0.
4 
± 
0.
0
22
.8
 ±
 1
.3
n/
a
22
.8
 ±
 1
.3
18n
W
at
er
 C
on
su
m
pt
io
n 
(m
l/d
ay
)
Ni
tra
te
 C
on
su
m
pt
io
n 
(m
m
ol
/k
g/
da
y)
Ni
tra
te
 C
on
su
m
pt
io
n 
(m
g/
kg
/d
ay
)
Tr
ea
tm
en
t
Av
er
ag
e
St
ar
t o
f S
tu
dy
En
d 
of
 S
tu
dy
W
ei
gh
t G
ai
n
Av
er
ag
e
Be
fo
re
 P
um
p
W
ith
 P
um
p
KN
O
3 C
on
tr
ol
25
.2
 ±
 0
.4
23
.1
 ±
 0
.5
26
.7
 ±
 0
.4
3.
6 
± 
0.
5
3.
6 
± 
0.
1
3.
6 
± 
0.
1
3.
6 
± 
0.
1
18
KC
l C
on
tr
ol
25
.7
 ±
 0
.5
23
.6
 ±
 0
.6
27
.3
 ±
 0
.5
3.
7 
 ±
 0
.4
3.
5 
± 
0.
1
3.
5 
± 
0.
1
3.
6 
± 
0.
1
20
AN
G
II 
+ 
KN
O
3 P
re
22
.6
 ±
 0
.3
**
**
22
.4
 ±
 0
.4
23
.6
 ±
 0
.3
**
**
1.
3 
± 
0.
3 
**
3.
3 
± 
0.
1
3.
3 
± 
0.
1
3.
3 
±0
.2
19
AN
G
II 
+ 
KC
l P
re
22
.6
 ±
 0
.2
**
**
22
.3
 ±
 0
.3
23
.5
 ±
 0
.3
**
**
1.
2 
± 
0.
3*
**
3.
2 
± 
0.
1
3.
2 
± 
0.
1
3.
3 
± 
0.
1
20
AN
G
II 
+ 
KN
O
3 R
ev
23
.2
 ±
 0
.4
**
23
.4
 ±
 0
.5
24
.4
 ±
 0
.3
**
*
1.
0 
± 
0.
5*
**
3.
7 
± 
0.
1
n/
a
3.
7 
± 
0.
1
18
AN
G
II 
+ 
KC
l R
ev
23
.1
 ±
 0
.4
**
**
23
.7
 ±
 0
.5
23
.5
 ±
 0
.4
**
**
-0
.2
 ±
 0
.5
**
**
3.
6 
± 
0.
1
n/
a
3.
6 
± 
0.
1
18
Tr
ea
tm
en
t
n
Fo
od
 C
on
su
m
pt
io
n 
(g
/d
ay
)
M
ou
se
 W
ei
gh
t (
g)
Ta
bl
e 
3.
1 
Ta
bl
e 
ill
us
tr
at
in
g 
m
ou
se
 w
at
er
 c
on
su
m
pt
io
n 
of
 m
ic
e,
 a
nd
 th
er
ef
or
e 
re
su
lti
ng
 n
itr
at
e 
(N
O
3-
) d
os
e 
de
liv
er
ed
, d
ur
in
g 
AN
GI
I s
tu
di
es
. 
Av
er
ag
e 
w
at
er
 a
nd
 n
itr
at
e 
do
se
 w
er
e 
ca
lcu
la
te
d 
fro
m
 w
at
er
 w
ei
gh
ts
 re
co
rd
ed
 3
 ti
m
es
 w
ee
kl
y.
 D
os
e 
de
liv
er
ed
 is
 s
ho
w
n 
fo
r K
NO
3 a
nd
 K
Cl
 c
on
tr
ol
 m
ice
 (w
ith
 n
o 
AN
GI
I),
 A
N
GI
I +
 K
N
O 3
 a
nd
 K
Cl
 
pr
e-
tr
ea
tm
en
t (
Pr
e)
 a
nd
 re
ve
rs
al
 (R
ev
) m
ic
e.
 D
at
a 
ar
e 
br
ok
en
 d
ow
n 
in
to
 a
ve
ra
ge
 co
ns
um
pt
io
n,
 b
ef
or
e 
pu
m
p 
co
ns
um
pt
io
n 
an
d 
w
ith
 p
um
p 
co
ns
um
pt
io
n.
 D
at
a 
ar
e 
re
pr
es
en
te
d 
as
 m
ea
n 
± 
SE
M
 
w
ith
 n
 ≥
 1
8.
 P
re
 =
 p
re
-t
re
at
m
en
t s
tu
dy
 w
he
re
 n
itr
at
e 
tr
ea
tm
en
t w
as
 in
iti
at
ed
 2
 w
ee
ks
 p
rio
r t
o 
AN
GI
I i
nf
us
io
n.
 R
ev
 =
 re
ve
rs
al
 st
ud
y 
w
he
re
 n
itr
at
e 
tr
ea
tm
en
t i
ni
tia
te
d 
3 
w
ee
ks
 fo
llo
w
in
g 
AN
GI
I 
in
fu
sio
n.
 
Di
ffe
re
nc
es
 b
et
w
ee
n 
tr
ea
tm
en
t g
ro
up
s w
er
e 
te
st
ed
 fo
r s
ta
tis
tic
al
 si
gn
ifi
ca
nc
e 
us
in
g 
a 
on
e-
w
ay
 A
N
O
VA
 a
nd
 S
id
ak
’s
 p
os
t-
ho
c 
an
al
ys
is.
  
* 
= 
sig
ni
fic
an
tly
 d
iff
er
en
t f
ro
m
 K
N
O
3 o
r K
Cl
 c
on
tr
ol
 m
ice
 w
ith
 n
o 
AN
GI
I i
nf
us
io
n.
 
# 
= 
KN
O 3
 fe
d 
m
ice
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 K
Cl
 fe
d 
m
ice
 u
nd
er
 th
e 
sa
m
e 
AN
GI
I r
eg
im
en
. 
*/
# 
= 
P<
0.
05
, *
*/
##
 =
 P
<0
.0
1,
 *
**
/#
##
 =
 P
<0
.0
01
 a
nd
 *
**
*/
##
##
 =
 P
<0
.0
00
1 
Ta
bl
e 
3.
2 
Ta
bl
e 
ill
us
tr
at
in
g 
m
ou
se
 w
ei
gh
ts
 a
nd
 fo
od
 co
ns
um
pt
io
n 
of
 m
ic
e 
du
rin
g 
AN
GI
I s
tu
di
es
. 
Av
er
ag
e 
m
ou
se
 w
ei
gh
ts
 a
re
 sh
ow
n 
at
 th
e 
st
ar
t a
nd
 e
nd
 o
f s
tu
di
es
 fo
r K
N
O
3 a
nd
 K
Cl
 c
on
tr
ol
 m
ice
 (w
ith
 n
o 
AN
GI
I),
 A
NG
II 
+ 
KN
O
3 o
r K
Cl
 p
re
-
tr
ea
tm
en
t (
Pr
e)
 a
nd
 re
ve
rs
al
 (R
ev
) m
ic
e.
 A
ve
ra
ge
 fo
od
 co
ns
um
pt
io
n 
w
as
 c
al
cu
la
te
d 
bo
th
 b
ef
or
e 
an
d 
du
rin
g 
AN
GI
I i
nf
us
io
n,
 fr
om
 fo
od
 w
ei
gh
ts
 
re
co
rd
ed
 3
 ti
m
es
 w
ee
kl
y.
 D
at
a 
ar
e 
re
pr
es
en
te
d 
as
 m
ea
n 
± 
SE
M
 w
ith
 n
 ≥
 1
8.
  
Di
ffe
re
nc
es
 b
et
w
ee
n 
tr
ea
tm
en
t g
ro
up
s w
er
e 
te
st
ed
 fo
r s
ta
tis
tic
al
 si
gn
ifi
ca
nc
e 
us
in
g 
a 
on
e-
w
ay
 A
N
O
VA
 a
nd
 S
id
ak
’s
 p
os
t-h
oc
 a
na
ly
sis
.  
* 
= 
sig
ni
fic
an
tly
 d
iff
er
en
t f
ro
m
 K
N
O
3 o
r K
Cl
 c
on
tr
ol
 m
ice
 w
ith
 n
o 
AN
GI
I i
nf
us
io
n 
# 
= 
KN
O 3
 fe
d 
m
ice
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 K
Cl
 fe
d 
m
ice
 u
nd
er
 th
e 
sa
m
e 
AN
GI
I r
eg
im
en
. 
*/
# 
= 
P<
0.
05
, *
*/
##
 =
 P
<0
.0
1,
 *
**
/#
##
 =
 P
<0
.0
01
 a
nd
 *
**
*/
##
##
 =
 P
<0
.0
00
1 
 93 
 cGMP expression 
cGMP, a significant downstream molecule in NO signalling pathways was measured 
using a cGMP enzyme immunoassay. Despite there being a significant increase in plasma 
nitrite concentrations measured using ozone chemiluminescence in all nitrate-fed mice, 
unfortunately there was no detectable difference in plasma cGMP compared in ANGII-
infused mice fed KCl or KNO3 pre-treatment (Figure 3.8). 
Figure 3.8 cGMP enzyme immunoassay results in ANGII-infused mice with KCl or KNO3 pre-treatment. 
Data are represented as mean ± SEM with n = 8. P-value shows there was no statistical significance of results when 
data were compared using Student’s T-test. 
 Mortality  
Overall mortality in the ANGII model was recorded as 10.4% and 8.2% for KCl and KNO3 
pre-treated mice respectively. This was not statistically significant when the two groups 
when compared using the Gehan-Breslow-Wilcoxon test (Figure 3.9). 
Figure 3.9 Mortality in ANGII-infused mice with KCl or KNO3 pre-treatment.  
Kaplan-Meier mortality curves for ANGII-infused mice with KCl or KNO3 pre-treatment, n = 43 and 45 respectively. P-
value shows there was no statistical significance of results when curves were compared using Gehan-Breslow-
Wilcoxon test. 
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 Control C57Bl6 echocardiography – comparison to literature 
Echocardiography was carried out on C57Bl6 mice in order to ensure that the 
experimental protocol used resulted in data consistent with that published in the 
literature. Table 3.3 compares standard cardiac parameters of IVS (mm), LVPW (mm) 
and LVID (mm) (in diastole (d) and systole (s)) and ejection fraction (%) and fractional 
shortening (%), obtained from control C57Bl6 mice, compared to values obtained for 
each parameter which have been reported in literature using a similar experimental protocol 
(Ram et al. 2011). A typical echocardiographic trace from preliminary echocardiography 
imaging on a control C57Bl6 mouse, and the measurements taken, can be seen in Figure 
3.10. 
Figure 3.10 Example of a typical echocardiographic image from a C57Bl6 control mouse. 
Figure shows an example of an M-mode image, acquired using Vevo 770 echocardiography software and equipment, 
of a C57Bl6 mouse under ≈2% isofluorane inhalation anaesthetic. Measurements of the intra-ventricular septum (IVS), 
left ventricle posterior wall diameter (LVPW) and left ventricle internal dimension (LVID) were taken during diastole 
(d) and systole (s) respectively. Mouse ECG is shown in green and respiration rate in yellow. The image represents a 
total of 20ms of echocardiographic recording. 
Table 3.3 C57Bl6 echocardiography measurements obtained alongside data reported by Ram et al., 2011. 
Table shows intra-ventricular septum diameter (IVS), left ventricle posterior wall diameter (LVPW) and left ventricle 
internal dimension (LVID) measurements during diastole (d) and systole (s), as well as ejection fraction and fractional 
shortening of C57Bl6 mice. Data were obtained using a Vevo 770 machine and software, with C57Bl6 mice under ≈2% 
isofluorane inhalation anaesthetic. Values are shown as mean ± SEM, with n = 7 for in house data and n = 36 for Ram 
et al., 2011.  
Figure 28: Example of a typical echocardiographic image from a C57Bl6 control mouse
Figure shows an example of an M-mode image, acquired using Vevo 770 echocardiog raphy software and equipment, of a
C57Bl6 mouse under ≈2% isof luorane inhala tion anaesthetic. Measurements of the intra-ventricular septum (IVS), left
ventricle posteriorwall diameter (LVPW) and left ventricle internal dimension (LVID) were taken during diastole (d) and systole
(s) respectively. Mouse ECG is shown in g reen and respiration rate in yellow. The image represents a total of 20ms of
echocardiographic recording.
IVSs%(mm) 1.3%±%0.03 1.3%±%0.02
IVSd%(mm) 0.9%±%0.03 0.8%±%0.1
LVPWs%(mm) 1.2%±%0.03 1.2%±%0.02
LVPWd%(mm) 0.7%±%0.04 0.7%±%0.01
LVIDs%(mm) 1.8%±%0.21 1.6%±%0.04
LVIDd%(mm) 3.3%±%0.22 3.1%±%0.03
Ejection%Fraction%(%) 76.1%±%3.7 81%±%1
Fractional%Shortening%(%) 45.0%±%3.4 49%±%1
Values'Obtained'in'
C57Bl6'Controls
Cardiac'Parameters'
Measured
Values'Obtained'
By'Ram'et'al.,'2011
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 ANGII model verification  
3.8.1. Tail cuff BP measurements 
To confirm that ANGII induced a significant rise in BP, creating a BP-dependent model 
of cardiac hypertrophy, tail cuff BP measurement was used (Figure 3.11). ANGII 
significantly increased BP in C57Bl6 mice from 143 ± 3 to 175 ± 5 mmHg (P<0.001). In 
addition to the fact that there was no significant rise detected in heart rate in ANGII-
infused mice (see section 4.4). 
Figure 3.11 Tail cuff BP data from controls, ANGII and isoprenaline study mice. 
Figure shows Systolic tail cuff BP measured in control mice and mice infused with 2 mg/kg/day ANGII. Tail cuff data 
was obtained using a modified CODA tail cuff setup (Kent Scientific), with data averaged from 4 days of recording. 
Each day consisted of 5 acclimation cycles and 10 recorded data cycles. Data are represented as mean ± SEM with n 
= 10-16. Data were tested for statistical significance using a one-way ANOVA with Sidak’s post-hoc analysis. P-values 
for one-way ANOVA are shown in the graphs and stars represent statistical significance determined by post-hoc 
analyses: *** = P<0.001. 
3.8.2. Cardiac hypertrophy 
In addition to the aforementioned increase in BP, with no significant rise in heart rate of 
ANGII-infused mice (see section 4.4), cardiac hypertrophy was observed in ANGII treated 
mice both visually (Figure 3.12) and by increases in heart weights (
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Figure 3.13). These results verify the suitability of the primarily BP-dependent nature of 
this model. 
Figure 3.12 Heart images from mice harvested after 3 weeks of ANGII infusion. 
Figure shows photographs of hearts with a 1 cm scale from control mice and mice infused with 2 mg/kg/day ANGII 
with either 15 mM KCl or KNO3 pre-treatment. 
 
 Dietary nitrate pre-treatment in ANGII-infused mice 
3.9.1. The effect of nitrate pre-treatment on heart weight 
ANGII infusion increased overall heart weight, HW:BW ratios and LV:BW ratios 
(P<0.0001, 
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Figure 3.13A-C), and significantly reduced RV:LV ratios (P<0.0001) highlighting the 
development of LV hypertrophy (
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Figure 3.13D). LV:BW ratios were slightly, but significantly, attenuated by dietary nitrate 
pre-treatment (ANGII+KCl: 5.4 ± 0.3; ANGII+KNO3 Pre: 4.9 ± 0.2, P<0.05). However, 
whilst overall heart weight, HW:BW ratios and LV:BW ratios showed trends towards 
attenuation in ANGII-infused mice, these were not statistically significant. 
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Figure 3.13 Heart weight data from ANGII study mice. 
Figure shows A) whole heart weights as well as B) heart weight: body weight, C) left ventricle: body weight and D) 
right ventricle: left ventricle ratios for control mice and ANGII pre-treatment study mice fed either 15 mM KNO3 or 
KCl. Data are represented as mean ± SEM. Data were tested for statistical significance using a one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses: * = P<0.05, **** = P<0.0001. 
 
 
 
 
3.9.2. Oral nitrate reduces ANGII-induced LV wall thickening 
measured by echocardiography 
Echocardiography was performed at the end of each ANGII study in controls, ANGII pre-
treatment and ANGII reversal mice fed KNO3 or KCl. ANGII infusion caused a significant 
increase in LVPWd thickness in ANGII-infused mice with KCl pre-treatment when 
compared to KCl controls (KCl control: 0.8 ± 0.03 mm; ANGII+KCl Pre: 1.3 ± 0.09 mm; 
P<0.0001, Figure 3.14E) - representative M-mode images in Figure 3.14A and Figure 
3.14C. 
KNO3 pre-treatment significantly reduced the level of hypertrophy observed (P<0.0001), 
with LVPWd in this group similar to that of controls (KNO3 control: 0.7 ± 0.03 mm; 
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ANGII+KNO3 Pre: 0.8 ± 0.04 mm, Figure 3.14E) – see representative M-mode images in 
Figure 3.14C and Figure 3.14D. The same findings were also true of LVPWs dimensions 
(Figure 3.14F). 
IVS thickness and predicted LV mass were also increased by ANGII infusion (P<0.01 and 
P<0.0001 respectively), and significantly reduced by KNO3 pre-treatment (P<0.0001 and 
P<0.01) - see Figure 3.14G and Figure 3.14H.  
ANGII infusion also resulted in a reduction in ejection fraction (KCl control: 76 ± 2%; 
ANGII+KCl Pre: 57 ± 1.8%), which was not significantly changed by KNO3 feeding 
treatment (Figure 3.14L). There were no significant differences in LVIDd or LV end 
diastolic volumes when compared between treatment groups using one-way ANOVA 
(Figure 3.14I and Figure 3.14J). 
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Figure 3.14 End of study echocardiography measurements from ANGII pre-treatment and control study mice. 
Figure shows representative M-mode images, acquired using Vevo 770 echocardiography software and equipment 
from A) KNO3 control B) KCl control C) ANGII + KNO3 pre-treatment and D) ANGII + KCl pre-treatment mice. Images 
were acquired under ~2% isofluorane inhalation anaesthetic. Measurements of the intra-ventricular septum (IVS), 
left ventricle posterior wall (LVPW) and left ventricle internal dimension (LVID) were taken during diastole (d) and 
systole (s). The image represents a total of 20ms of echocardiographic recording. Resulting LVPWd, LVPWs, IVSd, IVSs, 
LVIDd dimensions, LV end diastolic volume, LV mass, ejection fraction and wall:lumen ratios are shown in E), F) G), 
H), I), J), K), L) and M) respectively. Data are represented as mean ± SEM with n = 11-13. Data were tested for statistical 
significance using a one-way ANOVA with Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the 
graphs and stars represent statistical significance determined by post-hoc analyses: 
** = P<0.01, *** = P<0.001 **** = P<0.0001. 
3.9.3. Effect of oral nitrate on cardiac fibrosis in ANGII-infused mice, 
measured by PSR staining 
3-week ANGII infusion caused a significant increase in fibrosis as measured by PSR 
staining in formalin-fixed mouse hearts (P<0.001, Figure 3.15A). Dietary nitrate 
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significantly attenuated the fibrosis observed in ANGII-infused mice when compared to 
KCl-fed controls under the same ANGII regimen (P<0.001). 
Figure 3.15 Collagen deposition as quantified by PSR staining in ANGII pre-treatment study mouse hearts. 
Figure shows PSR staining carried out on 4 μm sections of formalin fixed hearts, embedded in paraffin. Hearts were 
randomly assigned to be sectioned in either the transverse or dorsal plane and stained with PSR to identify areas of 
connective tissue deposition. Images were acquired using a NanoZoomer slide scanner (Hamamatsu) and viewed 
using NDP View software. Three left ventricle, three intraventricular septum and three right ventricle fields of view 
were randomly selected at x20 magnification and PSR staining quantified using manual thresholding techniques in 
ImageJ software. Figure shows A) quantification of staining in controls and ANGII-infused mice with KNO3 or KCl pre-
treatment. Sections B) – E) shown representative staining images at x 1.25 magnification in all treatment groups. Data 
are represented as mean ± SEM with n = 4-7. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis, with P-value shown in the graphs Stars represent statistical significance determined by post-
hoc analyses: *** = P<0.001 
3.9.4. Effect of oral nitrate on ANGII-induced BP Increases, measured 
by radiotelemetry  
Radiotelemetric probes were used to record BP of ANGII pre-treatment study mice at 
baseline and on Day 21 of ANGII infusion with KNO3 or KCl pre-treatment. At baseline, 
oral nitrate significantly reduced MAP (P<0.001) and DBP (P<0.0001), but had no 
significant effect on SBP or HR (Table 3.4). On Day 21 of ANGII infusion, although both 
KNO3 and KCl fed mice exhibited increases in BP compared to baseline, mice receiving 
KNO3 exhibited significantly lower DBP (P<0.0001) and HR (P<0.001) compared to KCl 
fed mice.  However, there was no significant difference in MAP and there was in fact a 
significant increase in SBP (P<0.001) compared to KCl fed mice (Table 3.4).  
However, it should also be noted that oral nitrate treatment, both at baseline and on 
Day 21 of ANGII infusion, resulted in a significant increase in mouse locomotor activity 
(P<0.0001, Table 3.4, Figure 3.16D and Figure 3.16H). As intensity of locomotor activity 
has a direct impact on murine BP (Adlam et al. 2011), this finding led us to normalize BP 
and HR data according to mouse activity level at corresponding time points. When 
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compared relative to activity level, MAP, DBP, SBP and HR all showed a significant 
reduction across the 24-hour recording window, both during ANGII infusion and at 
baseline (24-hour data traces shown in Figure 3.16A- Figure 3.16J with averages shown 
in Figure 3.17A - Figure 3.17D).   
Table 3.4 24-hour average BP measurements from ANGII pre-treatment study mice at baseline and on day 21 of 
ANGII infusion. 
Table shows mean, systolic and diastolic BP, activity and heart rates at baseline and on Day 21 of ANGII infusion in 
mice pre-treated with either 15 mM KNO3 or KCl water. Data were acquired using TA11PA-C10 radiotelemetric probes 
(Data Sciences International, USA), allowing BP recording in freely moving, conscious animals. Data are expressed as 
averages from across a 24-hour period of telemetric monitoring with mean ± SEM. n-numbers for each treatment 
group are shown in the table and arrows indicate direction of change with KNO3 treatment. Stars show statistical 
significance of results when 24-hour traces from KNO3 treated mice were compared to KCl treated mice using Two-
way ANOVA: 
*** = P<0.001, **** = P<0.0001 and NS = Not Significant 
 
 
Table	 6.	 24-hour	 average	 blood	 pressure	 measurements	 from	 ANGII	 pre-treatment	 study	 mice	 at	
baseline	and	on	day	21	of	ANGII	infusion.	
Table	shows	mean,	systolic	and	diastolic	blood	pressures,	ac6vity	and	heart	rates	at	baseline	and	on	Day	21	
of	 ANGII	 infusion	 in	mice	 pre-treated	with	 either	 15	mM	KNO3	 or	 KCl	water.	 Data	were	 acquired	 using	
TA11PA-C10	radiotelemetric	probes	(Data	Sciences	Interna6onal,	USA),	allowing	blood	pressure	recording	
in	freely	moving,	conscious	animals.	Data	are	expressed	as	averages	across	a	24	hour	period	of	telemetric	
monitoring	with	mean	 ±	 SEM,	 n-numbers	 for	 each	 treatment	 group	 are	 shown	 in	 the	 table	 and	 arrows	
indicate	 direc6on	 of	 change	with	 KNO3	 treatment.	 Stars	 show	 sta6s6cal	 significance	 of	 results	when	 24	
hour	traces	from	KNO3	treated	mice	were	compared	to	KCl	treated	mice	using	Two-way	ANOVAs:	
***	=	P<0.001,	****	=	P<0.0001	and	NS	=	Not	Significant	
KNO3 KCl n KNO3 KCl n
Mean	BP ê 106.1	±	2.8	*** 109.2	±	5.8 6 NS 141.1	±	5.8 141.8	±	3.5 8
Systolic	BP NS 119.8	±		3.6 119.9	±	5.7 6 é 166.8	±	7.2	*** 161.8	±	4.1 8
Diastolic	BP ê 91.8	±	2.3	**** 98.8	±	6.7 6 ê 119.5	±5.3	**** 124.5	±3.2 8
Activity é 6.8	±	0.9	**** 4.7	±	0.7 6 é 7.6	±1.5	**** 5.6	±1.2 8
Heart	Rate NS 588.9	±	4.6 598.7	±	19.8 6 ê 579.7	±16.6	*** 599.0	±	17.0 8
Baseline Day	21	ANGII
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Figure 3.17 BP telemetry data from ANGII pre-treatment study mice, normalised to activity level 
Figure shows mouse A) 24-hour traces and B) averages of activity level. Also shown are C) mean, D) systolic and E) 
diastolic BP and F) hearts rate normalised to activity. Data are shown at baseline and on Day 21 of ANGII infusion in 
mice with 15 mM KNO3 or KCl pre-treatment. Data are presented as averages of 24-hour data from telemetric 
monitoring, with mean ± SEM and n = 8. P-values show statistical significance when data are compared across a 24-
hour period using Two-way ANOVA. 
3.9.5. Effect of oral nitrate on organ bath pharmacology in ANGII-
infused mice 
Organ bath assays were carried out to compare the effects of oral nitrate treatment on 
the vasoreactivity of mouse aortas from controls and ANGII infused mice. In aortic rings 
from ANGII infused mice, pre-contracted with 10-5 M PE, both ACh and SNO 
concentration-dependent relaxation-response curves were rightward shifted 
(approximately 3-fold and 1.5-fold shift respectively) in KCl pre-treated mice, compared 
to tap water fed controls. However, this effect was significantly attenuated in KNO3 pre-
treated mice (P<0.001, Figure 3.18D). ANGII infusion also suppressed the maximum 
response to ACh (but not SNO) in KCl fed mice. When concentration response curves of 
KNO3 and KCl pre-treated mice were compared using a two-way ANOVA, the effect of 
KNO3 treatment was found to be significant in both ACh (P<0.01) and SNO (P<0.001) 
curves. KNO3 pre-treatment had no significant effect on SNO concentration-response 
curves in control mice (Figure 3.18B) but caused a slight leftward shift in ACh curves in 
controls (P<0.05, Figure 3.18A).  
Dietary nitrate also had no significant effect on PE concentration-response curves in 
control mice (Figure 3.18C and Figure 3.18F).  
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Figure 3.18 Organ bath vessel reactivity of thoracic aortas from control and ANGII pre-treatment study mice fed 15 
mM KNO3 or KCl. 
Graphs show A) and D) acetylcholine-induced (ACh) relaxation and B) and E) spermine NONOate-induced (SNO) 
relaxation concentration-responses with 10-5 M phenylephrine (PE) pre-contraction and C) and F) PE-induced 
contraction concentration-response of aortic rings. Data are shown from control, ANGII pre-treatment and ANGII 
reversal study mice fed either 15 mM KNO3 (grey) or 15 mM KCl (white) pre-treatment. Data are shown as mean ± 
SEM, with n ≥ 5. Mice were sacrificed aged 13-15 weeks. P-values show statistical significance when curves were 
compared with two-way ANOVA. 
3.9.6. Effect of nitrate on mRNA markers in ANGII-infused mice 
3.9.6.1. TGFb, CTGF, Col1 and Col3  
A significant increase in CTGF mRNA expression was measured in heart homogenates 
from ANGII-infused mice when compared to KCl control mice using RT-PCR. This increase 
was significantly attenuated by KNO3 pre-treatment (Figure 3.19B). There was also a 
trend towards increased Col1a expression, which again appeared to be attenuated by 
KNO3 pre-treatment (Figure 3.19C). However, this did not reach statistical significance 
with the sample size which was available.  
Col3 mRNA also showed a trend towards being increased by ANGII infusion, but with no 
apparent effect from KNO3 pre-treatment (Figure 3.19D). 
Despite no clear results, there seemed to be a slightly greater increase in TGFb 
expression in KNO3 fed ANGII-infused mice compared to ANGII + KCl-fed mice in the pre-
treatment study (Figure 3.19A). But again, this was not statistically significant.  
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Figure 3.19 mRNA expression of TGBFβ, CTGF, Col1 and Col3 in heart tissue from control and ANGII pre-treatment 
study mice. 
Figure shows mRNA expression of A) transforming growth factor β (TGFβ) B) connective tissue growth factor (CTGF), 
C) type I collagen (Col1a) and D) type III collagen (Col3) in whole heart homogenate from controls and ANGII pre-
treated mice fed 15 mM KNO3 or KCl. For RT-PCR, all samples were plated in duplicate, with gene expression measured 
relative to internal control 18S. Results are expressed relative to KCl fed controls using ΔΔCT analysis. Data are 
expressed as mean ± SEM with n = 6-12. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses: * = P<0.05. 
3.9.6.2. AT1Ra and BNP 
AT1Ra mRNA showed a trend towards being increased by ANGII infusion in both KCl and 
KNO3 fed mice, with no apparent effect from KNO3 pre-treatment (Figure 3.20A). BNP 
mRNA showed a trend towards being increased by ANGII infusion in both KCl and KNO3 
fed mice, with no clear effect from KNO3 pre-treatment (Figure 3.20B). 
Figure 3.20 mRNA expression of AT1Ra and BNP in heart tissue from control and ANGII pre-treatment study mice. 
Figure shows mRNA expression of A) angiotensin type 1 receptor (AT1Ra) and B) brain natriuretic peptide (BNP) in 
whole heart homogenate from controls and ANGII pre-treated mice fed 15 mM KNO3 or KCl. For RT-PCR, all samples 
were plated in duplicate, with gene expression measured relative to internal control 18S. Results are expressed 
relative to KCl fed controls using ΔΔCT analysis. Data are expressed as mean ± SEM with n = 6-12. Data were tested 
for statistical significance using one-way ANOVA with Sidak’s post-hoc analysis. P-values for one-way ANOVA are 
shown in the graphs and stars represent statistical significance determined by post-hoc analyses. 
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3.9.6.3. XDH, NLRP1 and NLRP3 
There was no clear effect of either ANGII infusion, or KCl or KNO3 feeding on XDH mRNA 
expression in the ANGII pre-treatment study (Figure 3.21A).  
There was no clear effect of either ANGII infusion, or KCl or KNO3 feeding on NLRP1 and 
NLRP3 mRNA expression in the ANGII pre-treatment study (Figure 3.21B and Figure 
3.21C).  
Figure 3.21 mRNA expression of AT1Ra and BNP in heart tissue from control and ANGII pre-treatment study mice. 
Figure shows mRNA expression of A) xanthine oxidoreductase (XDH), B) NLR family pyrin domain containing 1 (NLRP1) 
and C) NLR family pyrin domain containing 3 (NLRP3) in whole heart homogenate from controls and ANGII pre-treated 
mice fed 15 mM KNO3 or KCl. For RT-PCR, all samples were plated in duplicate, with gene expression measured 
relative to internal control 18S. Results are expressed relative to KCl fed controls using ΔΔCT analysis. Data are 
expressed as mean ± SEM with n = 6-12. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses. 
3.9.7. Effect of oral nitrate on oxidative stress in hearts from ANGII 
pre-treatment mice 
Whole heart homogenates from ANGII-infused mice were incubated with substrates, 
including xanthine, NADH and NADPH, and resulting superoxide generation measured 
using lucigenin chemiluminescence quantification.  
Inorganic nitrate significantly reduced baseline oxidative stress generation in mouse 
heart homogenates from ANGII-infused mice (P=0.04), as well as oxidative stress 
generated in the presence of xanthine (P=0.01), NADH (P=0.09) and NADPH (P=0.02, 
Figure 3.22). 
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Figure 3.22 Superoxide generation quantified by lucigenin chemiluminescence in heart homogenates from ANGII 
study mice. 
Figure shows superoxide generation in mouse heart homogenates from ANGII-infused mice with either 15 mM KNO3 
or KCl pre-treatment. Superoxide generation was measured by quantifying lucigenin chemiluminescence generated 
at baseline or upon homogenate incubation with substrates including Xanthine, NADPH, NADH. Data are represented 
as mean ± SEM with n = 13. P-values show statistical significance of results when data are compared to KCl fed mice 
under the same ANGII regimen using Student’s T-tests. 
3.9.8. The effects of dietary nitrate on XOR protein expression in 
control and ANGII-infused mice 
ANGII-infusion resulted in a significant increase in XOR protein expression in mouse 
livers as measured by western blot immunoassay. There was no significant attenuation 
of this increase in mice with dietary nitrate pre-treatment (Figure 3.23). 
Figure 3.23 The effects of dietary nitrate on XOR protein expression in control and ANGII-infused mice. 
Figure shows A) an example blot with XOR and beta-actin protein expression measured in liver homogenates by 
western blot analysis and B) XOR data normalised to beta actin expression. Data are expressed as mean ± SEM, with 
n = 4-8. Data were tested for statistical significance using one-way ANOVA with Sidak’s post-hoc analysis. The P-value 
for one-way ANOVA is shown in the graph but there were no significant differences according to post-hoc analyses.  
3.9.9. Enhanced XOR activity in ANGII mice pre-treated with KCl 
compared to ANGII mice pre-treated with KNO3 
ANGII-infusion increased the H2O2 generating capacity of XOR in mouse liver 
homogenates (P<0.0001, Figure 3.24). There were significantly lower levels of 
conventional XOR activity measured in pre-treatment study mice fed KNO3 compared to 
KCl-fed mice under the same ANGII regimen (P<0.001, Figure 3.24).  
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Figure 3.24 XO activity in liver homogenates from control, ANGII pre-treatment and reversal study mice. 
Figure shows level of conventional XO activity present in mouse liver homogenates from control and ANGII infused 
mice with either 15 mM KNO3 or KCl pre-treatment or reversal treatment. XO activity was measured by quantifying 
H2O2 generation using a commercially available kit. Data are represented as mean ± SEM with n = 8. Data were tested 
for statistical significance using one-way ANOVA with Sidak’s post-hoc analysis (A) or Student’s T-tests (B). P-values 
for one-way ANOVAs and T-tests are shown in the graphs. Stars represent statistical significance determined by post-
hoc analyses: *** = P<0.001 and **** = P<0.0001. 
3.9.10. The effects of dietary nitrate on nitrite reductase 
activity in control and ANGII-infused mice 
Nitrite reductase capacity, as measured by gas phase ozone chemiluminescence, in 
mouse heart homogenate was significantly greater in mice receiving dietary nitrate 
compared to KCl-fed mice in both control (P=0.005, Figure 3.25A) and ANGII-infused 
mice (P=0.004, Figure 3.25B). 
Figure 3.25 The effect of dietary nitrate on nitrite reductase capacity of heart tissue in a chemiluminescence assay. 
Cardiac nitrite reductase activity was measured by ozone chemiluminescence at pH 7.4 by incubating heart 
homogenate with nitrite at incremental doses. Data are represented as mean ± SEM with n = 6-7. P-values show 
statistical significance when curves were compared with two-way ANOVA. Stars represent statistical significance with 
Sidak’s post-hoc analysis: * = P<0.05. 
3.9.11. The effects of dietary nitrate on Nox2 protein 
expression in ANGII-infused mice 
The expression of Nox2 protein was quantified by western blot analysis in mouse aortas. 
Due to the restricted number of available samples, and the fact that XOR was of more 
significant interest to our studies, this preliminary data was obtained only in ANGII pre-
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treatment mice. There was a trend towards reduced expression of Nox2 in nitrate fed 
ANGII-infused mice compared to KCl fed controls under the same ANGII regimen. 
However, this was not statistically significant (Figure 3.26). 
Figure 3.26 The effects of dietary nitrate on Nox2 protein expression in ANGII-infused mice. 
Figure shows Nox2 protein expression measured in aorta homogenates by western blot analysis, with protein levels 
normalised to beta actin expression. Data are represented as mean ± SEM with n = 7. Data were tested for statistical 
significance using Students’ T-test and the P-values is shown in the graph. 
 Nitrate reversal treatment in ANGII infused mice 
3.10.1. The effect of nitrate on heart weights in ANGII-
pretreated mice 
Although HW:BW ratios, overall heart weight and LV:BW ratios showed subtle, but 
consistent, trends towards attenuation in ANGII-infused mice with KNO3 reversal 
treatment (Figure 3.27), these were not statistically significant when compared to KCl-
fed mice. 
Figure 3.27 Heart weight data from ANGII study mice. 
Figure shows A) whole heart weights as well as B) heart weight: body weight, C) left ventricle: body weight and D) 
right ventricle: left ventricle ratios for control mice and ANGII pre-treatment study mice fed either 15 mM KNO3 or 
KCl. Data are represented as mean ± SEM. Data were tested for statistical significance using a one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses: * = P<0.05, **** = P<0.0001. 
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3.10.2. Nitrate reversal treatment reduces ANGII-induced LV 
wall thickening measured by echocardiography 
Echocardiography was performed at the end of the study in ANGII reversal mice fed 
KNO3 or KCl. LVPWd thickness was significantly reduced in mice fed KNO3 reversal 
treatment when compared to KCl fed mice under the same ANGII regimen (ANGII+KCl: 
1.2 ± 0.09 mm; ANGII+KNO3 Pre: 1.0 ± 0.04 mm;  P=0.02) – see representative M-mode 
images in Figure 3.28A and Figure 3.28B, and data in Figure 3.28C. The same findings 
were also true of LVPWs dimensions (Figure 3.28D). LV mass was also significantly 
reduced in mice fed KNO3 reversal treatment when compared to KCl fed mice (P<0.05, 
Figure 3.28I). Ejection fraction was not significantly changed by KNO3 reversal treatment 
in ANGII-infused mice (Figure 3.28G). 
There were also no significant differences in IVSd, IVSs, LVIDd, LV end diastolic volumes 
or wall:lumen ratios when compared between treatment groups using one-way ANOVA 
(Figure 3.28E-H and Figure 3.28K). 
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Figure 3.28 End of study echocardiography measurements from ANGII reversal study mice. 
Figure shows representative M-mode images, acquired using Vevo 770 echocardiography software and equipment 
from A) ANGII + KNO3 reversal and B) ANGII + KCl reversal mice. Images were acquired under 1.5-2% isofluorane 
inhalation anaesthetic. Measurements of the intra-ventricular septum (IVS), left ventricle posterior wall (LVPW) and 
left ventricle internal dimension (LVID) were taken during diastole (d) and systole (s). The image represents a total of 
20ms of echocardiographic recording. Resulting LVPWd, LVPWs, IVSd, IVSs, LVIDd dimensions, LV end diastolic 
volume, LV mass, ejection fraction and wall:lumen ratios are shown in C), D) E), F), G), H), I), J) and K) respectively. 
Data are represented as mean ± SEM with n = 17-18. Data were tested for statistical significance using Student’s T-
test, and p-values shown in the graphs. 
3.10.3. Effect of nitrate reversal treatment on cardiac fibrosis, 
measured by PSR staining 
There was no significant attenuation of fibrosis with oral nitrate in ANGII reversal mice 
(P = 0.7, Figure 3.29A). 
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Figure 3.29 Collagen deposition as quantified by PSR staining in ANGII reversal study mouse hearts. 
Figure shows PSR staining carried out on 4 μm sections of formalin fixed hearts, embedded in paraffin. Hearts were 
randomly assigned to be sectioned in either the transverse or dorsal plane and stained with PSR to identify areas of 
connective tissue deposition. Images were acquired using a NanoZoomer slide scanner (Hamamatsu) and viewed 
using NDP View software. Three left ventricle, three intraventricular septum and three right ventricle fields of view 
were randomly selected at x20 magnification and PSR staining quantified using manual thresholding techniques in 
ImageJ software. Figure shows quantification of staining in ANGII-infused mice with KNO3 or KCl reversal treatment. 
Sections B) and C) show representative staining images at x 1.25 magnification in all treatment groups. Data are 
represented as mean ± SEM with n = 7. Data were tested for statistical significance using Student’s T-test, with 
resulting P-value shown in the graph.  
3.10.4. Effect of nitrate reversal treatment on organ bath 
pharmacology 
KNO3 reversal treatment had no significant effect on ACh, SNO or PE concentration-
response curves in ANGII-infused mice (Figure 3.30).  
Figure 3.30 Organ bath vessel reactivity of thoracic aortas from ANGII reversal study mice fed 15 mM KNO3 or KCl. 
Graphs show G) acetylcholine-induced (ACh) relaxation and H) spermine NONOate-induced (SNO) relaxation 
concentration-responses with 10-5 M phenylephrine (PE) pre-contraction and I) PE-induced contraction 
concentration-response of aortic rings. Data are shown from control, ANGII pre-treatment and ANGII reversal study 
mice fed either 15 mM KNO3 (grey) or 15 mM KCl (white) pre-treatment. Data are shown as mean ± SEM, with n ≥ 5. 
Mice were sacrificed aged 13-15 weeks. P-values show statistical significance when curves were compared with two-
way ANOVA. 
3.10.5. Effect of nitrate on mRNA markers in ANGII-infused 
mice 
3.10.5.1. TGFb, CTGF, Col1 and Col3 
There was a slight, but non-significant increase in TGFb expression with KNO3 feeding in 
the ANGII reversal study compared to KCl fed mice (Figure 3.31D), and there was a 
significant increase in Col3 expression (P=0.04, Figure 3.31D). There was no significant 
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effect of KNO3 reversal treatment on CTGF or Col1a mRNA expression in ANGII-infused 
mice (Figure 3.31B and Figure 3.31C).  
Figure 3.31 mRNA expression of TGBFβ, CTGF, Col1 and Col3 in heart tissue from ANGII reversal study mice. 
Figure shows mRNA expression of A) transforming growth factor β (TGFβ) B) connective tissue growth factor (CTGF), 
C) type I collagen (Col1a) and D) type III collagen (Col3) in whole heart homogenate from ANGII reversal study mice 
treated with 15 mM KNO3 or KCl. For RT-PCR, all samples were plated in duplicate, with gene expression measured 
relative to internal control 18S. Results are expressed relative to KCl fed controls using ΔΔCT analysis. Data are 
expressed as mean ± SEM with n = 10-11. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses: * = P<0.05. 
3.10.5.2. AT1Ra and BNP 
There was no difference in AT1Ra mRNA expression when KNO3 and KCl ANGII reversal 
mice were compared (Figure 3.32A), but there was a significant increase in BNP 
expression with KNO3 reversal treatment (P<0.02, Figure 3.32B). 
Figure 3.32 mRNA expression of AT1Ra and BNP in heart tissue from ANGII reversal study mice. 
Figure shows mRNA expression of A) angiotensin type 1 receptor (AT1Ra) and B) brain natriuretic peptide (BNP) in 
whole heart homogenate from ANGII reversal study mice treated with 15 mM KNO3 or KCl. For RT-PCR, all samples 
were plated in duplicate, with gene expression measured relative to internal control 18S. Results are expressed 
relative to KCl fed controls using ΔΔCT analysis. Data are expressed as mean ± SEM with n = 10-11. Data were tested 
for statistical significance using one-way ANOVA with Sidak’s post-hoc analysis. P-values for one-way ANOVA are 
shown in the graphs and stars represent statistical significance determined by post-hoc analyses. 
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3.10.5.3. XDH, NLRP1 and NLRP3 
There was no difference in XDH or NLRP1 mRNA expression when KNO3 and KCl ANGII 
reversal mice were compared (Figure 3.33A and Figure 3.33B), but there was a 
significant increase in NLRP3 expression with KNO3 reversal treatment (Figure 3.33C).  
Figure 3.33 mRNA expression of XDH, NLRP1 and NLRP3 in heart tissue from ANGII reversal study mice. 
Figure shows mRNA expression of A) xanthine oxidoreductase (XDH), B) NLR family pyrin domain containing 1 (NLRP1) 
and C) NLR family pyrin domain containing 3 (NLRP3) in whole heart homogenate from ANGII reversal study mice 
treated with 15 mM KNO3 or KCl. For RT-PCR, all samples were plated in duplicate, with gene expression measured 
relative to internal control 18S. Results are expressed relative to KCl fed controls using ΔΔCT analysis. Data are 
expressed as mean ± SEM with n = 6-12. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses. 
3.10.6. Enhanced XOR activity in reversal ANGII mice treated 
with KCl compared to with KNO3 
There were significantly lower levels of conventional XOR activity measured in reversal 
(P=0.004) study mice fed KNO3 compared to KCl-fed mice under the same ANGII regimen 
(P=0.04, Figure 3.34).  
Figure 3.34 XO activity in liver homogenates from control, ANGII pre-treatment and reversal study mice. 
Figure shows level of conventional XO activity present in mouse liver homogenates from control and ANGII infused 
mice with 15 mM KNO3 or KCl reversal treatment. XO activity was measured by quantifying H2O2 generation using a 
commercially available kit. Data are represented as mean ± SEM with n = 8. Data were tested for statistical significance 
using Student’s T-test, with P-value shown in the graph.  
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 Result One – Summary 
In summary, we have confirmed the ANGII model to be an effective method for 
producing a BP-dependent model of cardiac dysfunction in mice – inducing endothelial 
dysfunction, hypertension and a reduction in ejection fraction with a significant increase 
in heart weight, LVH and cardiac fibrosis and superoxide generation.  
In this model, dietary nitrate pre-treatment significantly attenuated: 
• Endothelial dysfunction (P<0.01) and hypertension (P<0.002). 
• LVH as measured by echocardiography (P<0.0001) and LV:BW ratios (P<0.05). 
• Cardiac CTGF mRNA expression (P<0.05) as measured by RT-PCR, and fibrosis 
(P<0.001) as measured by PSR staining. 
• XOR-mediated H2O2 production (P<0.01) and superoxide generation (P<0.05). 
• NADPH oxidase-mediated superoxide generation (P<0.05). 
Furthermore, dietary nitrate pre-treatment increased nitrite reductase capacity in heart 
homogenate (P<0.01).  
Dietary nitrate reversal treatment significantly attenuated: 
• LVH as measured by echocardiography (P<0.0001), with borderline significance 
in LV:BW ratios (P<0.06). 
However, there were no further significant differences when other parameters were 
compared. 
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4. CHAPTER FOUR - The effect of dietary nitrate on a BP-indepent model of 
cardiac dysfunction 
Following our findings that dietary nitrate could significantly attenuate cardiac 
hypertrophy in a BP-dependent mouse model, as well as reducing oxidative stress, it 
was of particular interest to establish whether all of the benefits observed were 
attributed to BP reduction. 
As one way in which many currently available treatments aim to reduce pathological 
hypertrophy is by reducing BP, it makes sense that the effects of nitrate on BP in the 
ANGII model could significantly attenuate cardiac hypertrophy. However, in clinical 
studies, not all anti-hypertensives reverse cardiac hypertrophy to the same degree, 
despite producing similar reductions in BP (Ferreira Filho et al. 2010).  
With both animal and clinical studies having previously highlighted NO as a direct 
negative-modulator of cardiac hypertrophy (Buys et al. 2007; Hou et al. 1995; Ichinose 
et al. 2004; McNamara et al. 2003; Pechánová et al. 1999), independent of its actions as 
a vasodilator, we set out to investigate the potential of dietary nitrate in an isoprenaline 
(BP-independent) model of cardiac dysfunction. 
 BP-independent model of cardiac dysfunction – isoprenaline 
hydrochloride 
In an identical study design to the ANGII pre-treatment model, mice were randomly 
assigned to one of 4 treatment groups – KNO3 control, KCl control, isoprenaline + KNO3 
pre-treatment or isoprenaline + KCl pre-treatment (see Figure 4.1). 
Controls - Mice received 15 mM KNO3 or 15 mM KCl in drinking water ad libitum for 5 
weeks. 
Isoprenaline Pre-treatment - Mice received 15 mM KNO3 or 15 mM KCl in drinking water 
ad libitum for 2 weeks prior to beginning a 3-week subcutaneous (SC) infusion of 15 
mg/kg/day isoprenaline hydrochloride (Sigma® Life Science, UK) in 0.25% (w/v) ascorbic 
acid (Sigma Aldrich®, UK) from an ALZET® 1004 osmotic minipump (Durect Corporation, 
USA). Water feeding treatments were continued concomitantly for the remainder of the 
study, alongside isoprenaline infusion. In this study echocardiography was conducted 
sequentially at baseline (the day before minipump implantation surgery), and at weekly 
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intervals thereafter for 3 weeks. Another subset of mice underwent tail cuff BP 
measurements during the final week of isoprenaline infusion. 
Figure 4.1 Experimental Design for isoprenaline studies. 
Schematic illustrating the experimental design for isoprenaline pre-treatment studies. Schematics illustrate the 
duration of 15mM KCl (control) or 15mM KNO3 (treatment) feeding and 15 mg/kg/day isoprenaline hydrochloride 
infusion. The points of osmotic minipump (*) implantation are marked, and days on which echocardiography (Echo) 
and tail cuff BP (tail cuff) measurements were taken are indicated. 
 Isoprenaline formulation 
For the filling of osmotic minipumps, isoprenaline hydrochloride (Sigma® Life Science, 
UK) was weighed out and formulated in 0.25% ascorbic acid as required according to 
mouse weights and pump specifications. Ascorbic acid (Sigma Aldrich®, UK) was 
formulated in sterile saline.  This isoprenaline hydrochloride solution was filtered using 
a 2 ml syringe and MILLEX® GP 0.22μm filter (Merck Millipore, UK) prior to minipump 
filling. 
 Isoprenaline oxidation assay 
In preparation for isoprenaline formulation, 0.25%, 0.5%, 0.625%. 1.25%, 2.5% and 5% 
w/v solutions of ascorbic acid in saline were each used to formulate a 180 mg/ml 
isoprenaline hydrochloride solution (Sigma® Life Science, UK). These solutions were kept 
in 5 ml Eppendorf tubes for 12 days and tested periodically for oxidation measured by 
colour change by plating 150 μl of each sample in duplicate and measuring using a 
TECAN Sunrise 96 well plate reader at 405 nm light wavelength.  
After analysing results from this assay after 12 days (Figure 4.2A), the assay was 
repeated with the two most optimal concentrations of ascorbic acid (0.25% and 5%) for 
23 days (the length of time that the isoprenaline formulation would be in the mice in 
osmotic minipumps) - Figure 4.2B). Isoprenaline exhibited minimal oxidation (as 
measured by colour change) when formulated in 0.25% ascorbic acid. For this reason, 
0.25% ascorbic acid was used for formulating isoprenaline in preparation for filling 
osmotic minipumps in this study. 
15 mM KCl or 15 mM KNO3
15 mg/kg/day Isoprenaline 
Day 0 Day 7 Day 14 Day 21 Day 28 Day 35
*
Isoprenaline Pre-treatment
EchoEchoEcho Echo
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Figure 4.2 Isoprenaline oxidation following formulation in varying concentrations of ascorbic acid. 
Graphs show oxidation of 180 mg/ml isoprenaline hydrochloride (Sigma® Life Science, UK) solution over time, when 
formulated in varying concentrations of ascorbic acid. Oxidation was quantified by measuring average colour change 
using a TECAN Sunrise 96 well plate reader at 405 nm light wavelength, with 150μl of each solution plated in duplicate. 
Assay 1 compared A) 0%, 0.25%, 0.5%, 0.625%. 1.25%, 2.5% and 5% and Assay 2 B) 0%, 0.25% and 0.5% w/v solutions 
of ascorbic acid in saline over a 12-day period and 23-day period respectively.  
 Model verification – the effects of isoprenaline on heart rate and BP 
In order to confirm that isoprenaline induces a significant increase in heart rate, without 
a significant rise in BP (inducing a BP-independent model of cardiac hypertrophy), 
mouse heart rate was recorded during echocardiography imaging under light 
anaesthesia. Isoprenaline induced a significant increase in heart rate compared to 
control mice (P<0.001, Figure 4.3A), and this increase was maintained throughout the 3 
weeks of isoprenaline infusion (Figure 4.3B). In addition to the fact that there was no 
significant rise detected in isoprenaline-infused BP (Controls: 143 ± 3 vs. Isoprenaline: 
159 ± 4 mmHg see section 3.8), and cardiac hypertrophy was observed both visually 
(Figure 4.3C) and by increases in heart weights (see section 4.9), these results confirm 
the  BP-independent nature of this model of cardiac hypertrophy. 
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Figure 4.3 Heart rates recorded during echocardiography in isoprenaline study mice pre-treated with 15 mM KNO3 
or KCl and resulting heart images from harvesting after 3 weeks of isoprenaline infusion. 
Figure shows A) average heart rates recorded during echocardiography on control mice and mice receiving 2 
mg/kg/day or 15 mg/kg/day isoprenaline fed 15 mM KCl. Also shown are B) weekly heart rates recorded during 
echocardiography in isoprenaline-infused mice with 15 mM KNO3 (Grey) or KCl (white) pre-treatment. Heart rates are 
shown at baseline (Week 0 – the day prior to isoprenaline minipump implantation) and an average of values recorded 
in subsequent weeks (Week 1-3 following minipump implantation). Heart rates were recorded while under ~2% 
isofluorane inhalation anaesthetic. Data are expressed as mean ± SEM with n = 14-15. Also shown are C) Photographs 
of hearts following harvesting from control and isoprenaline-infused mice, with KCl or KNO3. Data are represented as 
mean ± SEM. Data were tested for statistical significance using one-way ANOVA with Sidak’s post-hoc analysis. P-
values for one-way ANOVA are shown in the graphs and stars represent statistical significance determined by post-
hoc analyses: **** = P<0.0001. 
 Dietary nitrate increases plasma nitrite and nitrate in isoprenaline-
infused mice 
Figure 4.4 Nitrate and nitrite concentrations in plasma of isoprenaline pre-treatment and reversal study mice. 
Graphs show A) nitrate (mM) and B) nitrite (μM) concentrations in plasma of control, isoprenaline pre-treatment 
mice, fed either 15 mM KNO3 or KCl water. Data are represented as mean ± SEM with n ≥ 18. Data were tested for 
statistical significance using a one-way ANOVA with Sidak’s post-hoc analysis. P-values for one-way ANOVAs are 
shown in the graphs. Stars represent statistical significance determined by post-hoc analyses: 
* = P<0.05, **** = P<0.0001 
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Ad libitum 15 mM KNO3 feeding through drinking water successfully raised plasma 
nitrate in both controls and isoprenaline infused mice (P<0.0001, Figure 4.4A). 
Furthermore, dietary nitrate feeding significantly increased plasma nitrite in controls 
(1.1 ± 0.1 vs. 1.6 ± 0.2, mean ± SEM, P<0.01)  and isoprenaline infused mice (1.0 ± 0.1 
vs. 1.5 ± 0.2, P<0.03) - Figure 4.4B.  
 The effect of isoprenaline infusion on mouse weight, and food and 
water consumption 
4.6.1. Water and nitrate consumption  
Water consumption was slightly, but significantly raised in KNO3 and KCl fed isoprenaline 
study mice compared to control (P<0.01 and P<0.05 respectively, Table 4.1). Increased 
water consumption resulted in slightly increased doses of nitrate being received by the 
nitrate-fed isoprenaline-infused mice compared to KNO3 controls (P<0.05, Table 4.1). 
4.6.2. Body weight 
There were no significant differences in the starting body weights of mice in any of the 
studies conducted (Table 4.2). However, isoprenaline infused mice had significantly 
greater rises in body weight compared to controls when end of study body weights were 
compared (P<0.05, Table 4.2). There was no significant difference in body weights 
between KNO3 and KCl treatment groups. 
4.6.3. Food consumption 
Food consumption was significantly increased in isoprenaline-infused mice with both 
nitrate (P<0.05) and KCl (P<0.01) feeding compared to controls (Table 4.2). There was 
no significant difference in food consumption between KNO3 and KCl treatment groups. 
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 cGMP Assay 
In the cGMP enzymeimmunoassay, despite there being a significant increase in plasma 
nitrite concentrations measured using ozone chemiluminescence in all nitrate-fed mice, 
there was no detectable difference found when cGMP expression was compared in 
isoprenaline-infused mice fed KCl or KNO3 pre-treatment (Figure 4.5). 
Figure 4.5 cGMP immunoassay results in 
isoprenaline-infused mice with KCl or 
KNO3 pre-treatment. 
Data are represented as mean ± SEM with 
n = 7-8. P-value shows there was no 
statistical significance of results when data 
were compared using Student’s T-test. 
 
 
 
 
 
 
 Mortality 
Overall mortality was reported as 21.5% and 14.3% for KCl and KNO3 pre-treated 
isoprenaline-infused mice respectively. Deaths tended to occur within the first 5 days 
following minipump implantation. Mice did not present with overt health issues prior to 
death and were found unexpectedly dead in their cages. Importantly, survival curves 
were not significantly different when isoprenaline-infused mice with KCl or KNO3 pre-
treatment were compared using the Gehan-Breslow-Wilcoxon test (Figure 4.6). 
Figure 4.6 Mortality in isoprenaline-
infused mice with KCl or KNO3 pre-
treatment.  
Kaplan-Meier mortality curves for 
isoprenaline-infused mice with KCl or 
KNO3 pre-treatment with n = 42. P-value 
shows there was no statistical 
significance of results when curves were 
compared using two-way ANOVA. 
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 Effect of nitrate on heart weights in isoprenaline-infused mice 
Isoprenaline infusion significantly increased overall heart weight (P<0.0001), HW:BW 
ratios (P<0.0001) and LV:BW ratios (P<0.01) in our model (Figure 4.7A-C). Overall heart 
weights were significantly attenuated by dietary nitrate pre-treatment (Iso+KCl: 179 ± 4 
g; Iso+KNO3 Pre: 166 ± 4 g, P<0.05, Figure 4.7A) as well as HW:BW ratios (Iso+KCl: 6.1 ± 
0.1; Iso+KNO3 Pre: 5.7 ± 0.1, P<0.05, Figure 4.7B). There were no significant effects on 
RV:LV ratios (Figure 4.7D). 
Figure 4.7 Heart weights data from isoprenaline study mice. 
Figure shows A) whole heart weights as well as B) heart weight: body weight, C) left ventricle: body weight and D) 
right ventricle: left ventricle ratios for control mice and isoprenaline pre-treatment study mice fed either 15 mM KNO3 
or KCl. Data are represented as mean ± SEM. Data were tested for statistical significance using a one-way ANOVA 
with Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses: 
* = P<0.05, ** = P<0.01, **** = P<0.0001. 
 Oral nitrate improves cardiac ejection fraction in an 
isoprenaline model of cardiac dysfunction 
Echocardiography was performed at baseline and at 1, 2 and 3 weeks in control and 
isoprenaline infused mice fed KNO3 or KCl pre-treatment. Ejection fraction was 
significantly reduced across the 3-week isoprenaline infusion period in KCl-fed 
isoprenaline-infused mice compared to KCl controls (P<0.001). However, KNO3 pre-
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treatment significantly preserved ejection fraction in isoprenaline-infused mice 
(P<0.0001, Figure 4.8L and Figure 4.10G).  
Significant increases in LVIDd (P<0.01, Figure 4.8I and), LV end diastolic volume (P<0.01, 
Figure 4.8J) and LV mass (P<0.001, Figure 4.8K) were also observed in KCl fed mice 
following isoprenaline infusion. These effects were significantly attenuated by KNO3 pre-
treatment when compared across the 3-week infusion period Figure 4.10C (P=0.001), 
and Figure 4.10E (P=0.001) and Figure 4.10I (P=0.0005).  
Slight, but significant increases in LVPW thickness were observed in KCl-fed isoprenaline-
infused mice when compared to KCl controls (P<0.01, Figure 4.8E). There was no 
significant attenuation with dietary nitrate when curves from KNO3 and KCl pre-treated 
mice were compared across the 3-week infusion period (P=0.3, Figure 4.10A).  
There were no significant differences in IVSd, IVSs, LVIDd, LV end diastolic volumes or 
wall:lumen ratios when compared between treatment groups and there were no 
significant effects of KNO3 compared to KCl feeding on cardiac structure and 
performance in controls (Figure 4.9). 
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Figure 4.8 End of study echocardiography measurements from isoprenaline pre-treatment and control study mice. 
Figure shows representative M-mode images, acquired using Vevo 770 echocardiography software and equipment 
from A) KNO3 control B) KCl control C) isoprenaline + KNO3 pre-treatment and D) isoprenaline + KCl pre-treatment 
mice. Images were acquired under ~2% isofluorane inhalation anaesthetic. Measurements of the intra-ventricular 
septum (IVS), left ventricle posterior wall (LVPW) and left ventricle internal dimension (LVID) were taken during 
diastole (d) and systole (s). The image represents a total of 20ms of echocardiographic recording. Resulting LVPWd, 
LVPWs, IVSd, IVSs, LVIDd dimensions, LV end diastolic volume, LV mass, ejection fraction and wall:lumen ratios are 
shown in E), F) G), H), I) and J) respectively. Data are represented as mean ± SEM with n = 15. Data were tested for 
statistical significance using a one-way ANOVA with Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown 
in the graphs and stars represent statistical significance determined by post-hoc analyses: *= P<0.05, ** = P<0.01, 
*** = P<0.001. 
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Figure 4.9 Echocardiography measurements from isoprenaline study control mice fed 15 mM KNO3 or KCl. 
Figure shows echocardiography data collected at baseline (0) and after 1, 2 and 3-weeks. Data were acquired using 
Vevo 770 echocardiography software and equipment in KNO3 control and KCl control mice, fed 15mM KNO3 or KCl 
for a total of 5 weeks (with 2 weeks of feeding prior to baseline Week 0 echocardiography session). Resulting A) 
LVPWd, B) LVPWs, C) LVIDd, D) LVIDs, E) LVVd, F) LVVs, G) Ejection fraction, H) Fractional shortening, I) LV mass, J) 
Wall:lumen ratios and K) Stroke volume are shown. Data are represented as mean ± SEM with n = 15. P-values show 
statistical significance when curves were compared with two-way ANOVA. 
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Figure 4.10 Echocardiography measurements from isoprenaline-infused mice fed 15 mM KNO3 or KCl pre-
treatment. 
Figure shows echocardiography data collected at baseline (0) and after 1, 2 and 3-weeks of isoprenaline infusion. 
Data were acquired using Vevo 770 echocardiography software and equipment in isoprenaline + KNO3 pre-treatment 
and isoprenaline + KCl pre-treatment mice. Resulting A) LVPWd, B) LVPWs, C) LVIDd, D) LVIDs, E) LVVd, F) LVVs, G) 
Ejection fraction, H) Fractional shortening, I) LV mass, J) Wall:lumen ratios and K) Stroke volume are shown. Data are 
represented as mean ± SEM with n = 15. P-values show statistical significance when curves were compared with two-
way ANOVA. Stars shown statistical significance with Tukey’s post-hoc comparisons: * = 0.05, ** = P<0.01 
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 Effect of oral nitrate on cardiac fibrosis in isoprenaline treated 
mice, measured by PSR staining 
3-week isoprenaline infusion caused a significant increase in fibrosis as measured by PSR 
staining in formalin-fixed mouse hearts (P<0.05, Figure 4.11). Although not statistically 
significant, dietary nitrate showed a trend towards attenuating fibrosis in isoprenaline-
infused mice compared to KCl-fed isoprenaline controls (Figure 4.11).  
Figure 4.11 Level of collagen deposition as quantified by picrosirius red (PSR) staining. 
Figure shows PSR staining carried out on 4 μm sections of formalin fixed hearts, embedded in paraffin. Hearts were 
randomly assigned to be sectioned in either the transverse or dorsal plane and stained with PSR to identify areas of 
connective tissue deposition. Images were acquired using a NanoZoomer slide scanner (Hamamatsu) and viewed 
using NDP View software. Three left ventricle, three intraventricular septum and three right ventricle fields of view 
were randomly selected at x20 magnification and PSR staining quantified using manual thresholding techniques in 
ImageJ software. Figure shows quantification of staining in controls and isoprenaline-infused mice with KNO3 or KCl 
pre-treatment Sections B) – E) show representative staining images at x 1.25 magnification in all treatment groups. 
Data are represented as mean ± SEM with n = 6-7. Data were tested for statistical significance using one-way ANOVA 
with Sidak’s post-hoc analysis. P-value for one-way ANOVA is shown in the graph, with stars representing statistical 
significance determined by post-hoc analyses: * = P<0.05. 
 
 Effect of oral nitrate on organ bath pharmacology in 
isoprenaline-infused mice 
Organ bath assays were carried out to compare the effects of oral nitrate treatment on 
the vasoreactivity of mouse aortas from isoprenaline infused mice. KNO3 pre-treatment 
had no significant effect on ACh or SNO concentration-response curves in isoprenaline 
infused mice (Figure 4.12A and Figure 4.12B). Dietary nitrate also had no significant 
effect on PE concentration-response curves in isoprenaline infused mice (Figure 4.12C). 
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Figure 4.12 Organ bath vessel reactivity of thoracic aortas from isoprenaline study mice fed 15 mM KNO3 or KCl 
pre-treatment. 
Graphs show A) acetylcholine-induced (ACh) relaxation and B) spermine NONOate-induced (SNO) relaxation 
concentration-responses of aortic rings pre-contracted with 10-5 M phenylephrine (PE) and C) PE-induced contraction 
concentration-response of aortic rings from isoprenaline study mice fed either 15 mM KNO3 (Grey) or 15 mM KCl 
(White) pre-treatment. Data are shown as mean ± SEM, with n ≥ 5. Mice were sacrificed aged 13-15 weeks. P-values 
show statistical significance of results when compared using two-way ANOVA. 
 Effect of nitrate on mRNA markers in isoprenaline-infused mice 
4.13.1. TGFb, CTGF, Col1 and Col3 
Figure 4.13 mRNA expression of TGBFβ, CTGF, Col1 and Col3 in heart tissue from isoprenaline study mice. 
Figure shows mRNA expression of A) transforming growth factor β (TGFβ) B) connective tissue growth factor (CTGF), 
C) type I collagen (Col1a) and D) type III collagen (Col3) in whole heart homogenate from isoprenaline pre-treatment 
study mice treated with 15 mM KNO3 or KCl. For RT-PCR, all samples were plated in duplicate, with gene expression 
measured relative to internal control 18S. Results are expressed relative to KCl fed controls using ΔΔCT analysis. Data 
are expressed as mean ± SEM with n = 6-10. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses: * = P<0.05, ** = P<0.01. 
There was a significant increase in CTGF (P<0.01) and Col1a (P<0.01) mRNA expression 
in hearts from isoprenaline-infused mice compared to KCl controls. These increases 
were significantly attenuated by KNO3 pre-treatment (P<0.05, Figure 4.13A and P<0.05, 
Figure 4.13B). There was a trend towards increased expression of Col3 in isoprenaline 
infused mice, but no clear effect with nitrate feeding. There was a trend towards 
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increased TGFb expression following isoprenaline infusion, which was less pronounced 
in KNO3-fed isoprenaline-infused mice (Figure 4.13D). 
4.13.2. AT1Ra and BNP 
There was no clear effect of isoprenaline infusion or KNO3 feeding on AT1Ra mRNA 
expression (Figure 4.14A). There was a trend towards increased BNP expression 
following isoprenaline infusion, which was potentially more pronounced in KNO3-fed 
isoprenaline-infused mice (Figure 4.14B). 
Figure 4.14 mRNA expression of AT1Ra and BNP in heart tissue from isoprenaline study mice. 
Figure shows mRNA expression of A) angiotensin type 1 receptor (AT1Ra) and B) brain natriuretic peptide (BNP) in 
whole heart homogenate from isoprenaline pre-treatment study mice treated with 15 mM KNO3 or KCl. For RT-PCR, 
all samples were plated in duplicate, with gene expression measured relative to internal control 18S. Results are 
expressed relative to KCl fed controls using ΔΔCT analysis. Data are expressed as mean ± SEM with n = 6-10. Data 
were tested for statistical significance using one-way ANOVA with Sidak’s post-hoc analysis. P-values for one-way 
ANOVA are shown in the graphs and stars represent statistical significance determined by post-hoc analyses. 
4.13.3. Xdh, NLRP1 and NLRP3 
There was no statistically significant effect of either isoprenaline infusion or KNO3 
feeding on XDH mRNA expression (Figure 4.15A). There was no significant effect of 
either isoprenaline infusion or KNO3 feeding on NLRP1 or NLRP3 mRNA expression 
(Figure 4.15B and Figure 4.15C). 
Figure 4.15 mRNA expression of XDH, NLRP1 and NLRP3 in heart tissue from isoprenaline study mice. 
Figure shows mRNA expression of A) xanthine oxidoreductase (XDH), B) NLR family pyrin domain containing 1 (NLRP1) 
and C) NLR family pyrin domain containing 3 (NLRP3) in whole heart homogenate from isoprenaline pre-treatment 
study mice treated with 15 mM KNO3 or KCl. For RT-PCR, all samples were plated in duplicate, with gene expression 
measured relative to internal control 18S. Results are expressed relative to KCl fed controls using ΔΔCT analysis. Data 
are expressed as mean ± SEM with n = 6-10. Data were tested for statistical significance using one-way ANOVA with 
Sidak’s post-hoc analysis. P-values for one-way ANOVA are shown in the graphs and stars represent statistical 
significance determined by post-hoc analyses. 
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 Effect of oral nitrate on oxidative stress in the isoprenaline-
infused heart measured by lucigenin chemiluminescence  
Whole heart homogenates from isoprenaline-infused mice were incubated with 
substrates including xanthine, NADPH and NADH, and resulting superoxide generation 
measured using lucigenin chemiluminescence quantification.  
Nitrate feeding significantly reduced baseline superoxide generation (P=0.02, Figure 
4.16A) as well as NADPH-driven superoxide formation (P=0.02). However, there was no 
significant effect on superoxide formation when heart homogenates were incubated 
with xanthine or NADH (Figure 4.16B).  
Figure 4.16 Superoxide generation quantified by lucigenin chemiluminescence in heart homogenates from 
isoprenaline study mice. 
Figure shows superoxide generation in mouse heart homogenates from isoprenaline-infused mice with either 15 mM 
KNO3 or KCl pre-treatment. Superoxide generation was measured by quantifying lucigenin chemiluminescence 
generated at baseline or upon homogenate incubation with substrates including Xanthine, NADPH, NADH. Data are 
represented as mean ± SEM with n = 5. P-values show statistical significance of results when data are compared to 
KCl fed mice under the same isoprenaline regimen using Student’s T-tests. 
 The effects of dietary nitrate on XOR protein expression in 
control and isoprenaline-infused mice 
There was no significant difference in XOR protein expression as measured by western 
blot immunoassay in livers from control and isoprenaline-infused mice. Furthermore, 
there was no difference in XOR expression between KNO3 and KCl treatment groups 
(Figure 4.17). 
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Figure 4.17 The effects of dietary nitrate on XOR protein expression in control and isoprenaline-infused mice 
Figure shows XOR protein expression measured in liver homogenates by western blot analysis, normalised to beta 
actin expression. Data are expressed as mean ± SEM, with n = 4-7. Data were tested for statistical significance using 
one-way ANOVA with Sidak’s post-hoc analysis. The P-value for one-way ANOVA is shown in the graph but there were 
no significant differences according to post-hoc analyses.  
 XOR activity in isoprenaline mice pre-treated with KCl 
compared to isoprenaline mice pre-treated with KNO3 
There was no significant difference in conventional XO activity measured in liver 
homogenates from isoprenaline-infused mice, fed KCl or KNO3 pre-treatment (Figure 
4.18). 
Figure 4.18 XO activity in liver homogenates from isoprenaline treated mice. 
Figure shows level of conventional XO activity present in mouse liver homogenates from isoprenaline-infused mice 
with either 15 mM KNO3 or KCl pre-treatment. XO activity was measured by quantifying H2O2 generation using a 
commercially available kit. Data are represented as mean ± SEM with n = 8. Data were tested for statistical significance 
using Student’s T-test. The P-value for the T-test is shown in the graph. 
 The effects of dietary nitrate on nitrite reductase activity in 
isoprenaline-infused mice 
Nitrite reductase capacity, as measured by gas phase ozone chemiluminescence in 
mouse heart homogenate, was significantly greater in isoprenaline-infused mice 
receiving dietary nitrate compared to KCl-fed mice (P<0.0001, Figure 4.19). 
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Figure 4.19 The effect of dietary nitrate on nitrite reductase capacity of heart tissue in an ozone chemiluminescence 
assay. 
Cardiac nitrite reductase activity was measured by ozone chemiluminescence at pH 7.4 by incubating heart 
homogenate with nitrite at incremental doses. Data are represented as mean ± SEM with n = 6-7. P-values show 
statistical significance when curves were compared with two-way ANOVA. Stars represent statistical significance with 
Sidak’s post-hoc analysis: * = P<0.05, *** = P<0.001 
 Result Two – Summary 
In summary, we have confirmed the isoprenaline model to be an effective method for 
producing a BP-independent model of cardiac dysfunction in mice – inducing a 
significant and sustained increase in heart rate, reduction in ejection fraction, increases 
in heart weight, LVH, cardiac fibrosis and superoxide generation, but with no significant 
hypertension observed.  
In this model, dietary nitrate pre-treatment significantly attenuated: 
• Isoprenaline-induced decline in ejection fraction (P<0.0001). 
• Cardiac hypertrophy as measured by HW:BW ratios (P<0.05), but with no effect 
on wall thickness.  
• NADPH-oxidase mediated superoxide generation (P<0.05). 
• Cardiac CTGF and Col1a mRNA expression as measured by RT-PCR (P<0.05), with 
a trend towards reduced cardiac fibrosis as measured by PSR staining. 
Furthermore, dietary nitrate pre-treatment increased nitrite reductase capacity in heart 
homogenate (P<0.01). 
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5. CHAPTER FIVE - Examining the cardiovascular phenotype of Xdh KO mice 
Findings from both the ANGII and isoprenaline studies highlighted the potential of 
dietary nitrate to reduce oxidative stress in our models of cardiac dysfunction and 
identified XOR as one of the key sources of superoxide generation (particularly in the 
ANGII model of cardiac dysfunction). With XOR also capable of acting as a nitrite 
reductase, it has been previously hypothesised that this complex enzyme may have the 
potential to be ‘repurposed,’ acting as a beneficial nitrite reductase, as opposed to a 
detrimental superoxide generator when an abundance of nitrate/nitrite is provided as 
a substrate (Tripatara et al. 2007; Khambata et al. 2015). This hypothesis seemed to be 
supported by the findings of various experiments in mice supplemented with dietary 
nitrate in the ANGII study.  
With the recent generation of Xdh KO mice, we therefore set out to further probe the 
importance of this complex enzyme in both cardiovascular health and disease, by 
examining the cardiovascular phenotypes of WT and Het mice, both with and without 
ANGII. 
 Xdh KO mice – generation and genotyping 
The Xdh gene codes for XDH protein. Xdh KO mice were first reported in a paper in 2004 
by Ohtsubo et al., where they were generated following disruption of exons 3 and 4, and 
intron 3, which were all replaced by a phosphoglycerate kinase/neo cassette (Figure 
5.1A). Embryonic stem cells were deposited in the mutant mouse resource and research 
centres (MMRRC) following their initial development (Ohtsubo et al. 2004). Het 
breeding pairs were set up in-house, resulting in WT (+/+), Het (+/-) and KO (-/-) mice. 
Mouse colonies were maintained, and genotyping conducted, by Tipparat Parakaw and 
offspring allocated randomly to the various projects in the lab. To identify genotypes of 
offspring, ear clips were lysed overnight at 55oC using proteinase K (0.3 mg/ml) in 
DirectPCR ear lysis buffer (Bioquote, UK). These samples were incubated at 85oC for 
45min and then kept at 4oC. Two primers pairs were used to identify WT and KO gene 
sequences. WT primers; forward 5'-CCTATGCCTTCCACAGTTGT-3' and reverse 3'-
CACCGTGATGATCTCCAAGT-5'. KO primers: forward 5'-ATGCGATGTTCGCTTGGTGG-3 
and reverse 3'-CTATTCGGCTATGACTGGGC -5'. For each sample 2 different master mixes 
were used containing 12.5 µl 2x Biomix Red (Bioline, UK), 9.5 µl H2O and 1 µl forward 
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and 1 µl reverse primers (10 µM) for either WT or KO primers. These were each added 
to 1 µl of DNA sample in PCR tubes. PCR conditions used: 94°C for 3 min, then 35 cycles 
of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min, and 72°C for 7min. The amplified 
products (WT 1500bp and KO 350bp) were loaded and run on a 1.5% agarose gel. 
Resulting bands were visualised using a FlourChem Imager (Protein Simple, USA), see 
Figure 5.1B. 
 Study design – The impact of knocking out the Xdh gene on ANGII-
induced hypertension and cardiac dysfunction 
Full global Xdh KO mice do not survive past 5 weeks of age (Ohtsubo et al. 2004). 
Therefore, with the long-term nature of this study, Het mice (which exhibit	~50% Xdh 
transcript reduction compared to WT) were compared to WT littermate controls. Mice 
were randomly assigned to one of 4 treatment groups – WT control, Het control, WT + 
ANGII or Het + ANGII. Tail cuff BP measurements were carried out at 4, 8, 12, 14 and 16 
weeks of age in these mice, as well as echocardiographic measurements at the 8, 12, 14 
and 16-week timepoints (See 
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Figure 5.1 Schematic of WT and targeted alleles in Xdh KO mouse colonies, and examples 
of bands visible on a 1.5% agarose gel from PCRs for Xdh WT (+/+), Het (+/-) and KO (-/-) 
mice. 
Figure with A) Schematic illustrating a WT Xdh allele and a targeted Xdh allele with 
disruption of intron 3 and exons 3 and 4 with a phosphoglycerate kinase/neo expression 
cassette in KO mice, and B) examples of PCR gels with resulting bands from Xdh WT (+/+), 
Het (+/-) and KO (-/-) mice. PCR products were loaded onto a 1.5% agarose gel and visualised 
using a FlourChem Imager (Protein Simple, USA). Xdh WT = 1500 bp, KO = 350 bp and Het = 
1500 bp and 350 bp. 
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Figure 5.2). At 12 weeks of age some of the mice received a 4-week subcutaneous (SC) 
infusion of 2 mg/kg/day ANGII (Sigma Aldrich®, UK) in saline, from ALZET® 1004 osmotic 
minipumps (Durect Corporation, USA). The minipumps were implanted after the 12-
week tail cuff and echo measurements had been taken, meaning the 4, 8 and 12-week 
data represents baseline, with 14 and 16-week data post ANGII infusion.  
 
Figure 5.2 Experimental Design for Xdh KO mouse studies with and without ANGII. 
Schematic illustrating the experimental design for A) Xdh Het (+/-) or WT (+/+) littermate control mice cardiovascular 
phenotyping and B) investigating the effects of 2 mg/kg/day ANGII for 4 weeks on Xdh Het (+/-) compared to WT (+/+) 
littermate control mice. The points of osmotic minipump (*) implantation are marked, and days on which tail cuff BP 
telemetry (BP) and echocardiography (Echo) measurements were taken are indicated. 
 ANGII formulation 
For the filling of osmotic minipumps, ANGII (Sigma Aldrich®, UK) was dissolved under 
sterile conditions to yield a 25 mg/ml stock solution in sterile saline. This 25 mg/ml stock 
was then diluted accordingly in LoBind tubes (Eppendorf, UK) for minipump filling 
according to mouse weights and pump specifications. 25 mg/ml ANGII was stored at 4°C 
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for up to 3 days or at -20°C for up to 1 month. If stored at -20°C, ANGII was not freeze-
thawed more than twice.  
 Tail cuff BP in Xdh WT (+/+) and Het (+/-) mice 
When tail cuff BP was measured in Xdh WT (+/+) and Het (+/-) mice across a 24-week 
period, Het mice had significantly higher BP than WT littermate controls. This was 
observed in systolic, diastolic and mean BP (P<0.0001, Figure 5.3). 
 
Figure 5.3 Tail cuff BP of Xdh Hets compared to WT littermate controls. 
Figure shows A) Systolic B) Diastolic and C) Mean tail cuff BP measured in WT (+/+) and Het (+/-) Xdh mice at 4, 8, 12, 
14, 16, 20 and 24 weeks of age. Tail cuff data was collected using a modified CODA tail cuff setup (Kent Scientific) 
with data for each time point averaged from 4 days of recording, with each day consisting of 5 acclimation cycles and 
10 recorded data cycles. Data are represented as mean ± SEM (n=6-7) with p-values shown following comparison with 
two-way ANOVA. Stars represent statistical significance of points when Sidak’s multiple comparisons post-hoc 
analysis is carried out: 
* = P<0.05, ** = P<0.01, *** = P<0.001 
 Tail cuff BP in ANG-infused Xdh WT and Het mice 
When tail cuff BP was measured in ANGII-infused Xdh WT and Het mice, ANGII-induced 
increases in BP were significantly attenuated in Xdh Het mice (Figure 5.4). This was 
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observed in systolic (P<0.0001), diastolic (P=0.0003) and mean BP (P=0.003) alike (Figure 
5.4). 
Figure 5.4 Tail cuff BP of Xdh Hets (+/-) compared to WT (+/+) littermate controls at baseline (4, 8 and 12 weeks) 
and following ANGII infusion (14 and 16 weeks). 
Figure shows A) Systolic B) Diastolic and C) Mean tail cuff BP measured in WT (+/+) and Het (+/-) Xdh mice at baseline 
(4, 8, 12 weeks of age) and with ANGII 2 mg/kg/day infusion by osmotic minipump (14 and 16 weeks of age). Osmotic 
minipumps were implanted at 12 weeks of age following the 12-week baseline tail cuff measurements. Tail cuff data 
was collected using a modified CODA tail cuff setup (Kent Scientific) with data for each time point averaged from 4 
days of recording, with each day consisting of 5 acclimation cycles and 10 recorded data cycles. Data are represented 
as mean ± SEM (n=6-7) with p-values shown following comparison with two-way ANOVA. Stars represent statistical 
significance of points when Sidak’s multiple comparisons post-hoc analysis is carried out: 
* = P<0.05, ** = P<0.01, *** = P<0.001 
 Echocardiography in Xdh WT and Het mice 
At 8 weeks of age there were no significant differences detected in any 
echocardiographic parameters when Xdh WT and Het mice were compared (Figure 5.5). 
At 16 weeks of age there were trends observed towards increased LVID (Figure 5.5C and 
Figure 5.5D), LV Volume (Figure 5.5E and Figure 5.5F) and LV mass (Figure 5.5I) 
compared to 8 weeks in both WT and Hets. This increase may appeared somewhat more 
pronounced in Xdh Het mice.  
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There was also a possible trend towards reduced ejection fraction, fractional shortening 
and stroke volume in Xdh Het mice at 16 weeks old compared to WT age-matched 
controls (Figure 5.5G, Figure 5.5H and Figure 5.5K). 
Figure 5.5 Echocardiography measurements at 8 and 16 weeks of age in Xdh WT and Het mice. 
Figure shows data acquired using Vevo 3100 echocardiography software and equipment with A) LVPWd, B) LVPWs, 
C) LVIDd, D) LVIDs, E) LVVd, F) LVVs, G) Ejection fraction, H) Fractional shortening, I) LV mass, J) Wall:Lumen ratio, K) 
Stroke volume and L) E’A’ Ratios shown for Xdh WT and Het mice at 8 and 16 weeks of age. Data are represented as 
mean ± SEM with n= 5-10. P-values show statistical significance of results when data are compared using two-way 
ANOVA. 
 
Doppler flow data in Xdh WT and Het mice showed there was no clear difference 
between 8 and 16-week old mice. However, VTI was significantly greater in WT 
compared to Xdh Het mice (P=0.03, Figure 5.6A). Trends towards higher mean velocity, 
mean gradient, peak velocity and peak gradients were observed in WTs compared to 
age-matched Xdh Het mice (Figure 5.6B-E). 
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Figure 5.6 Aortic flow measurements obtained during echocardiography recording at 8 and 16 weeks of age in Xdh 
WT and Het mice. 
Figure shows A) Aorta VTI, B) Mean velocity, C) Mean gradient, D) Peak velocity and E) Peak gradient data acquired 
using doppler flow on the Vevo 3100 echocardiography software and equipment. Data are shown for Xdh WT and 
Het mice at 8 and 16 weeks of age. Data are represented as mean ± SEM with n= 5-10. P-values show statistical 
significance of results when data are compared using two-way ANOVA. 
 Echocardiography in ANG-infused Xdh WT and Het mice 
In the control mice from the ANGII Xdh KO study we observed the same trends in LVPW, 
LVID, LV volume, ejection fraction, fractional shortening and LV mass that had been seen 
in 16-week old Xdh WT and Het mice (Figure 5.7). 
Following 3 weeks of ANGII infusion we saw a similar reduction in ejection fraction in 
both Xdh WT and Het mice (Figure 5.7G) and similar increases in LVPW dimensions 
(Figure 5.7A and Figure 5.7B). However, trends suggest that LVID and LV volume may 
be somewhat attenuated in Xdh Hets compared to WT mice. 
Doppler flow data in control Xdh WT and Het mice from the ANGII Xdh KO study, 
exhibited the same differences as those seen previously in 16-week old mice (Figure 
5.8). Following 3 weeks of ANGII infusion we observed a trend towards reduced VTI, 
mean gradient, mean velocity, peak gradient and peak velocity in both Xdh WT and Het 
mice. Both in controls and following ANGII infusion there were significantly reduced 
measures of aortic velocity in Xdh Het mice compared to WT littermate controls, with 
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reduced VTI (P=0.06), mean gradient (P=0.02), mean velocity (P=0.02), peak gradient 
(P=0.03) and peak velocity (P=0.03). 
Figure 5.7 Echocardiography measurements in 16-week old control and ANGII-infused Xdh WT and Het mice.  
Figure shows data acquired using Vevo 3100 echocardiography software and equipment with A) LVPWd, B) LVPWs, 
C) LVIDd, D) LVIDs, E) LVVd, F) LVVs, G) Ejection fraction, H) Fractional shortening, I) LV mass, J) Wall:Lumen ratio and 
K) Stroke volume shown for Xdh WT and Het mice at 16 weeks of age with or without ANGII 2 mg/kg/day. Data are 
represented as mean ± SEM with n= 4-6. P-values show statistical significance of results when data are compared 
using two-way ANOVA.  
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Figure 5.8 Aortic flow measurements obtained during echocardiography recording in 16-week old control and 
ANGII-infused Xdh WT and Het mice.  
Figure shows A) Aorta velocity time interval (VTI), B) Mean velocity, C) Mean gradient, D) Peak velocity and E) Peak 
gradient data acquired using doppler flow on the Vevo 3100 echocardiography software and equipment. Data are 
shown for Xdh WT and Het mice at 16 weeks of age with or without ANGII 2 mg/kg/day. Data are represented as 
mean ± SEM with n= 4-6. P-values show statistical significance of results when data are compared using ANCOVA.  
 Langendorff cardiac function in Xdh WT and Het mice, with and 
without ANGII infusion 
Ex vivo hearts from control and ANGII-infused mice, both Xdh WTs and Hets, were set 
up in a Langendorff preparation. Basal coronary perfusion pressures (CPP) in control 
mice (with no ANGII infusion) followed the same trends as BP data from these mice 
acquired at 16-weeks by tail cuff 
methodology, with higher CPP observed in 
Hets compared to WT (Figure 5.9). ANGII-
infused mice also followed the same trends 
observed in BP data from ANGII-infused Xdh 
WTs and Hets, with WTs exhibiting raise BP 
compared to controls, but this effect 
attenuated in Hets (Figure 5.9). 
Figure 5.9 Coronary perfusion pressure data from ex vivo Langendorff hearts of 16-week old control and ANGII-
infused Xdh WT (+/+) and Het (+/-) mice.  
Figure shows A) Basal CPP and B) CPP AUC following L-NAME infusion. Data are shown for Xdh WT (+/+) and Het (+/-
) mice at 16 weeks of age with or without ANGII 2 mg/kg/day. Data are represented as mean ± SEM with n= 4-8. P-
values show statistical significance of results when data are compared using one-way ANOVA but there were no 
significant differences according to post-hoc analyses.  
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There was a significantly greater response to Bradykinin in Xdh Hets when 
concentration-response curves were compared in control mice (P=0.03, Figure 5.10A), 
but no significant difference in ANGII-infused mice (even perhaps a trend towards the 
opposite). There were potentially reduced responses to SNP when comparing Xdh Hets 
to WTs in both control and ANGII-infused mice. However, these results were not 
statistically significant.  
Figure 5.10 Concentration-response bradykinin and SNP data from ex vivo Langendorff hearts of 16-week old 
control and ANGII-infused Xdh WT and Het mice.  
Figure shows bradykinin concentration-response curves in ex vivo Langendorff hearts from 16-week old controls (A) 
or ANGII-infused (B) mice. Also shown are SNP concentration-response curves in the same 16-week old mice either 
C) controls or D) ANGII-infused mice. Data are represented as mean ± SEM with n= 4-6. P-values shown following 
comparison with two-way ANOVA. 
 Results Three - Summary 
In summary, Xdh Hets at baseline exhibited: 
• Significantly higher BP measured by tail cuff (P<0.0001) and trends towards 
higher CPP in Langendorff when compared to their WT counterparts. 
• Trends towards increased LVID, LV Volume and LV mass at 16 weeks of age 
compared to WTs. 
• Trends towards reduced ejection fraction, fractional shortening and stroke 
volume at 16 weeks of age compared to WTs.  
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• Significantly reduced VTIs as measured by doppler flow in the descending aorta 
compared to WTs (P=0.03), with consistent trends towards lower mean and 
peak velocities and gradients. 
Following 3 weeks of ANGII infusion, Xdh Hets exhibited: 
• Significant attenuation of ANGII-induced hypertension compared to WTs 
(P<0.0001) and a trend towards attenuation in ANGII-induced increases in CPP.  
• A trend towards attenuation in ANGII-induced increases in LVID, LV volumes and 
LV mass. 
• No difference in ANGII-induced decline in ejection fraction or increases in LVPW 
dimensions compared to WTs.  
• Significantly reduced measures of aortic velocity compared to WTs, with reduced 
VTI (P=0.06), mean gradient (P=0.02), mean velocity (P=0.02), peak gradient 
(P=0.03) and peak velocity (P=0.03). 
Table 5.1 Table highlighting the key BP and cardiac phenotyping observations noted which differed between Xdh 
Het and WT mice. 
Xdh WT 
(+/+)
Xdh Het 
(+/-)
Co
nt
ro
l
Blood pressure
LV Volume
Ejection fraction 
LV mass
Peak Velocity
Basal CPP
130 mmHg 
37 μl
70%
52 mg
736 mm/s
75 mmHg
137 mmHg 
47 μl
65%
71 mg
645 mm/s
134 mmHg
AN
GI
I
Blood pressure
LV Volume
Ejection fraction 
LV mass
Peak Velocity
Basal CPP
180 mmHg
56μl
59%
122mg
662 mm/s
115 mmHg
129 mmHg
47μl
61%
114mg
561 mm/s
76 mmHg
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6. CHAPTER SIX – Discussion 
 Study background – Nitrate in HF and LVH 
NO has long been recognised as a potent endogenous vasodilator, with constitutive 
production by eNOS in the vascular endothelium vital in mediating hormone-induced 
vasorelaxation and helping maintain healthy BP (Furchgott & Zawadzki 1980; Ignarro et 
al. 1987; Palmer et al. 1987; Huang et al. 1995). More recently, it has been discovered 
that inorganic nitrate (the end product of NO oxidative metabolism) can be reduced 
back to bioactive NO via the enterosalivary circuit (Webb, Milsom, et al. 2008; Lundberg, 
Weitzberg & Gladwin 2008b; Lundberg & Weitzberg 2010b). Furthermore, these studies 
(and those discussed below) highlight how it is possible to increase circulating 
nitrate/nitrite to physiologically relevant levels in the clinic through nitrate salt 
supplementation or a diet rich in green leafy vegetables such as spinach and beetroot 
(or their juices) thus providing a cheap, effective, long-term, exogenous source of NO. 
Beneficial effects of dietary nitrate supplementation include reducing BP (Kapil et al. 
2015; Webb et al., 2008b), platelet activity (Apostoli et al. 2014; Webb et al., 2008a) 
inflammation (Jädert et al. 2012; Raubenheimer et al. 2017; T. Yang et al. 2017) and 
oxidative stress (Ashor et al. 2016; Carlstrom et al. 2011; T. Yang et al. 2015), as well as 
improving endothelial function (D. A. Hobbs et al. 2013), mitochondrial efficiency 
(Larsen et al. 2011), exercise capacity  (Eggebeen et al. 2016; A. M. Jones 2014; Zamani 
et al. 2014; Zamani et al. 2015) and muscle contractile function (Coggan et al. 2015; 
Zamani et al. 2014; Zamani et al. 2015). 
These aforementioned benefits could potentially improve quality of life and clinical 
outcomes significantly for HF patients. Indeed, through chemical reduction to NO, 
dietary nitrate has already proven to be beneficial in HFpEF (Eggebeen et al. 2016; 
Zamani et al. 2015). However, the mechanisms resulting in these clinical observations 
are yet to be elucidated. The data presented in this thesis suggest that dietary nitrate 
can improve cardiac function by exerting direct effects upon cardiac structure as well as 
by mediating BP lowering (which leads to improvements in cardiac structure/function 
secondary to BP lowering). This data highlights that the beneficial cardiac effects relate 
to anti-hypertrophic mechanisms driven predominantly by reductions in XOR-derived 
ROS at the level of the blood vessel and within the heart when BP is the primary 
stumulus. However, in the absence of hypertension, the benefits of dietary nitrate, at 
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least in part, relate to reductions in NADPH oxidase driven ROS production as well as 
reductions in pro-fibrotic signalling pathways. Therefore, irrespective of the underlying 
cause of cardiac dysfunction, dietary nitrate treatment could potentially improve 
cardiac function through reductions in damaging ROS and cardiac fibrosis, in the clinical 
setting of cardiac disease.  
In data soon to be published by the Ahluwalia lab, in patients with treated yet 
uncontrolled hypertension, significantly lower plasma nitrite levels were associated with 
pathological LVH compared to individuals without hypertrophy. Flow mediated 
dilatation was also significantly worse when LVH cases were compared to controls 
(unpublished Gee et al., 2020). With plasma nitrite concentration being inversely 
correlated to baseline BP (Kapil et al. 2013; Bondonno et al., 2015) and changes in 
plasma nitrite concentrations strongly correlated with changes in BP in both directions 
(Kapil et al. 2015), these findings further support our hypothesis that dietary nitrate 
provision in individuals with LVH would be clinically beneficial, particularly in those with 
treated, but uncontrolled blood pressure. 
 Clinical translation of dietary nitrate - circulating intermediates and 
metabolites 
Dietary nitrate, as expected, caused an increase in circulating levels of nitrate and nitrite 
in both models of cardiac dysfunction; confirming that the enterosalivary circuit remains 
intact in these models. Interestingly, plasma nitrite and nitrate concentrations in ANGII-
infused mice were ~2 and ~10-fold greater than those of nitrate-fed controls. Water 
consumption measured during the experimental protocol indicates that this increase 
relates to ANGII-induced polydipsia, likely due to stimulation of thirst receptors in the 
brain (Rowland & Fregly 1988).  Importantly, the amount of water consumed was not 
different in mice receiving KNO3 or KCl. 
However, most importantly, the increases in plasma nitrite concentrations (the key 
intermediate responsible for the beneficial effects of dietary nitrate) demonstrated 
using 15 mM KNO3 in drinking water available ad libitum are clinically translatable to a 
patient population. In clinical studies by Kapil et al., average increases in plasma nitrite 
concentrations, of 0.3 and 0.5 µM respectively, resulted in demonstrable clinical 
reductions in BP (Kapil et al. 2010; Kapil et al. 2015). The 15 mM dosing regimen used in 
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the present animal studies, provided between 3 and 10 mmol/kg/day KNO3 dependent 
on treatment group, and resulted in increases of 0.6 µM, 1.8 µM, 3.0 µM and 0.5 µM in 
controls, ANGII pre-treatment, ANGII reversal and isoprenaline pre-treatment mice 
respectively.  It should be noted that whilst the daily dose provided is 100-fold greater 
than the typical 0.07-0.8 mmol/kg/day given in a 5.5 or 6.4 mmol daily dose in the Kapil 
et al., clinical studies, it is shown both in our results and by other labs using animal 
models with dietary nitrate (e.g. Baliga et al., 2012) that the rises in plasma nitrite 
observed are comparable to those measured in in clinical studies. It is uncertain why in 
mice higher doses of nitrate are required, compared to those needed in humans, to 
achieve similar levels of circulating nitrite. It is possible that the pharmacokinetics of 
nitrite are slightly different between the species; relating perhaps to the renal clearance 
of nitrite, decreased capacity of the microbiome, or more avid oxidation of nitrite to 
nitrate. Further studies to investigate this are therefore required.  
Further still, the dose of nitrate required to increase plasma nitrite to a clinically relevant 
level in humans is achievable by consumption of a diet rich in green leafy vegetables 
(Hord et al. 2009), and can provide an equivalent nitrate dose to those of beetroot juice 
regimens. Our intervention is therefore highly translatable to a human patient 
population, and it would be possible to increase plasma nitrite to a similar level in HF 
patients through dietary supplementation using beetroot juice, or a diet rich in green 
leafy vegetables.  
Clinical studies, including those in our lab, have shown that raising circulating nitrite 
results in NO generation that is reflected by elevations in the downstream signalling 
molecules for NO, namely cGMP (Velmurugan et al., 2013). However, unlike the 
published human studies, in the mouse (despite elevations in circulating nitrite and clear 
biological activity of the dietary nitrate dosing regimen) no rise in plasma cGMP levels 
could be detected. With cGMP hypothesised to be a mediator of many of the beneficial 
effects of dietary nitrate/nitrite this is unfortunate, but not unprecedented. In a study 
by Baliga et al., despite having shown beneficial effects of 15 mM KNO3 in a mouse 
hypoxia-induced model of pulmonary hypertension, increases in cGMP were not 
detectable. However, in mice with 45 mM KNO3 feeding, a significant increase in cGMP 
was detectable with n=12-16 (Baliga et al. 2012). It is therefore possible, that with higher 
n-numbers we may have been able to uncover significant results. It is unclear exactly 
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why measurement of differences in cGMP concentrations in plasma has proven 
particularly difficult in mouse samples. It could be that PDE activity is significantly higher 
in mice compared to humans and despite the addition of IBMX to our samples, cGMP 
may be too rapidly metabolised for precise measurement to be feasible. As cGMP 
changes in cGMP expression have been detected in mouse platelets (Gambaryan et al. 
2007) it could be possible that measurement in platelets in future may provide a more 
sensitive assessment of this parameter. 
Additionally, it must be noted that although cGMP is highly likely to be a key mediator 
involved in the beneficial effects of dietary nitrate observed in our studies (particularly 
since pM concentrations of NO are capable of activating guanylyl cyclase (Batchelor et 
al. 2010)), it is by no means the only mechanism for NO signalling which may be 
occurring. Nitrosation of various proteins has been reported to underlie the biological 
effects of nitrite under various conditions. For example, nitrite exerts cardioprotective 
effects during ischaemia, that are associated with the selectively s-nitrosation of specific 
protein thiols. The s-nitrosation of mitochondrial proteins in particular has been 
highlighted by Couchani et al., and thought to influence mitochondrial energy 
metabolism in hypoxia and hence positive effects of nitrite. The methods employed by 
this group of identifying s-nitrosated thiols is a tool which could be extremely useful in 
future when searching for potential protein modifications of importance occurring in 
specific tissues and models following dietary nitrate/nitrite regimens (Chouchani et al. 
2017). Chouchani et al., employed ‘SNOxICAT’ methodology on harvested mouse 
myocardial tissue following four in vivo interventions. The thiols in the samples were 
stabilized by homogenization in 20% TCA containing 0.5% sulphanilamide. Unmodified 
protein thiols were labelled with ‘light’ C0-ICAT. S-nitrosated thiols were then chemically 
reduced in ascorbic acid and CuSO4 and labelled with ‘heavy’ C9-ICAT. The biotin tagging 
from ICAT allowed the tagged proteins to be isolated, separated by liquid 
chromatography, then analysed by mass spectrometry. Crucially, this enables distinction 
between identical proteins of different S-nitrosation states. 
However, the theory that s-nitrosation of proteins in itself represents a stable change in 
protein regulation is a somewhat controversial topic. The reactivity of s-nitrosothiols 
(Broniowska & Hogg 2012) has been suggested to point towards the importance of these 
groups as transient intermediates prior to disulphide formation, as opposed to having 
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direct implications on protein function themselves (Wolhuter et al. 2018). Such 
advocates for the importance of disulphide bond formation in affected proteins are not 
disputing the existence or importance of s-nitrosation. However, they argue that the 
functional importance lies more-so with the resulting disulphide bond formation, rather 
than the transient protein s-nitrosation step. For some proteins, resistance to reduction 
and disulphide bond formation may occur due to the microenvironment they are found 
in (Paige et al. 2008). However, this is potentially the exception rather than the norm. 
Further assessment of s-nitrosation in the heart tissue of the experimental models used 
in this study would provide some insight into whether whether this pathway may be of 
importance in the setting of cardiac hypertrophy. 
 Model verification and mouse mortality 
The ANGII (BP-dependent) and isoprenaline (BP-independent) models were each 
validated by measuring tail cuff BP and mouse heart rates during echocardiography and 
comparing to values from control mice. The results showed a significant increase in BP 
in ANGII-infused mice, with no significant increase in isoprenaline-infused mice. 
Furthermore, in ANGII-infused mice no change was evident in heart rate compared to 
control mice. But isoprenaline-infused mice (as expected) exhibited significantly 
increased heart rates, which were sustained throughout the 3-week duration of study. 
Although in both the ANGII and isoprenaline models some mouse deaths were observed 
within the first 1-7 days following minipump implantation, the mortality recorded from 
each treatment group was not significantly different between KCl and KNO3-fed mice 
under each regimen. And importantly, the average mortality in the ANGII and 
isoprenaline studies were both under the 20% threshold deemed by the Home Office 
inspector to be worthy of re-assessing the methodology used. The use of osmotic mini-
pumps for both models provided an excellent opportunity to compare pathways 
without the confounding of distinct methods of generating cardiac hypertrophy.  
 Effects of dietary nitrate on BP, activity and endothelial function 
By measuring ambulatory BP, I was able to confirm that dietary nitrate significantly 
reduces BP both at baseline and in ANGII-infused mice. These findings are in accord with 
observations in healthy volunteers (Webb et al., 2008) and patients with hypertension 
(Kapil et al., 2015). However, the BP data was confounded by an increase in activity in 
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mice receiving nitrate. These experiments exposed an important aspect of measuring 
BP in mice receiving treatments that improve cardiac function i.e. that positive effects 
upon the heart may result in increased activity of mice and this in turn will result in 
‘apparent’ increases in BP (Adlam et al. 2011). Thus, to account for this we normalized 
BP to activity and in doing this a clear BP-lowering effect of dietary nitrate is evident 
with respect to both SBP and DBP. Whilst in some mouse studies using BP telemetry, 
activity levels are reported by the authors to not differ between treatment groups (e.g. 
Labonté et al. 2008; Kawada et al. 2005), other studies do not reference activity levels 
recorded during BP telemetry recording (e.g. Forrester et al. 2017; Manhiani et al. 2015). 
The findings in our present study highlight how important activity levels are when 
measuring BP in freely moving, conscious animals. It must therefore be considered that 
in some studies which have not taken into account such potential differences in their 
analyses, it is possible that by normalising BP to activity levels, differences in BP may be 
evidenced. 
Whilst in the ANGII model one can explain that the increased activity is due to improved 
cardiac health, the increased activity observed at baseline in the nitrate group (prior to 
ANGII infusion) indicates that other mechanisms are also likely involved. Indeed, dietary 
nitrate improves energy metabolism (Larsen et al. 2011), exercise capacity (Zamani et 
al. 2015; Eggebeen et al. 2016; Hirai et al. 2017; Zamani et al. 2017), as well as 
haemodynamic and muscle performance (Hernández et al. 2012; Ferguson et al. 2013; 
Coggan et al. 2015; Borlaug et al. 2016; Ferguson et al. 2016; Pironti et al. 2016). It 
should be considered that these improvements could in themselves be sufficient to 
stimulate mice to perform increased spontaneous activity in their home environment. 
It has also been previously reported that sildenafil (a selective phosphodiesterase 5 
inhibitor) enhances activity in a cGMP-mediated manner in mice (Demirci et al. 2014).  
Additionally, NO inhibition by L-NAME also blocks phenylcyclidine-induced locomotor 
activity (Johansson et al. 1997). These findings, taken together with our data, suggest 
that NO likely underlies the observations.  As increased activity can have a significant 
effect on mouse BP (Adlam et al. 2011), we therefore normalised BP values to their 
corresponding locomotor activity measured at all timepoints. 
With ANGII infusion inducing such a severe BP phenotype, the reductions observed in 
this study may appear modest at »9 mm/Hg and »7 mm/Hg respectively. However, such 
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reductions would indeed be clinically significant if similar reductions were observed in 
hypertensive patients. For example, a meta-analysis investigating the effects of lowering 
BP on HF, determined that reducing SBP by just 5 mmHg reduced risk of HF development 
by »24% (Verdecchia et al. 2009). Furthermore, effectively controlling high BP by 
reducing it to a target of <140 mmHg, it is possible to reduce one’s risk of developing 
heart failure by ≈52% (Meredith & Ostergren 2006). Thus, suggesting that a level of BP 
reduction similar to that observed in our study would indeed be of clinical benefit, and 
may have been enough to instigate some of the improvements in cardiac structure 
observed in our echocardiographic assessments.  
The published findings of the SPRINT study in 2015 has  emphasised the significance of 
BP lowering in HF development further still (SPRINT Research Group et al. 2015). With 
an intensive BP treatment strategy (to a target BP of <120 mmHg) having been shown 
to have a significant effect on the incidence of HF in this population over and above a 
traditional BP treatment target of <140 mmHg, clinicians should ultimately be looking 
towards utilising as many safe and effective BP lowering treatments as needed to reduce 
an individual’s risk of developing or worsening cardiac function. If dietary nitrate has the 
potential to work independently of, or in concert with, currently used pharmacological 
interventions, the addition of dietary nitrate to a treatment regimen in order to push 
‘controlled’ BP of ~ 140 mmHg towards a more intensive treatment threshold of 120 
mmHg may indeed be of significant clinical benefit. 
In the ANGII model, in addition to a shift in ACh concentration-dependent relaxation 
response curves, there was also a modest shift in SNO relaxation response curves in 
nitrate pre-treated mice.  It is therefore possible that dietary nitrate targets recovery of 
basal endothelial NO generation and activity and not just agonist-stimulated activation 
of the endothelium. This in part could be related to the attenuation of oxidative stress 
observed (see below) and thus restoration of NO-mediated control of vascular tone. 
Previous findings have suggested that endothelium-independent relaxation via sGC 
signalling can be regulated by the presence/absence of NO in certain disease models 
(Hussain et al. 1999). Regardless, both findings highlight pathways which can contribute 
significantly to improved vasorelaxation, and reduced BP in this model. Moreover, as 
oxidative stress has been widely associated with direct and indirect impairment of 
endogenous NO production and a consequent increase in vascular tone, the reduction 
 157 
of superoxide production in nitrate-fed mice may also contribute to improved 
endothelium- and NO-dependent vasodilation (Kojda & Harrison 1999).   
In isoprenaline-treated mice the maximum PE response was increased and the 
maximum ACh response was reduced compared to control mice, however this effect 
was unaltered by dietary nitrate treatment. Isoprenaline is a selective b-adrenoceptor 
agonist with no a-agonist activity (Alexander et al. 2017). Studies with parotid cells have 
shown that prolonged treatment with isoprenaline results in an up-regulation of a-
adrenoceptor signalling (Tanimura et al. 1999) through sensitization of IP3 receptors and 
it is possible that this underlies the increased activity of phenylephrine in the 
experiments. Despite some change in vascular reactivity in this model, the prevailing 
view is that b1 adrenoceptors primarily localized in the cardiomyocyte, rather than cells 
of the vasculature, are the target for isoprenaline-induced cardiac hypertrophy (Lohse 
et al. 2003; Puhl et al. 2016). The absence of any significant difference in BP between 
the treatment groups and echocardiographic evidence suggests no role for an afterload-
mediated hypertrophy in this model, indicating that it is unlikely that changes in vascular 
resistance underlie this reduction in ACh responses. To our knowledge this phenomenon 
has not been previously reported and warrants further investigation.  
 The effects of dietary nitrate on cardiac hypertrophy 
Dietary nitrate reduced cardiac hypertrophy to some degree in both the BP-dependent 
and BP-independent models as reflected by echocardiographic measures of LV mass, 
wall thickening and estimates of LV volumes. With ANGII-infusion prominent LV wall 
thickening was observed with reduced LV volume, indicating a maladaptive concentric 
hypertrophy. This was inhibited with nitrate pre-treatment, and even attenuated to 
some degree in the dietary nitrate reversal study.  
That the impact upon cardiac structure occurs relatively rapidly is demonstrated by the 
fact that similar changes in LV mass and wall thickness occurred even when dietary 
nitrate was introduced only after ANGII-induced cardiac hypertrophy was in place. 
However, longer term treatment would likely be required to provide full restoration of 
cardiac muscle function in a non-prophylactic setting. These observations were 
supported further by reductions in HW:BW and LV:BW measured in our models - these 
reductions were mild, but consistent, and were evident irrespective of the model i.e. BP-
 158 
dependent or -independent. The fact that LV mass was reduced in all models suggests 
that whether the maladaptive hypertrophy is concentric (ANGII) or eccentric 
(isoprenaline), delivery of NO via dietary nitrate could still be clinically effective.  
Since ANGII-induced LV wall thickening was so drastically attenuated by nitrate pre-
treatment the modesty of reductions in heart weight data was somewhat surprising. 
However, it should be noted that with cardiac hypertrophy known to occur in two forms, 
eccentric and concentric (reflecting the multiple signalling pathways that can differently 
modulate the cardiac structure and performance) this may help explain our 
observations. Eccentric hypertrophy occurs when cardiac myocytes enlarge and grow in 
length (with sarcomeres added in series and LV volume increasing), as opposed to 
concentric hypertrophy where myocytes grow in width (with sarcomeres added in 
parallel and LV volume becoming smaller). Therefore, it may be that whilst ANGII-
induced wall thickening is prevented/slowed with nitrate supplementation, the mass of 
the heart has still increased somewhat due to the development of eccentric rather than 
concentric hypertrophy. For that reason, in ANGII-infused mice with inorganic nitrate 
pre-treatment, cardiac hypertrophy may not have been entirely prevented per se, as 
cardiac mass still increased, but the type of remodelling occurring may be different.   
In patients with pathological concentric hypertrophy, progression towards a dilated LV 
with wall thinning is often observed following a cardiac event, such as myocardial 
infarction, and accompanies transition from pathological cardiac hypertrophy to HF, 
with concurrent worsening of cardiac function (de Simone 2004). Therefore, a more 
dilated ventricle, with thinner walls, may be regarded by some as a sign of poorer clinical 
outcome. However, it should be noted that increased heart weight is not always 
detrimental and eccentric hypertrophy is different to dilated HF, where dilation occurs 
at the same time as cardiac output being compromised.  Generally, eccentric 
hypertrophy results in dilation without compromised function, and it should be 
recognised that in terms of being a prognostic indicator for cardiac outcome, concentric 
hypertrophy has actually been associated with worse outcome. Regression of wall 
thickening (reverting back to eccentric hypertrophy), on the other hand, has been 
associated with improved prognosis (Muiesan et al. 2004). 
 159 
Also, despite the fact that many assume that exercise-induced hypertrophy refers to 
reversible concentric adaptations, this occurs only in cases of resistance training. Intense 
aerobic exercise training is in fact known to induce eccentric hypertrophy, without 
reduction in cardiac function (Fernandes et al. 2011). In our study, we saw dilation 
occurring without wall thickening and without concurrent worsening of cardiac function, 
meaning LV diastolic chamber volume was increased – resulting in improved stroke 
volume. This type of adaptation would be more similar to changes observed during 
exercise-induced eccentric hypertrophy, rather than typical progression to HF. See 
Figure 6.1 for schematic illustrating the differences between concentric and eccentric 
hypertrophy.  
Figure 6.1 Differentiation between a normal adult heart, concentric hypertrophy and eccentric hypertrophy. 
Schematic illustrating fundamental structural differences between concentric and eccentric cardiac hypertrophy. 
Sarcomeres are added in parallel in concentric hypertrophy and in series in eccentric hypertrophy. Sarcomeres are 
represented as the individual units spanning the two “Z” markers (indicating Z-discs). Concentric hypertrophy (B) 
results in reduction in left ventricle diameter and an increase in wall thickness, apparent during intense resistance 
training. Eccentric hypertrophy (C) results in increased left ventricle diameter (dilation), occurring with or without 
wall thinning. Dilation occurs without wall thinning in exercise-induced eccentric hypertrophy, but with wall thinning 
in pathological eccentric hypertrophy.  
 The effects of dietary nitrate on cardiac function 
ANGII infusion resulted in a significant reduction in ejection fraction measured by 
echocardiography in the BP-dependent model. Unfortunately, this was not significantly 
improved by nitrate pre-treatment. However, following a significant reduction in wall 
thickness, and a resultant increase in diastolic volume, stroke volume was preserved by 
nitrate pre-treatment in ANGII-infused mice - a finding which could be of significant 
Left ventricleRight ventricle
Sarcomere
ZZ
A) Normal Adult Heart
B) Concentric Hypertrophy
C) Eccentric Hypertrophy
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clinical benefit. In the clinical setting, dietary nitrate may have potential to provide 
symptomatic improvement relatively quickly, and thus restore LV volumes.  
In contrast to the ANGII model, in the BP-independent isoprenaline model, ejection 
fraction was significantly improved in mice receiving nitrate as well as reductions in 
HW:BW. Recent studies have shown that nitrate supplementation can increase force of 
skeletal muscle contraction (Hernández et al. 2012; Coggan et al. 2015) and improve 
mitochondrial function (Larsen et al. 2011) – phenomena which would likely extend to 
being true for cardiac muscle. It is possible that s-nitrosation may be a key mechanism 
through which exogenous NO exerts beneficial effects with regards to maintaining 
ejection fraction, as reductions in protein s-nitrosation have been found in HF, and s-
nitrosation of proteins such as the ryanodine receptor/calcium channel (RyR2) and L-
type calcium channel have been associated with increasing/maintaining cardiac 
contractility (L. Xu et al. 1998; Sun et al. 2009). However, the question of why this 
observation was present in the isoprenaline model, but not ANGII makes this hypothesis 
less easy to support.  
Interestingly, the increased presence of NO (via NO donors) in both animal and cellular 
models has also been associated with increased β-adrenergic receptor expression and 
prevention of agonist-induced downregulation of receptors by prevention of GPCR 
Kinase 2-mediated β-adrenergic receptor phosphorylation and recruitment of β-
arrestin. This therefore results in attenuation of receptor desensitisation/internalisation 
(Whalen et al. 2007) and may therefore have helped sustain cardiac contractility during 
isoprenaline infusion in our mouse model. However, further molecular investigation is 
required to conclude which mechanisms are responsible for the physiological effects 
observed.  
It has previously been recognized that reduced NO levels in the heart can result in 
increases in cytosolic Ca2+ and the occurrence of diastolic dysfunction. The study 
reporting these findings highlighted uncoupling of NOS as the principle mechanism 
responsible (Silberman et al. 2010), and therefore, we could hypothesise that by 
restoring NO and improving endothelial function in the ANGII model, it may be possible 
that whilst ejection fraction may not be significantly improved in the ANGII model, 
diastolic function may be preserved. Future investigations into cardiovascular 
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haemodynamics in these models is therefore warranted to further understand the 
implications of the structural cardiac changes observed. 
 The effects of dietary nitrate on cardiac fibrosis and the molecular 
pathways involved 
The reduction of PSR staining suggests that fibrosis was significantly reduced by nitrate 
pre-treatment in the ANGII model, and this may also have some impact on diastolic 
function. CTGF expression is induced by ANGII (Ruperez et al. 2003) and in RT-PCR 
analysis of heart samples I discovered that CTGF was one of the genes significantly down 
regulated with dietary nitrate treatment in both the ANGII and isoprenaline models. 
CTGF has been investigated widely in many disease models with regards to fibrosis, 
including renal and skin models. In general an important balance exists with regards to 
CTGF and wound healing/fibrosis where in most tissues there is an importance in 
mediating physiological healing, but without causing excessive scarring (S. Liu et al. 
2011). However, the findings from such studies should be extrapolated with care when 
attempting to translate to the heart – where any degree of fibrosis is likely to 
compromise function.  
In vivo assays have shown TGFb-induced collagen synthesis in both neonatal rat kidney 
and human foreskin fibroblasts to be blocked with anti-CTGF antibodies and by 
suppressing TGFb-induced gene expression by elevating intracellular cAMP levels with 
adenylyl cyclase activator, cholera toxin (CTX). Elevated cAMP levels inhibited collagen 
synthesis induced by CTGF. In animal models, CTX injected intradermally in transgenic 
mice suppressed TGFb activation of a human CTGF promoter/lacZ reporter transgene, 
and also blocked TGFb-induced collagen deposition in a wound chamber assay (Duncan 
et al. 1999).  
In an ANGII rat model it was shown that CTGF is upregulated extremely quickly following 
ANGII infusion and may be an important mediator in vascular fibrosis development 
(Ruperez et al. 2003). In an in vitro model of cardiac fibrosis, the importance of CTGF 
signalling has recently been placed on fibroblasts, particularly with regards to autocrine 
signalling in activated fibroblasts which worsens cardiac fibrosis. However, arguing 
against this is the finding that ANGII-stimulated CTGF expression by cardiomyocytes in 
vitro did not have any effect on fibroblasts and was not pro-fibrotic (Dorn et al. 2018). 
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One recent paper has in fact shown that transgenic mice over-expressing CTGF in 
general are protected from ANGII-induced hypertrophy (Yang et al. 2009). The exact 
reason for this is not made clear, and as the overexpression in this model is not tissue 
specific or temporal, it may be that overexpression of CTGF in certain tissues or in 
health/development is capable of over-riding its potential negative effects in fibroblasts. 
Further investigation in tissue-specific and/or temporal KO mouse models would be of 
particular benefit with regards to better understanding how this relates to the 
attenuated outcomes observed in our study.  
Regardless, in in heart homogenates significant reductions in CTGF with dietary nitrate 
treatment was evidenced in ANGII- and isoprenaline-infused mice. NO has been shown 
previously to downregulate CTGF expression in a cGMP-mediated manner in cultured 
rat mesangial cells (Keil et al. 2002), and in a double transgenic rat model of HFpEF, NO-
sensitive guanylyl cyclase simulation improved cardiac dysfunction and significantly 
reduced CTGF expression in this model (Wilck et al. 2018). 
The canonical TGFb signalling pathway is one that is strongly upregulated in cardiac 
dysfunction in both hypertensive heart disease, dilated and infarct-induced 
cardiomyopathy leading to heart failure (Dobaczewski et al., 2011; Liu et al., 2017). The 
lack of an effect of nitrate treatment upon TGFb mRNA expression, an upstream 
modulator of CTGF signalling (Chen et al. 2000), indicated that this cytokine likely was 
not the target of NO. However, it has been previously shown that NO is capable of 
inhibiting TGFb/SMAD signalling, but not necessarily via changing TBGb expression but 
rather by altering TGFb-triggered SMAD phosphorylation and signalling. NO has been 
shown to significantly attenuate TGFb phosphorylation and downstream signalling via 
SMAD2/3, a process which was found to be cGMP dependent. These findings could be 
mimicked by a soluble cGMP analogue, and inhibiting protein kinase 1 (PKG-1), or 
overexpressing a dominant-negative version of PKG-1, was sufficient to inhibit NO-
induced inhibition of TGFb expression. Conversely, overexpression of PKG-1 blocked 
TGFb/SMAD signalling. It was found that NO reduced SMAD2/3 phosphorylation and 
nuclear translocation, but L-NAME increased SMAD phosphorylation and signalling 
(Saura et al. 2005). Therefore, future experiments focused on phosphorylation of these 
proteins could be key in uncovering molecular pathways associated with the beneficial 
effects of dietary nitrate and NO. Furthermore, NO has been found suppress TGFb-
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induced epithelial-to-mesenchymal transition in mouse hepatocytes (a key stage in 
fibrosis development) as well as hepatocyte apoptosis (Pan et al. 2009). Whilst the 
model used here was an in vitro example of the cell transitions which occur during liver 
fibrosis pathogenesis, it is possible that similar pathways may be involved in cardiac 
fibrosis and could also benefit from nitrate/NO supplementation. 
Interestingly, eNOS KO mice exhibit increased basal levels of TGFb/SMAD signalling 
(Saura et al. 2005), but TGFb/SMAD signalling has also been shown to be involved in 
regulating eNOS expression (Saura et al. 2002). These findings highlight the complexity 
of the relationship between eNOS/NO and TGFb/SMAD and potential for the existence 
of negative feedback loops regulating expression and activity, further complicating 
interpretation of TGFb/SMAD/CTGF expression being inherently good or bad. However, 
with CTGF and Col1a expression, as well as PSR staining all being reduced by dietary 
nitrate in our models, this suggests that dietary nitrate has had a generally beneficial 
impact on fibrosis development.  
Similar findings have been reported in models of renal fibrosis where activators of cGMP 
signalling exerted protective effects by inhibiting SMAD phosphorylation (Schinner et al. 
2017). Furthermore, in a model of pulmonary hypertension a significant reduction in 
lung fibrosis was observed following dietary nitrate intervention. Whilst this may be due, 
in part, to a reduction in pulmonary hypertension, it is also possible that direct NO 
signalling may have played a role in the protective benefits observed (Baliga et al. 2012). 
In L-NAME-induced hypertensive rats dietary nitrite reduced cardiac remodelling via 
reductions in TGFb-mediated signalling (Sonoda et al. 2017). The authors hypothesised 
that this was due to supressed ANGII signalling, which may indeed be part of the story. 
However, we did not see a significant reduction in AT1Ra expression in our models and 
saw benefits of nitrate treatment even in an ANGII model where the RAAS system is 
pushed to the extreme. Therefore, whilst it is possible that there could be some impact 
of nitrate/nitrite/NO on RAAS signalling, there are other RAAS-independent pathways 
which are more likely to be responsible for the beneficial effects observed in our studies, 
for example reducing oxidative stress. 
One other key mediator of fibrosis which may be altered by dietary nitrate is the nuclear 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) 
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(Ma et al. 2018). It has been shown previously that NFkB binding can be significantly 
inhibited by NO (Matthews et al., 1996). Not only that, but ROS are also able to activate 
NFkB. With dietary nitrate having been shown to reduce the oxidative stress in both the 
ANGII and Isoprenaline models, it is possible that just via NFkB there are multiple pro-
fibrotic pathways attenuated by treatment with dietary nitrate.  
The lack of reduction in fibrosis in the reversal study is likely due to the fact that fibrosis 
can develop rapidly following hypertension, even prior to LVH development (Müller-
Brunotte et al. 2007). In mice receiving 3 weeks of ANGII infusion prior to beginning 
nitrate intervention, it is likely that fibrosis developed prior to beginning nitrate feeding 
and could not be reversed by nitrate treatment. Even in clinical studies where marked 
reductions in CTGF and Col1a have been exhibited in response to pressure unloading, 
this has not been reflected in a marked reduction in fibrosis (Koshman et al. 2013). 
However, despite no reduction in fibrosis, it did appear that the progression of 
hypertrophy could be slowed to some degree, as wall thickening measured by 
echocardiography was significantly less than that of KCl-fed mice on the same ANGII 
regimen.  
 Oxidative stress in our models of cardiac dysfunction 
Despite some seemingly disparate effects of dietary nitrate in the two models, one other 
key mechanism which was shared across the two models, in addition to the reduction 
in CTGF/fibrosis, was a reduction in oxidative stress. Over the last two decades, 
numerous clinical and experimental studies have shown that oxidative stress is 
implicated in the progression of a number of CVD pathologies, including cardiac 
hypertrophy (J.-M. Li et al. 2002; Satoh et al. 2006) and HF (Lakshmi et al. 2009; Tsutsui 
et al. 2011). Studies in isolated cardiomyocytes have shown that by reducing oxidative 
stress using treatments such as vitamin E, hydroxyanisole and catalase, the pro-
hypertrophic effects of ANGII and TNF-α on neonatal cardiac myocytes could be 
prevented (Nakamura et al. 1998). Whilst translation of the use of antioxidants to the 
clinic has not been straightforward (Myung et al. 2013), it should not be ruled out that 
reducing oxidative stress and accumulating superoxide damage via downstream 
mechanisms, with other specifically targeted treatments, may still be beneficial. In this 
regard, a large body of evidence have reported that targeting the nitrate-nitrite-NO 
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pathway therapeutically may be beneficial in models of renal and cardiovascular disease 
by reducing the oxidative stress (Carlstrom et al. 2011) and increasing NO bioavailability. 
In light of these observations, in both models of cardiac dysfunction, we investigated 
the effects of dietary nitrate on oxidative stress, evaluating the individual contributions 
of XOR and NAD(P)H oxidase by measuring the superoxide production in presence of 
Xanthine, NADH and NADPH. In line with previous findings (Ling et al. 2018; Peleli et al. 
2016) reporting that NO bioavailability can impact superoxide production, we showed 
that dietary inorganic nitrate attenuates basal superoxide production in both a BP-
dependent and -independent model of cardiac dysfunction. ANGII-induced superoxide 
generation was found to be increased in the presence of Xanthine, NADH and NADPH. 
In the isoprenaline model, however, superoxide generation was primarily driven by 
NADPH and NADH substrates, with a much smaller contribution from xanthine. 
Inorganic nitrate in ANGII-infused mice significantly reduced both xanthine and NADPH-
induced superoxide generation, with a similar trend when NADH was present. Whilst, 
unlike ANGII-infused mice, in the isoprenaline model, nitrate reduced only NADPH-
mediated oxidative stress. Importantly, XOR and NADPH oxidative effects were 
prevented by enzymatic antagonists, allopurinol/febuxostat or DPI respectively. 
Together, these findings clearly indicate that both models of HF are characterised by an 
increase of ROS production, and that XOR and NADPH oxidase can have a pivotal role in 
the development of oxidative stress in such conditions. However, whilst ANGII 
represents a stimulus for both enzymes, isoprenaline seems to primarily affect NADPH 
oxidase.  
Differences in the enzymatic mediators of superoxide generation in the ANGII and 
isoprenaline models are likely to be as a result of the different pathophysiological 
mechanisms at play. ANGII drives cardiac pathology both in the vasculature and directly 
within the heart, but isoprenaline largely drives pathology from direct cardiac signalling 
and tachycardia. Differences in the triggers and sources of superoxide generation are 
also therefore likely to influence the improvement reported in response to nitrate 
treatment. Attenuating NADPH oxidase-mediated oxidative stress for example, may 
have a greater effect on direct cardiac signalling and cardiac output, whereas reducing 
XO-mediated oxidative stress may have more benefit in the vasculature, for example 
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improving endothelial function and subsequently BP-dependent wall thickening and 
fibrosis. However, regardless of the exact pathway(s) responsible, oxidative stress from 
a variety of sources has been widely implicated in the development and progression of 
cardiac hypertrophy and HF, and reductions in ROS generation are highly likely to be of 
benefit with regards to improving clinical outcome in patients (Tsutsui et al. 2011). 
Relating these types of molecular findings to the exact physiological improvements 
observed remains the main challenge, which is why using multiple cardiac dysfunction 
models (as we have done here) has proved invaluable as we look to tease apart both 
similarities and differences in the models and results observed.  
However, in both models we detected a significant reduction in NADPH oxidase-driven 
oxidative stress. The fact that nitrate reduced NADPH oxidase-driven oxidative stress in 
both ANGII and isoprenaline models was particularly interesting as changes in this 
particular pathway may (at least in part) be directly driven by direct signalling in the 
heart, independent of vascular function and changes in BP.  
Some may argue that as lucigenin can itself generate superoxide in some circumstances, 
and furthermore, superoxide is not the only radical that could react with lucigenin to 
induce the luminescence (e.g. hydrogen peroxide) that there are other, more reliable 
methods of measuring superoxide generation. For example, methods such as 
fluorescent staining of cells and tissues, using dihydroethidium (DHE) or dichlorodihydro 
fluorescein diacetate (DCFH-DA), or chromatography methods, may be preferable in 
some instances (Zhang et al., 2018). 
However, due to the somewhat unique ability of the lucigenin assay to enable 
examination of the impact of particular enzymatic contributions to superoxide 
generation in tissues, the lucigenin method was used for these studies. It enabled us to 
probe the importance of specific enzymes of interest (namely NADPH oxidase and XOR) 
by adding substrates (xanthine, NADH and NADPH) to the assays, as well as inhibitors 
(DPI and allopurinol).  
 
Although the reactivity between lucigenin and superoxide is quite low, and this is by no 
means a biological reflection of the in tissue level of superoxide produced, it enabled us 
to quantify the relative contributions of enzymes of interest to the oxidative stress 
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burden in cardiac tissue, and was therefore an appropriate method for use in our 
models. 
 Dietary nitrate reduces XOR-mediated superoxide generation 
Due to the particular involvement of XOR in the ANGII model, XOR expression and 
activity was investigated further by measuring protein expression as well as H2O2 
generating capacity. As expected, XOR protein expression was significantly increased 
following ANGII infusion. But with no significant reduction in expression in nitrate-fed 
mice. XO-mediated H2O2 generation was also increased following ANGII infusion, but 
contrary to changes in protein expression, this increase was significantly attenuated by 
nitrate feeding in both pre-treatment and reversal mice. In line with LECL findings, XOR 
expression and XOR-driven H2O2 production was much higher in the ANGII (BP-
dependent) model compared to the isoprenaline (BP-independent) model. 
With no reduction of XOR expression by dietary nitrate in the ANGII model, the question 
remained, how was XOR-dependent superoxide production being reduced by dietary 
nitrate if it wasn’t having an effect on enzyme expression? XOR is an extremely complex 
enzyme, with varying activities depending on substrate/binding site, oxidation state and 
availability of terminal electron acceptors (Battelli et al. 2014). XOR exists in two 
interconvertible states - XDH (the reduced form of the enzyme) and XO. The principal 
form present under physiological conditions in vivo is XDH, but this can be converted to 
XO by either sulfhydryl oxidation (reversible) or proteolysis (irreversible) (Stirpe & Corte 
1969; Enroth et al. 2000). The importance of this oxidation state is critical, as following 
the hydroxylation of purines at the molybdenum site, electrons are generated here and 
go on to be used at the FAD site. However, depending on the oxidation state of the FAD 
site, the resulting products will differ. XDH typically uses NAD+ as its terminal electron 
acceptor (and molecular oxygen only in times of NAD+ deficiency). However, XO utilizes 
only oxygen as a terminal acceptor, resulting in substantial superoxide formation (Hille 
& Massey 1981) and contributing to accumulating oxidative stress in pathological 
conditions, including HF (Tsutsui et al. 2011). However, of particular importance for this 
study, XO has also been known for some time to catalyse the reduction of nitrate to 
nitrite, and nitrite to NO  (Millar et al. 1998; Zhang et al. 1998; Godber et al. 2000; H. Li 
et al. 2001), and the functional importance of this phenomenon has been demonstrated 
in vivo (Webb et al. 2004; Ghosh et al. 2013). 
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We have previously proposed that one particular benefit of dietary nitrate 
supplementation, may be the ability to encourage ‘XOR repurposing’ (Tripatara et al. 
2007; Khambata et al. 2015). It is possible that the mechanism by which XOR-mediated 
oxidative stress is reduced in the ANGII model is simply through repurposing of already 
present XOR.  One can speculate that XOR is being redirected by the increased 
concentrations of plasma nitrite to generate beneficial NO (via nitrite reduction) from 
the electron transport chain, instead of generating harmful superoxide. The fact that 
oxidative stress in the isoprenaline model is less XOR-driven and more by NADPH 
oxidase, may explain why XOR repurposing with nitrate has less of an impact in the LECL 
assay with isoprenaline-treated mice. In further support of this theory are the findings 
from the XO activity assay in which nitrate feeding in controls, ANGII pre-treatment and 
ANGII reversal study mice expressed significantly reduced H2O2 generation, but not in 
isoprenaline-treated mice. Additionally, our findings highlight that in cardiac tissue, 
when mice have been fed dietary nitrate, the nitrite reductase capacity of cardiac 
enzymes significantly increases. With no change in XOR expression following dietary 
nitrate, but a reduction in XOR-mediated superoxide generation and a concurrent 
increase in nitrite reduction, this supports the hypothesis that XOR activity may indeed 
be re-directed towards favourable nitrite reduction and away from generating harmful 
superoxide. Thus, the beneficial effects of dietary nitrate in the ANGII model in 
particular, may be two-fold. Not only could the resulting NO be of benefit in terms of 
encouraging blood vessel dilation and reducing hypertrophy via direct signalling, but 
with nitrite acting as a substrate for XOR, the ability of XOR to generate superoxide may 
also be reduced due to a ‘repurposing’ of the enzyme (discussed in Khambata et al. 
2015).  
 Dietary nitrate reduces NADPH oxidase-mediated superoxide 
generation 
The mechanisms behind the beneficial effects of dietary nitrate on NADPH oxidase 
activity remain to be fully elucidated. NOX2 and NOX4 subunits have been identified 
throughout the cardiovascular system (Bedard & Krause 2007), and along with XOR are 
considered the most probable sources of superoxide anion, which is one of the most 
reactive ROS. As previously reported from in vivo, in vitro, and clinical studies, ANGII 
represents one of the main stimuli of NADPH oxidase and XOR enzymes. Indeed, it has 
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been reported (Landmesser et al. 2007) that bovine endothelial cells exposed to ANGII 
(10-7 mol/l) show a time dependent increase of XOR expression and activity, followed 
by an increase in superoxide production. These effects were blocked by the AT1 receptor 
antagonist losartan. Furthermore, as reported by Ling et al., immunoblotting in protein 
extract from aortas from ANGII-infused mice, showed an increase in NOX2 and NOX4 
subunits. Such upregulation explains the increases in superoxide generation observed 
in the presence of xanthine and NADPH in this model should the same be true of cardiac 
tissue (Ling et al. 2018).  
To begin investigating the possible mechanisms involved in attenuating NADPH oxidase-
mediated superoxide generation we began by probing for NOX2 protein expression. 
With limited heart samples available for molecular analysis, aorta homogenates were 
used to investigate NOX2 protein expression in ANGII-infused mice. In western blot 
immunoassays probed for NOX2 protein expression, and tissues from nitrate-treated 
mice a trend towards reduced protein expression was seen, but this was not statistically 
significant. Such results are in accordance with the study by (Ling et al. 2018), where 
with dietary nitrite there was no detectable change in ANGII-induced NOX2 
upregulation. In this study by Ling et al., they did however see a reduction in the NOX4 
subunit – suggesting this may be an avenue to explore in further studies. 
Furthermore, the protein kinase B (Akt)/mammalian target of rapamycin (mTOR) 
pathway has also been found to be attenuated by dietary nitrite (Guimaraes et al. 2018). 
NOX4 is a mediator of cardiac hypertrophy and remodelling via Akt/mTOR and NFkB 
signalling (Zhao et al. 2015), and these pathways have been shown to be upregulated in 
both pressure overload (Sciarretta et al. 2014) and spontaneous hypertension models 
(Soesanto et al. 2009). Further investigation of NOX4/Akt/mTOR signalling pathways 
would therefore be of particular interest in future, with regards to the reductions in 
NADPH oxidase-mediated oxidative stress in our models, and how this translates to 
reduced cardiac hypertrophy and fibrosis. 
 The Xdh KO mouse model – further understanding the complex 
roles of XOR in health and disease 
Due to the apparent implications of XOR in the benefits of dietary nitrate on BP and 
cardiac dysfunction, the Xdh KO mouse model was used to further understand the 
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importance of this complex enzyme. It was of interest to characterise the cardiovascular 
phenotype of mice who lack, at least in part, the XOR enzyme and further understand 
the physiological role of XOR in cardiovascular health as a nitrite reductase. However, it 
was of equal interest to understand the implications of removing XOR with regards to 
superoxide generation in a model of cardiovascular disease, such as the ANGII model. 
Due to the lethal nature of the KO mouse model, Xdh Het (+/-) mice and WT (+/+) 
littermate controls were used. In other work conducted in our lab (yet to be published), 
it has been established that we have successfully generated a colony of Xdh KO mice - 
with XO activity (as measured by the XO assay discussed in Section 2.18) partially 
reduced in Hets and completely abolished in KOs (Khambata et al., unpublished). 
Furthermore, liver Xdh mRNA and XOR protein expression both demonstrated a 
substantial reduction, confirming that this observation was due to reduced XOR 
expression. Importantly, Hets exhibited a partial, but significant reduction in Xdh mRNA 
and XOR protein expression.  
 BP in Xdh Het and WT mice – with and without ANGII infusion 
In unchallenged Xdh Het mice, BP (as measured using tail cuff methodology) was 
significantly increased compared to WT littermate controls. The nitrite reductase 
capacity of tissue homogenates in the Xdh KO mice has also been investigated in our lab, 
with results as of yet to be published. Nitrite reductase activity of liver homogenate was 
determined under physiological (pH 7.4), ischaemic (pH 6.8) and severe ischaemic (pH 
5.5) conditions. Reduced nitrite reductase activity was observed in both Het and KO liver 
homogenates across all pHs and was most evident when the highest concentration of 
nitrite (1mM) was used. Furthermore, there was a significant increase in both liver and 
plasma nitrite and nitrate concentrations in KO mice, with a trend towards increased 
nitrite concentration in Hets, when compared using ozone chemiluminescence 
(Khambata et al., unpublished). Together, these finding support the notion that XOR acts 
as a nitrite reductase under physiological conditions and contributes towards 
maintaining low BP in health by reducing nitrite to bioactive NO. Reducing the 
expression of the Xdh gene in Hets therefore had a significant impact on cardiovascular 
phenotype, with an increase in DBP, SBP and MAP measured at baseline compared to 
WT controls.  
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However, interestingly, in Het mice which were infused with ANGII for 3 weeks, BP was 
significantly lower than that of WT controls under the same ANGII regimen. It can 
therefore be suggested that whilst Xdh expression is beneficial under physiological 
conditions, contributing to maintenance of healthy BP by reducing nitrite to NO, in 
diseased states XOR has the potential to contribute towards oxidative stress. It is 
therefore understandable that its absence (or reduction) in a disease model could be of 
benefit, helping reduce further vascular dysfunction/hypertension in the ANGII model.  
 Cardiac phenotyping Xdh Het and WT mice – with and without 
ANGII infusion 
Due to the preliminary nature of the investigations into cardiac phenotypes of Xdh Het 
mice, this study was not powered to see significance in echocardiographic measures. 
However, using our findings as a basis to generate power calculations will provide an 
indication of the further work required to reach statistical significance in 
echocardiographic data for these studies.  
When carrying out echocardiographic imaging in Xdh Het mice and WT littermate 
controls at 8 and 16 weeks of age, understandably there was a trend towards increased 
LV volume and LVID with age. This increase was present in both Het and WT mice. There 
However, this increase showed trends towards being somewhat greater in the Het 
group. In addition to this, there was a trend towards LV wall thickening and reduction in 
ejection fraction in the Xdh Het group at 16 weeks old. Whilst the data is not sufficiently 
powered to see statistical significance, should these findings be corroborated in 
subsequent mice, this may indicate some level of cardiac hypertrophy development 
alongside the hypertension measured by tail cuff methods.  
In an in vitro cancer model XDH downregulation in cells has been found to increase 
TGFb/SMAD signalling (G.-L. Chen et al. 2017). This could potentially be due to less NO 
being present, which (as previously discussed) can act as an inhibitor of this signalling 
pathway. Should similar patterns in expression be identified in Xdh Het cardiac tissue in 
future, along with the hypertension observed, this would go a long way towards helping 
explain increased levels of cardiac hypertrophy and dysfunction in Xdh Hets at baseline. 
In experiments where Xdh Het and WT mice were challenged with ANGII and had 
echocardiographic parameters measured at 16 weeks of age, both Hets and WTs 
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exhibited LV wall thickening, increase in LV mass and reductions in ejection fraction. 
However, the LV volume increase was less pronounced in Xdh Hets. Comparing the 
values of ANG+Het and ANG+WT to those of Het and WT controls, it can be seen that 
the wall thickness of ANG+Het mice is not much different from Het controls. However, 
ANGII+WT mice exhibit more severe wall thickening compared to WT controls. This 
aligns with the fact that that ANGII infusion caused a much greater rise in BP in WT mice 
compared to Hets.  
Doppler flow data, measured in the descending aorta of these mice, indicated that Xdh 
Het mice (regardless of age) have reduced mean and peak velocities in comparison to 
WT controls – potentially indicating reduced aortic stiffening, despite increased BP. This 
is particularly interesting, as with reduced Xdh expression we hypothesised that an 
increase in BP in Xdh Het mice would be due to a reduction in physiological nitrite 
reductase capacity. However, typically we would expect that along with raised BP and 
cardiac dysfunction would come aortic stiffening. However, it appears in the Xdh Het 
mice this may not necessarily be the case.  
As previously discussed, XOR is a complex enzyme and can act both as a nitrite reductase 
and a generator of oxidative stress. It is therefore possible that in 16-week old Xdh Het 
mice, the loss of endogenous NO produced by XOR as a nitrite reductase is significant 
enough to raise BP and begin to initiate cardiac changes as a result of the raised BP and 
increased TGFb signalling. However, with the absence of XOR in the setting of raised BP 
and cardiac dysfunction, it may be that superoxide generation, which is usually present 
in such disease states, is significantly reduced. Therefore, in the blood vessels for 
example the improved measures of aortic stiffening in mice who lack Xdh could 
potentially be a reflection of this. This is an area which warrants further investigation, 
for example using organ bath assays to explore the effects of vasoactive substances in 
an ex vivo set up. Unfortunately, in the Langendorf assays conducted thus far, the 
differences observed in basal CPP could mean that any potential differences in 
vasoreactivity to SNP and Bradykinin were confounded by this variable. This could make 
it difficult to detect any other potential differences. 
It is also worth noting that in a study by Adelsperger et al., ANGII-infused mice were 
studied using echocardiography at the beginning and end of a 4-week period, 
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investigating the development of abdominal aortic aneurysms (AAA). In this study, 
greater peak velocity was associated with the development of AAA in the diseased group 
following ANGII infusion, with a lower velocity in the non-diseased group (Adelsperger 
et al. 2018). The non-diseased mice, which did not develop AAA, had a significantly 
reduced velocity at Day 28 compared to Day 0 baseline. Whereas the mice which 
developed AAA had significantly increased velocity at Day 28 compared to Day 0 
baseline. With this in mind, it is possible that the lower velocities observed in our Xdh 
Hets both in controls and following ANGII infusion may indicate some level of vascular 
protection, for example against AAA development. 
Table 6.1 As published in Adelsperger et al.,2018 (Table 3) highlighting the longitudinal ultrasound metrics 
compared between Non-diseased and diseased (AAA) mice infused with 1000ng/kg/min ANGII for 28 days.  
 Future investigations of interest 
In the ANGII and isoprenaline models, future investigations of particular interest to help 
elucidate the molecular mechanisms behind the phenotypic effects observed include: 
• NOX4/Akt/mTOR protein expression in cardiac and vascular tissue. 
• SMAD2/3p protein expression and phosphorylation in cardiac and vascular 
tissue. 
Due to the preliminary nature of the Xdh KO mouse studies, it will be important in future 
to bring these n-numbers to those indicated by the power calculations below. Based on 
the preliminary data, it can be determined that n = 21 would be required to detect a 
significant difference in LV mass between Xdh Hets and WT with an effect size of 1.16, 
with 95% power (Figure 6.2). There were several suggestions of trends observed in 
directions which would support the hypothesis that XOR acts predominantly as a nitrite 
reductase in health, but as a superoxide generator in disease, and that this activity can 
be somewhat directed by the substrates and stimuli available. Having now calculated 
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the n-numbers required to reach statistical power, it will be important to complete these 
studies. In the Xdh mouse models, further to increasing n-numbers to power, future 
investigations of particular interest include:  
• Comparing nitrite reductase activity in tissues from Hets and WTs (controls and 
ANGII-infused) and comparing superoxide generation using the XO assay and 
LECL. This will be particularly important in order to see whether the nitrite 
reductase/superoxide generation from XOR is impacted as hypothesized in the 
Xdh KO mice. 
• Furthermore, the introduction of dietary nitrate to the Xdh KO mouse model 
would be of particular interest, to see whether the activity of XOR can be 
impacted either in health or under ANGII-infusion.  
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Figure 6.2 G*Power results for power calculations based on preliminary data from Xdh Het and WT mice. 
 
 Final Summary 
In conclusion, data presented in this thesis supports the hypothesis that inorganic 
nitrate has the potential to attenuate both BP-dependent and -independent cardiac 
dysfunction. In the ANGII (BP-dependent) model, inorganic nitrate significantly 
attenuated endothelial dysfunction, hypertension, left ventricular (LV) hypertrophy and 
cardiac fibrosis. Furthermore, nitrate significantly reduced H2O2 and superoxide 
generation, whilst increasing nitrite reductase capacity of heart tissue. In the 
Isoprenaline (BP-independent) model, inorganic nitrate prevented isoprenaline-induced 
decline in ejection fraction, significantly reduced cardiac fibrosis and superoxide 
generation, and increased nitrite reductase capacity. 
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Molecular pathways of particular importance which we identified as being of interest 
for further investigation include: 
• cGMP signaling pathways - Likely cGMP-dependent benefits of nitrate include 
vasodilation and BP reduction (which in turn can reduce the level of 
hypertrophy/cardiac dysfunction observed), as well as direct inhibition of fibrosis 
by reduction in TGFβ/SMAD/CTGF signaling. 
• XOR repurposing - XOR-dependent benefits of nitrate include repurposing of 
XOR towards nitrite reductase activity (generating NO from nitrite) as opposed 
to superoxide generation. 
• NADPH oxidase-mediated superoxide generation – dietary nitrate reduced 
NADPH oxidase-mediated superoxide generation. Whilst Nox2 protein 
expression was not significantly changed by dietary nitrate, Nox4 has yet to be 
measured in heart tissue from our studies and may represent the mechanism by 
which nitrate reduces this reduction in oxidative stress.  
• Protein nitrosation – it is possible that nitrosation of various proteins, yet to be 
identified, could be impacting cardiac function in our models.  
• Mitochondrial and smooth muscle function - Furthermore, potential 
improvements in mitochondrial function and muscle contractility in these 
models may also be of clinical benefit – whether by improving cardiac or skeletal 
muscle efficiency. 
Furthermore, the importance of the enzyme XOR in both health and disease has been 
further emphasised by our studies in Xdh KO mice. We report evidence supporting its 
importance as a nitrite reductase enzyme in health, but with significant superoxide 
generating capacity in disease. It became apparent that XOR expression helps maintain 
physiological BP in WT mice (acting as a nitrite reductase), but upon ANGII infusion is 
detrimental (acting as a superoxide generator). Furthermore, despite higher baseline 
BPs in Xdh Hets, these mice were protected from ANGII-induced hypertension and 
associated worsening of cardiac function, truly highlighting the complexity of XOR’s role 
in health and disease.   
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A summary figure highlighting particular pathways of relevance in the benefits of NO, 
and thus inorganic nitrate, on cardiac hypertrophy and dysfunction are shown in Figure 
6.3. Our data supports the hypothesis that inorganic nitrate has the potential to improve 
cardiac remodelling both directly (by attenuating fibrosis and reducing superoxide 
generation) and indirectly (through BP-lowering). Thus, we have demonstrated in these 
animals models that dietary nitrate may indeed offer a relatively cheap, easily 
translatable and accessible therapeutic option for both BP-dependent and -independent 
HF, whether this be in isolation or in conjunction with existing therapies.  
Figure 6.3 Schematic illustrating the key pathways in NO generation and the proposed pathways responsible for  
the observed effects on cardiac and vascular structure/function in our mouse models of cardiac dysfunction. Yellow 
lines/arrows highlight pathways in relation to cardiac hypertrophy/dysfunction which can be attenuated or 
activated by inorganic nitrate/NO.
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